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Zusammenfassung
Die Alzheimer-Krankheit (AK), die erstmals vor mehr als einem Jahrhundert von Alzheimer 
beschrieben wurde, ist eine der häufigsten Formen der Demenz, von der über 30 Millionen 
Menschen weltweit betroffen sind (über 8 Millionen in Europa). Die Entstehung und Pathogenese 
von AK ist wenig verstanden und bis zum heutigen Zeitpunkt gibt es keine Heilung für diese 
Krankheit.   AK   ist   durch   die   Akkumulation   von   senilen   Plaques   charakterisiert,   die   aus 
Amyloid-Beta-Peptiden (Aβ 37-43) nach Spaltung des Amyloid- Precursor-Proteins durch den 
Gamma-Sekretase-(GS)-Komplex entstehen. Deshalb kann GS ein attraktives Ziel für Medikamente 
sein. Da GS auch andere Substrate wie Notch, CD44 und Cadherine hat, führt unspezifische 
Hemmung von GS zu vielen Nebenwirkungen. Auf Grund des Fehlens einer Kristallstruktur von GS, 
was den extremen Schwierigkeiten bei der Aufreinigung zugeschrieben wird, kann molekulares 
Modelling sinnvoll sein, um die Architektur dieses Enzyms zu verstehen. Bisher wurden nur niedrig 
aufgelöste Cryo-EM Strukturen des Komplexes gelöst, die nur eine ungenaues Bild bei einer 
Auflösung zwischen 12-15 Å liefern. Weiterhin kann die Aktivität von GS in vitro mittels zellfreier 
(CF)- Expression hergestellt werden. 
GS enthält katalytische Untereinheiten, nämlich Preseniline, und die Stützelemente Pen-2, Aph-1 und 
Nicastrin. Die Entstehung von AK liegt in der regulierten Intramembran-Proteolyse (RIP) begründet, 
die in verschiedenen physiologischen Prozessen und auch bei Leukämie eine Rolle spielt. Bisher 
wurde RIP für Wachstumsfaktoren, Cytokine, Rezeptoren, virale Proteine, Zelladhäsionsproteine, 
Signalpeptide und GS gezeigt. Während der RIP durchlaufen die Substrate extrazellulären Verdau 
und Intramembran Proteolyse. 
Diese These beruht auf Molecular Modelling, Molecular Dynamics (MD) Simulationen, zell-freie 
(CF)-Expression, Massenspektrometrie, NMR, Kristallisation sowie Aktivitätstests der Komponenten 
des GS und von G-Protein-gekoppelter Rezeptoren (GPCRs). 
Zuerst wurde die NMR-Struktur von PS1 CTF in Detergensmicellen und Lipiddoppelschichten mit 
Coarse-grained MD-Simulationen mit MARTINI Kraftfeld in Gromacs validiert. CTF wurde in 
DPC-Mizellen, DPPC- und DLPC- Lipiddoppelschichten simuliert. Ausgehend von zufälligen 
Konfigurationen von Detergens und Lipiden wurden Mizellen und Lipiddoppelschichten jeweils in 
Gegenwart   von   CTF   ausgebildet,   das   während   der   Simulation   in   der   Mizelle   und   in   der 
Lipiddoppelschicht   ausgerichtet   wurde.   DPC-Moleküle   haben   Mizellen   um   CTF   geformt,   in 
Übereinstimmung der experimentellen Ergebnisse, in denen 80 bis 85 DPC-Moleküle erforderlich Zusammenfassung 11
sind, um Mizellen zu bilden. Die Struktur in DPC ist der NMR-Struktur ähnlich, unterscheidet sich 
aber in Simulationen Lipiddoppelschichten bezüglich der Möglichkeit des Substrat-Docking im 
konservierten PAL-Motiv. Simulationen von CTF in impliziter Membran (IMM1) in CHAMM ergab 
eine ähnliche Struktur wie die aus Coarse-grained MD. 
Die zell-freie Expression wurde optimiert gefolgt von Kristallisation und NMR-Spektroskopie von 
Pen-2 in verschiedenen Detergens-Micellen. Zusätzlich wurde Pen-2 durch eine Kombination der 
Rosetta Membran ab-initio-Methode, HHPred Homologiemodellierung unter Einbeziehung von 
NMR-Constraints   modelliert.   Die   Modelle   wurden   von   All-Atom-   und 
Coarse-Grained-MD-Simulationen in Detergens-Mizellen und POPC / DPPC Lipid-Doppelschichten 
mit MARTINI Kraftfeld validiert. 
GS-Operon bestehend aus allen vier Untereinheiten wurde mittels CF coexprimiert und aufgereinigt. 
Das Vorhandensein von GS-Untereinheiten nach Pull-Down mit Aph-1 wurde mittels Western Blot 
(Pen-2) und Massenspektrometrie (Presenilin-1 und Aph-1) bestimmt. Darüber hinaus wurden 
zusätzlich Interaktionen von PS1 CTF, APP und NTF mittels Docking und MD untersucht. 
Modelle und Kontaktflächen von Pen-2 und PS1 NTF wurden geprüft und ihre Stabilität aus 
MD-Simulationen mit experimentellen Ergebnissen verglichen. Das Ziel war die Kontaktflächen 
zwischen GS-Untereinheiten durch Molecular Modelling mit den verfügbaren experimentellen Daten 
aus Cross-linking, Mutationsstudien und mittels NMR-Struktur des C-terminalen Fragments von PS1 
und   der   Transmembran-Domäne   APP   zu   modellieren.   Die   erhaltenen   Kontaktflächen   von 
GS-Untereinheiten können helfen, den Katalyse-Mechanismus aufzuklären, der für ein neues 
Lead-Design genutzt werden kann. Auf Grund des Fehlens einer Kristall-/ NMR-Struktur der 
GS-Untereinheiten mit Ausnahme des PS1 CTF, ist es nicht möglich, die Wirkung von Mutationen in 
Bezug auf APP-Spaltung vorherzusagen. Daher wurde zusätzlich ein Sequenz-basierter Ansatz auf 
maschinellem Lernen mit Support-Vektor-Maschine entwickelt, um die Wirkung von PS1 CTF L383 
Mutationen in Bezug auf das Aβ40/Aβ42-Verhältnis mit 88% iger Genauigkeit vorherzusagen. 
Mutations-Daten aus der MOLGEN Datenbank, von PS1-Mutationen abgeleitet, wurden zum 
Training verwendet. 
GPCRs (auch genannt 7TM-Rezeptoren) bilden eine große Superfamilie von Membranproteinen, die 
durch kleine Moleküle, Lipide, Hormone, Peptide, Licht, Schmerz, Geschmack und Geruch aktiviert 
werden können. Obwohl 50% der Medikamente auf dem Markt GPCRs als Ziel haben, werden nur 
wenige therapeutisch angegangen. Eine solche Vielzahl von Zielen kommt durch Einbeziehung von 
GPCRs in Signalwegen im Zusammenhang mit vielen Krankheiten zu Stande, welche Demenz (wie Zusammenfassung 12
Alzheimer-Krankheit), Stoffwechselerkrankungen (wie Diabetes) einschließlich endokrinologischen 
Störungen, viraler Infektionen, kardiovaskulärer, entzündlicher, Sinnes-Störungen, Schmerzen und 
Krebs mit einbezieht. 
Cannabinoid und adrenerge Rezeptoren gehören zu der Klasse A (ähnlich Rhodopsin) GPCRs. 
Docking von Agonisten und Antagonisten an CB1-und CB2-Cannabinoid-Rezeptoren zeigte die 
Bedeutung eines zentral gelegenen Rotamer Kippschalters und seine mögliche Rolle in dem 
Mechanismus der Agonist/Antagonist-Erkennung. Der Schalter wird von zwei Resten gebildet, F3.36 
und W6.48, die sich auf den gegenüberliegenden Transmembranhelices TM3 und TM6 im zentralen 
Teil   der   Transmembran-Domäne   von   Cannabinoid-Rezeptoren   befinden.   Die   CB1-   und 
CB2-Rezeptor-Modelle   wurden   basierend   auf   dem   Adenosin-A2A-Rezeptor   als   Template 
konstruiert. Die zwei am genausten beschriebenen Konformationen jedes Rezeptors wurden für die 
Docking-Versuche verwendet. In allen Posen (Ligand-Rezeptor-Konformationen), die durch die 
niedrigste intermolekulare Ligand-Rezeptor Energie und freie Bindungsenergie charakterisiert sind, 
entsprach der Liganden-Typ dem Zustand des Rotamer Kippschalters: Antagonisten fixierten einen 
inaktiven Zustand des Schalters, wohingegen Agonisten ihn veränderten. Unter Beibehaltung der 
gleichen   mittleren   Position   des   Liganden   an   der   Bindungsstelle,   haben   die   Molecular 
Dynamics-Simulationen im Falle der β2AR-Agonisten, (R, R)- und (S, S)-Stereoisomere von 
Fenoterol verschiedene Bindungsarten nachgewiesen. Das (S, S)-Isomer war viel labiler in der 
Bindungsstelle und nur eine stabile Wasserstoffbrücke wurde ausgebildet. Solche dynamischen 
Bindungsmodi können vielleicht auch für Liganden von Cannabinoid-Rezeptoren gültig sein und 
dies auf Grund der hydrophoben Natur ihrer Ligand-Rezeptor-Wechselwirkungen. Allerdings können 
nur sehr lange Molekulardynamik-Simulationen die Gültigkeit solcher Bindungsmodi und wie sie 
sich auf den Prozess der Aktivierung auswirken verifizieren. 
Humane N-Formyl Peptidrezeptoren (FPR) sind GPCRs, die an vielen physiologischen Vorgängen 
beteiligt sind, einschließlich Wirtsverteidigung gegen bakterielle Infektion und das Auflösen von 
Entzündungen.   Die   drei   humanen   FPRs   (FPR1,   FPR2   und   FPR3)   zeigen   signifikante 
Sequenzhomologie und erfüllen ihre Wirkung über die Kopplung an das Gi-Protein. Aktivierung von 
FPRs induziert eine Vielzahl von Antworten, welche von Agonist, Zelltyp, Rezeptorsubtyp, sowie 
Spezies abhängig sind. FPRs werden hauptsächlich durch phagozytozische Leukozyten exprimiert. 
Gemeinsam binden diese Rezeptoren eine große Anzahl strukturell verschiedener Gruppen von 
agonistischen Liganden, einschließlich N-Formyl und nicht-Formyl Peptiden unterschiedlicher 
Zusammensetzung, die über Chemotaxis  Phagozyten anziehen und aktivieren. Beispielsweise 
aktiviert N-Formyl-Met-Leu-Phe (fMLF), ein FPR1 Agonist, humane phagozytotische entzündliche 
Antworten, wie intrazelluläre Calciummobilisierung, die Produktion von Zytokinen, Erzeugung von Zusammenfassung 13
reaktiven   Sauerstoffspezies   und   Chemotaxis.   Dieser   Ligand   kann   effizient   die   wichtigsten 
bakterizide Neutrophilen-Funktionen aktivieren und es war eines  der ersten charakterisierten 
bakteriell chemotaktischen Peptide. Während fMLF das bei weitem am häufigsten verwendete 
chemotaktische   Peptid   in   Studien   von   Neutrophilen-Funktionen   ist,   sind   atomistische 
Beschreibungen für den fMLF-FPR1 Bindungsmodus noch mangelhaft, vor allem wegen des Fehlens 
einer   Kristallstruktur   dieses   Rezeptors.  Aufklärung   der   Bindungsmodi   kann   zur   Gestaltung 
neuartiger und effizienter Nicht-Peptid-FPR1 Medikamente beitragen. Molecular Modelling von 
FPR1, auf der anderen Seite, kann eine effiziente Möglichkeit sein, Details der Ligandenbindung und 
Aktivierung des Rezeptors zu offenbaren. Allerdings wurden kürzlich durchgeführte Modellierungen 
von FPRs nur auf Rinderrhodopsin als Vorlage beschränkt. 
Um spezifische Liganden-Rezeptor-Wechselwirkungen auf einer besser geeigneten Vorlage als 
Rhodopsin zu lokalisieren, wurde ein Homologie-Modell von FPR1 mit Hilfe der Kristallstruktur des 
Chemokinrezeptor CXCR4 generiert, das mehr als 30% Sequenzidentität mit FPR1 zeigt und in dem 
gleichen  γ-Strang des Stammbaums der GPCRs zugeordnet ist (Rhodopsin gehört zum α-Strang). 
Danach wurden Docking und Verfahren zur Modellverfeinerung verfolgt. Schließlich wurden 40 ns 
Full-Atom MD Simulationen für die Apo-Form sowie für Komplexe aus fMLF (Agonist) und 
tBocMLF (Antagonist) mit FPR1 in der Membran durchgeführt. Basierend auf der Lokalisierung der 
N-und C-Termini des Liganden konnte die extrazelluläre FPR1-Bindetasche in zwei Zonen unterteilt 
werden, nämlich den Anker- und die Aktivierungs-Regionen. Der formylierte M1-Rest von fMLF 
gebunden an den Aktivierungsbereich führte zu einer Reihe von Konformationsänderungen von 
konservierten Resten. Interne Wassermoleküle, die in erweiterte Wasserstoffbrücken-Netzwerke 
beteiligt   sind,   spielen   eine   entscheidende   Rolle   beim   Übertragen   der 
Agonist-Rezeptor-Wechselwirkungen. Ein Mechanismus der ersten Schritte der Aktivierung bei 
gleichzeitiger Ligandenbindung wird vorgeschlagen. 
Die Struktur und Ligandenbindungs-Pose des Dopamin-Rezeptor-3 (RMSD mit der Kristallstruktur: 
2.13 Å) und Chemokinrezeptor 4 (CXCR4, RMSD mit der Kristallstruktur 3,21 Å) wurde mit hoher 
Genauigkeit im GPCR-Dock 2010 Wettbewerb vorhergesagt. Dabei erzielte das hier beschrieben 
Homologie-Modell des Dopamin-Rezeptor-3 die achtbeste Gesamtleistung. Summary 14
Summary
Alzheimer’s disease (AD), which was first reported more than a century ago by Alhzeimer, is one of 
the commonest forms of dementia which affects >30 million people globally (>8 million in Europe). 
The origin and pathogenesis of AD is poorly understood and there is no cure available for the 
disease. AD is characterized by the accumulation of senile plaques composed of amyloid beta 
peptides (Ab 37-43) which is formed by the gamma secretase (GS) complex by cleaving amyloid 
precursor protein. Therefore GS can be an attractive drug target. Since GS processes several other 
substrates like Notch, CD44 and Cadherins, nonspecific inhibition of GS has many side effects. Due 
to the lack of crystal structure of GS, which is attributed to the extreme difficulties in purifying it, 
molecular modeling can be useful to understand its architecture. So far only low resolution cryoEM 
structures of the complex has been solved which only provides a rough structure of the complex at 
low 12-15 A resolution  Furthermore the activity of GS in vitro can be achieved by means of cell-free 
(CF) expression.
GS comprises  catalytic subunits namely presenilins and supporting elements containing Pen-2, 
Aph-1 and Nicastrin. The origin of AD is hidden in the regulated intramembrnae proteolysis (RIP) 
which is involved in various physiological processes and also in leukemia.  So far growth factors, 
cytokines, receptors, viral proteins, cell adhesion proteins, signal peptides and GS has been shown to 
undergo RIP. During RIP,  the target proteins undergo extracellular shredding and intramembrane 
proteolysis.
This thesis is based on molecular modeling, molecular dynamics (MD) simulations, cell-free (CF) 
expression, mass spectrometry, NMR, crystallization, activity assay etc of the components of GS 
complex and G-protein coupled receptors (GPCRs). 
First  I validated the NMR structure of PS1 CTF in detergent micelles and lipid bilayers using 
coarse-grained MD simulations using MARTINI forcefield implemented in Gromacs. CTF was 
simulated in DPC micelles, DPPC and DLPC lipid bilayer. Starting from random configuration of 
detergent and lipids, micelle and lipid bilyer were formed respectively in presence of CTF and it was 
oriented properly to the micelle and bilyer during the simulation. Around DPC molecules formed 
micelle around CTF in agreement of the experimental results in which 80-85 DPC molecules are 
required to form micelles. The structure obtained in DPC was similar to that of NMR structure but 
differed in bilayer simulations showed the possibility of substrate docking in the conserved PAL 
motif. Simulations of CTF in implicit membrane (IMM1) in CHAMM yielded similar structure to 
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I performed cell-free expression optimization, crystallization and NMR spectroscopy of Pen-2 in 
various detergent micelles. Additionally Pen-2 was modeled by a combination of rosetta membrane 
ab-initio method, HHPred distant homology modeling and incorporating NMR constraints. The 
models were validated by all atom and coarse grained MD simulations both in detergent micelles and 
POPC/DPPC lipid bilayers using MARTINI forcefield. 
GS operon consisting of all four subunits was co-expressed in CF and purified. The presence of of 
GS subunits after pull-down with Aph-1 was determined by western blotting  (Pen-2)  and mass 
spectrometry (Presenilin-1 and Aph-1).  I also studied interactions of especially PS1 CTF, APP and 
NTF by docking and MD. 
I also made models and interfaces of Pen-2 with PS1  NTF  and checked their stability by MD 
simulations and compared with experimental results. The goal is to model the interfaces between GS 
subunits   using   molecular   modeling   approaches   based   on   available   experimental   data   like 
cross-linking, mutations and NMR structure of C-terminal fragment of PS1 and transmembrane part 
of APP. The obtained interfaces of GS subunits may explain its catalysis mechanism which can be 
exploited for novel lead design. Due to lack of crystal/NMR structure of the GS subunits except the 
PS1 CTF, it is not possible to predict the effect of mutations in terms of APP cleavage. So I also 
developed a sequence based approach based on machine learning using support vector machine to 
predict the effect of PS1 CTF L383 mutations in terms of Aβ40/Aβ42 ratio with 88% accuracy. 
Mutational data derived from the Molgen database of Presenilin 1 mutations was using for training. 
GPCRs (also called 7TM receptors) form a large superfamily of membrane proteins, which can be 
activated by small molecules, lipids, hormones,  peptides, light, pain, taste and smell etc. Although 
50% of the drugs in market target GPCRs , only few are targeted therapeutically. Such wide range of 
targets is due to involvement of GPCRs in signaling pathways related to many diseases i.e. dementia 
(like   Alzheimer's   disease),   metabolic   (like   diabetes)   including   endocrinological   disorders, 
immunological including viral infections, cardiovascular, inflammatory, senses disorders, pain and 
cancer. 
Cannabinoid and adrenergic receptors belong to the class A (similar to rhodopsin) GPCRs. Docking 
of agonists and antagonists to CB1 and CB2 cannabinoid receptors revealed the importance of a 
centrally located rotamer toggle switch, and its possible role in the mechanism of agonist/antagonist 
recognition. The switch is composed of two residues, F3.36 and W6.48, located on opposite 
transmembrane helices TM3 and TM6 in the central part of the membranous domain of cannabinoid 
receptors. The CB1 and CB2 receptor models were constructed based on the adenosine A2A receptor 
template. The two best scored conformations of each receptor were used for the docking procedure. 
In   all   poses   (ligand-receptor   conformations)   characterized   by   the   lowest   ligand-receptor Summary 16
intermolecular energy and free energy of binding the ligand type matched the state of the rotamer 
toggle switch: antagonists maintained an inactive state of the switch, whereas agonists changed it. In 
case of agonists of β2AR, the (R,R) and (S,S) stereoisomers of fenoterol, the molecular dynamics 
simulations provided evidence of different binding modes while preserving the same average 
position of ligands in the binding site. The (S,S) isomer was much more labile in the binding site and 
only one stable hydrogen bond was created. Such dynamical binding modes may also be valid for 
ligands of cannabinoid receptors because of the hydrophobic nature of their ligand-receptor 
interactions. However, only very long molecular dynamics simulations could verify the validity of 
such binding modes and how they affect the process of activation.
Human N-formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) involved in 
many physiological processes, including host defense against bacterial infection and resolving 
inflammation. The three human FPRs (FPR1, FPR2 and FPR3) share significant sequence homology 
and perform their action via coupling to Gi  protein. Activation of FPRs induces a variety of 
responses, which are dependent on the agonist, cell type, receptor subtype, and also species involved. 
FPRs are expressed mainly by phagocytic leukocytes. Together, these receptors bind a large number 
of structurally diverse groups of agonistic ligands, including N-formyl and nonformyl peptides of 
different   composition,   that   chemoattract   and   activate   phagocytes.   For   example, 
N-formyl-Met-Leu-Phe   (fMLF),   an   FPR1   agonist,   activates   human   phagocyte   inflammatory 
responses, such as intracellular calcium mobilization, production of cytokines, generation of reactive 
oxygen species, and chemotaxis. This ligand can efficiently activate the major bactericidal neutrophil 
functions and it was one of the first characterized bacterial chemotactic peptides. Whereas fMLF is 
by far the most frequently used chemotactic peptide in studies of neutrophil functions, atomistic 
descriptions for fMLF-FPR1 binding mode are still scarce mainly because of the absence of a crystal 
structure of this receptor. Elucidating the binding modes may contribute to designing novel and more 
efficient non-peptide FPR1 drug candidates. Molecular modeling of FPR1, on the other hand, can 
provide an efficient way to reveal details of ligand binding and activation of the receptor. However, 
recent modelings of FPRs were confined only to bovine rhodopsin as a template. 
To locate specific ligand-receptor interactions based on a more appropriate template than rhodopsin 
we generated the homology models of FPR1 using the crystal structure of the chemokine receptor 
CXCR4, which shares over 30% sequence identity with FPR1 and is located in the same γ branch of 
phylogenetic tree of GPCRs (rhodopsin is located in α branch). Docking and model refinement 
procedures were pursued afterward. Finally, 40 ns full-atom MD simulations were conducted for the 
Apo form as well as for complexes of fMLF (agonist) and tBocMLF (antagonist) with FPR1 in the Summary 17
membrane. Based on locations of the N- and C-termini of the ligand the FPR1 extracellular pocket 
can be divided into two zones, namely, the anchor and activation regions. The formylated M1 residue 
of fMLF bound to the activation region led to a series of conformational changes of conserved 
residues. Internal water molecules participating in extended hydrogen bond networks were found to 
play a crucial role in transmitting the agonist-receptor interactions. A mechanism of initial steps of 
the activation concurrent with ligand binding is proposed. 
I accurately predicted the structure and ligand binding pose of dopamine receptor 3 (RMSD to the 
crystal structure: 2.13 Å) and chemokine receptor 4 (CXCR4, RMSD to the crystal structure 3.21 Å) 
in GPCR-Dock 2010 competition. The homology model of the dopamine receptor 3 was 8 th best 
overall in the competition.  Summary 18
Part I: Cell-free expression of the γ-secretase complex 
1 Introduction
1.1 Alzheimer's Disease
Alzheimer's Disease (AD) first described by Alzheimer in 1907 is one of the most common forms of 
dementia affecting the elderly [1]. It affects >30 million people worldwide (>8 million in Europe), 
and is a leading cause of death among the elderly population. It is projected to affect >1% population 
globally by 2050 [2].  The disability caused by AD among people older than 60 years is higher than 
that of cancer, stroke and cardiovascular disease. As a result the economic cost of treating AD is very 
high. AD is characterized by the progressive decline in memory and cognitive abilities. 
Currently there is no cure available to stop progression of AD, and therefore novel drugs are urgently 
required. Four drugs currently approved for AD e.g. tacrine, donepezil, rivastigmine, galantamine, 
and memantine only provides temporary relief. Memantine is an NMDA receptor antagonist while 
others are acetylcholinesterase inhibitors [3].  
There are two types of AD - early onset or Famial Alzheimer's Disease (FAD) and late onset. Early 
onset AD affected patients (~5%) have mutations in the genes related to the processing of APP (i.e 
Presenilin). The most prevalent late onset AD mainly affects people older than 65 years. The exact 
mechanism of development and progression of AD is controversial although Amyloid cascade 
hypothesis widely accepted. Review by Jakob-Roetne et al 2009 provides a good overview on it. The 
hypothesis states that the formation and aggregation of Aβ oligomers extracellularly (known as senile 
plaques) and tau proteins intracellularly (known as neurofibrillary tangles) and on the walls of 
cerebral blood vessels [4] resulting in malfunction and loss of synapse and neurons leads to AD. The 
aggregation of tau protein is proposed to be due to the imbalance between Aβ production and 
clearance. Loss of neurons takes place mainly in cortex and hippocampus (Fig 1.1).
The origin of AD is hidden in the regulated intramembrnae proteolysis of APP which is involved in 
various physiological processes and also in leukemia [5]. γ-secretase complex (GS) (Fig  1.3) is an 
intramembrane cleaving protease (iCLIP) [6] that cleaves the Amyloid Precursor Protein into 
Amyloid β peptides (Aβ 39-43), which aggregate in the brain of the Alzheimer's patients as senile 
plaques. So GS is a potential target for drugs and compounds that modulate its activity. Introduction 19
1.2 Regulated Intramembrane Proteolysis (RIP)
1.2.1 Overview
The cell uses a variety of ways to communicate or respond to the environment. Regulated 
Intramembrane Proteolysis (RIP) is one of the many ways of doing that. For detailed review of RIP, 
refer to [5,7]. The term RIP was coined by Brown et al in 2000 when only a handful of proteins were 
found to undergo two step processing: extracellular shredding and intramembrane proteolysis [8]. 
Recent evidences suggest that RIP is not only involved in normal physiological processes but also in 
disease. More than 60 substrates of RIP have been identified so far [9,10] Substrates of RIP include 
growth factors, cytokines, receptors, viral proteins, cell adhesion proteins, signal peptides etc have 
been shown to undergo RIP [7,8]. (Table 1) Lack of proper RIP leads to diseases like AD and 
leukemia. RIP takes place not only in plasma membrane, but also in golgi apparatus and endoplasmic 
reticulum. RIP is involved in signal transduction during growth, development, immune response, cell 
differentiation, transcriptional regulation, cell adhesion, axon guidance, lipid metabolism etc [10]. 
Soluble intracellular protein products of RIP either act as signal transducer or transcription factor (i.e. 
Notch, Growth Factors, CD44, TNF alpha) or gets degraded [11]. Although several hundred proteins 
are subjected to shredding of the juxtamembrane domain, the following intramembrane cleavage is 
yet to be determined for many of them [12]. For instance matrix metalloproteinases also cleave 
membrane proteins without leading to transmembrane cleavage. However it is still not clear how the 
Fig 1.1 Diagram showing various characteristics of AD: deposition of amyloid plaques and tau 
proteins   resulting   in   neuronal   death   and   shrinking   of   brain   regions.   Source: 
http://sierram.web.unc.edu/2011/04/22/caffeine-and-alzheimers-disease/Introduction 20
substrate recognition takes place during RIP and what are the common features of various RIP.
Generally proteases are classified into Serine, Threonine, Cysteine, Aspartate, Metalloproteases and 
Glutamic proteases. However the initial shredding of the substrate ectodomain is carried out by so 
called shredders which include:
• ADAM (a disintegrin and metalloprotease) family
• aspartyl proteases β-site APP-cleaving enzymes (BACE1/2)
The following transmembrane cleavage is carried out by intramembrane cleaving proteases (I-CLiPs) 
[6] which consists of:
• GxGD type aspartyl protease (G- Gly, x – any amino acid, D – Asp): GS, SPP, SPPLs, 
bacterial type four prepilin peptidases
• S2P metalloproteases  (zinc metalloprotease site 2 protease)  : S2P  is  involved in  the 
processing of sterol regulatory element binding protein. It has 4 TMDs and HEXXH motif.
• rhomboid serine proteases
1.2.2 Common Principles of RIP
• Substrate is a transmembrane protein
• Proteolysis is mediated by an I-CIiP
• Hydrolysis occurs within/close to the membrane
• Regulation by biological stimuli
• The cleaved intracellular domain of the substrate possesses a signaling function
• RIP results in a defined biological response [7]
1.2.3 I-CLiPs
I-CLiPs are integral membrane proteins which carry their active sites in the hydrophobic helices 
buried inside the hydrophobic membrane environment as shown in the crystal structure of rhomboid 
protease GlpG from E. coli [6,13]. Also the catalysis takes place in presence of water inside the 
membrane cavity. In case of GlpG, the catytic driad consists of His and Ser and is situated ~10 A 
below the membrane lumen interface in a water cavity formed by 6 transmembrane helices. The 
substrate enters into the hydrophobic cavity in a stepwise manner as revealed in case of GlpG where 
substrate enters between TM 3 and TM 5 in which TM 5 can be gating helix which modulate 
substrate accessibility to the active site [14,15]. Similar strategy for substrate catalysis is probably 
shared by other members of the family.
Often the I-CLiPs don't function until the length of the ectodomain of the substrate is reduced to <30 
amino acids by shredding at the extracellular scissile peptide bond.  Probably the longer substrates 
can not penetrate into the I-CLiP active site due to steric clashes. However rhomboid does not 
require prior cleavage of substrate unlike GS  [6].  Just the opposite i.e. extracellular shredding Introduction 21
without intramembrane cleavage takes place  in glycosyl phosphatidy inositol (GPI) anchored 
proteins like prion which is bereft of a transmembrane segment [12]. Failure of RIP regulation i.e. in 
case of Notch, higher and lower Notch signaling results in Leukemia and developmental defects 
respectively. In case of beta-secretase, higher RIP results in early onset AD.  Unraveling the 
regulatory mechanisms of RIP can be of potential benefit to drug targeting against various diseases. 
The regulation mostly takes place during ectodomain shredding. 
1.2.4 RIP of APP
One of the first discovered substrate of RIP is type I membrane protein APP, which was studied in 
detail in the past decade. APP undergoes initial juxtamembrane shredding either by α-secretase 
(which was identified to be ADAM10) or by β-secretase (which is BACE1). The product of BACE1 
is called APPsβ which is released in the lumen and the membrane bound c99, which is further 
cleaved by the GS resulting in Ab 37-43 peptides, which are released in lumen whereas the other 
product AICD (APP intracellular domain)  goes to the cytosol triggering signal transduction 
pathways. Ab42 and Ab38 species were shown to be the causative agents of the senile plaques 
observed in AD patients. Therefore both BACE1 and GS were subjects of intense research since past 
decade. 
In the alternative pathway, APP is cleaved to membrane bound c83 and soluble APPsα which is 
released in the lumen and is shown to have neurotropic effects. c83 is then cleaved by GS giving rise 
to p3 peptide released in the lumen is not pathogenic. α-, β- secretase compete with each other to 
process the APP.
Recently the structure of APP was solved (PDB ID: ) by NMR in LMPG micelles [16]. TMD of APP 
Fig  1.2  Sequential cleavage  (RIP) of 
APP by α-, β- and γ-secretase. APP is 
cleaved   in   two   competing   pathways: 
amyloidogenic and non-amyloidogenic. 
In amyloidogenic pathway, APP is first 
cleaved   by   β-secretase   in   the 
extracellular domain resulting in soluble 
APP   ectodomain   (APPsβ)   and 
membrane bound C-terminal 99 amino 
acid long fragment of APP called C99. 
C99 is futher cleaved by I-CLiP GS 
giving Aβ 37-43 species which is goes to 
the lumen and APP intracellular domain 
(AICD) secreted in the cytoplasm. On 
the   contrary   in   non-amyloidogenic 
pathway ADAM  metalloprotease α-secretase shreds APP giving rise to soluble APP ectodomain 
APPsα and C-terminal 83 amino acid long fragment of APP called C83. Then GS cleaves C83, 
producing secreted p3 peptide and AICD. Figure adapted from [5]Introduction 22
is a curved helix making it suitable for progressive cleavage by GS. The conserved GxxxG motif 
APP  (700-704)  which is involved in its dimerization also binds to cholesterol. Gly708 renders 
flexibility of APP. G700AIIG704 segment of APP plays pivotal role in biogenesis of Ab39-43 species. 
Pairwise replacement of Gly with Leu in APP enhances homodimerization but leads to a drastic 
reduction of Abeta secretion. Replica exchange MD simulations reveal that dimerization of the WT 
APP is mediated by  C(alpha)-H...O hydrogen bonds between two APP fragments contrary to the 
hydrophobic interactions responsible for the dimerization of the mutant. So in the tilted mutant the 
gamma cleavage site is shifted resulting in inhibition of Ab production [17,18] . 
1.3 GxGD type protease γ-Secretase (GS)
γ-Secretase (GS)  (for review see:  [19])  is an  ICLiP  (i.e. it processes its substrates inside the 
membrane in presence of water), which cleaves the amyloid precursor protein to amyloid beta 
peptides (Aβ 37-43), that accumulate in the brains of Alzheimer's patients as senile plaques. GS 
comprises four subunits aka, Presenilins (PS1 and PS2), Presenilin Enhancer 2 (Pen-2), Anterior 
pharynx defective phenotype 1 (Aph-1) and Nicastrin which together have in total 19 transmembrane 
spanning domains [20]. Presenilin 1 acts as the catalytic subunit of the complex harbouring two 
cataytic aspartate residues in N- and C-terminal fragments (NTF TMD 6- D257 and CTF TMD7 – 
D385) [21]. GS also cleaves Notch among many other substrates, and it was shown to be functional 
in vivo in presence of Pen-2 [22]. 
Fig 1.3 Schematic representation (A) and interactions (B) of the GS components Pen-2, Presenilin 
(NTF and CTF), Nicastrin and Aph-1. APP is processed by the catalytic aspartates located in the 
TMD 6 (NTF) and TMD 7 (CTF) of presenilin. NTF and CTF is formed by autoproteolysis by 
presenilin. B. Pen-2 was shown to interact with PS1 NTF whereas PS1 CTF, Aph-1 and Nicastrin 
interacts with each other [447].Introduction 23
Pen-2 plays crucial role in origin, maturation and functioning of the complex. Pen-2 is involved in 
the autoproteolysis of the PS1 into NTF and CTF, which is required for its functioning. Pen-2 
associates with NTF and the complex of CTF, Aph-1 and Nicastrin to form an active GS complex. 
GS also plays important role in tumor development and cancer progression through APP and Notch 
[23].  
The usefulness of GS as a drug target is limited by the fact that it has several other substrates 
including Notch, Cadherins, CD44 etc which are essential for viability. Consequently, nonspecific 
inhibition of GS have major side effects. Therefore the knowledge of the 3D architecture of the 
complex is required for rational drug design [5]. 
There are two isoforms of Presenilin : PS1 and PS2 and also Aph-1: Aph-1a and Aph-1b. Aph-1a can 
further have short (Aph-1aS) and long (Aph-1aL) splice variants [24]. However both of these PS 
isoforms are not associated to the complex simultaneously [25]. Thus there are six plausible GS 
complexes. However the role of these various GS  variants in pathogenesis of AD  has not been 
studied in detail. But specific inhibition of Aph1B GS reduced the phenotypes observed in mouse 
model of AD without affecting notch signalling [26]. However all the isoforms have been shown to 
form functional GS complex despite showing heterogeneity in substrate processing [27]. Although 
the activity of GS have been established in vitro only in presence of PS1 and Pen-2, nevertheless all 
four subunits are required for its functioning in vivo  [20,22]. The most studied  components of 
complex consist of PS1, Pen-2, Aph-1 and Nct. 
1.3.1 Structure and interaction between the subunits
GS subunits PS1, Pen-2, Aph-1 and Nct have 9, 2, 1, 7 TMDs respectively i.e. 19 TMDs in total. 
However crystallographic structure determination of the complex has not been possible so far due to 
technical difficulties in obtaining high amounts of the complex required for crystallization. So far 
only low resolution cryoEM structures of the complex has been solved which only provides a rough 
structure of the complex at low 12-18 Å resolution [28–30].
However the low resolution maps fail to deliver any information on molecular interactions between 
GS   subunits.  The   cyroEM   structure   has  several   domains   on   the   extracellular   side,   three 
solvent-accessible low-density cavities and a potential substrate-binding surface groove in the 
transmembrane region [29].Introduction 24
However biochemical chemical cross-linking and cysteine cross-linking experiments have revealed 
some conserved residues involved in the interface between GS subunits.  For example, the conserved 
WNF motif of PS1 TMD4 is interacting with another N in Pen-2 TMD1. However it is controversial 
whether the interacting N is located in N-termini or C-termini of Pen-2 TMD1. Pen-2 and PS1 NTF 
were shown to form separate complex than that of PS1 CTF, Nct and Aph-1 complex [31–33]. WNF 
motif of PS1 TMD4 was also shown to be involved in ER retention and retrieval. Further NN motif 
of Pen-2 TMD1 was proposed to bind to PS1 TMD4 [33]. TMD 1 and 8 of PS are close to each other 
and might interact with the active site. TMD 8 is a distorted form of an ideal helix [34]. Gly 22 and 
Pro 27 of Pen-2 was found to be essential for GS complex formation. The TMD 9 is also in close 
proximity to the active site [35].  PAL motif and TMD 9 of PS are involved in the formation of the 
catalytic pore [36]. 
Mutations in TMD4 (G126) and TMD5 (H171) of Aph-1aS inhibits the formation of the Nct/Aph-1 
subcomplex. Although mutations in TMD3 (Q83/E84/R85) and TMD6 (H197) of APH-1aS does not 
Fig  1.4  A comparison of 
the   γ-secretase   cryo-EM 
structure with the crystal 
structures of the bacterial 
and   archaeal 
intramembrane   proteases. 
Figure adapted from [29]. 
Fig 1.5: Intra- and intermolecular interactions in the 
γ-secretase complex. Given the hydrophobic nature 
of   γ-secretase,   most   prominent   and   primary 
interactions are likely to be governed through or 
include their TMDs and hydrophobic domains. Here 
we present a bird's eye view of the TMDs of PS1 
(yellow), NCT (green), APH1 (blue) and PEN2 (red), 
including   the   reported   intra-   (grey   arrows)   and 
intermolecular   (black   arrows)   interactions. 
Suggested interactions are shown by dotted arrows, 
such as intramolecular interactions in APH1 (via 
GxxG   motifs   in   TMD4)   and   the 
as-yet-uncharacterised interaction domains for APH1 in PS1 and for NCT in APH1. Ectodomain 
interactions of NCT with APP-CTF are indicated with a green arrow (see text for details). The 
red sparkle denotes the catalytic aspartate dyad. Figure adapted from [38]Introduction 25
affect  subcomplex  formation,  they   inhibit  further   association   and  autoproteolysis  [37].  Two 
conserved His 171 and His 197 of Aph-1 has been shown to be important for GS activity.
1.3.2 Processing and Maturation of GS
After ribosomal translation, GS is assembled first in ER where Nct and Aph-1 forms initial complex 
(Reviewed in [38]) which then associates to PS. Next Pen-2 enters in the trimeric complex leading to 
the endoproteolysis of PS into NTF and CTF [39]. Thus Pen-2 is involved in the maturation and 
stabilizing the complex. Then the complex is transported to the plasma membrane through ER and 
golgi apparatus. Glycosylation of Nct takes place in golgi complex. ER retains the unassembled PS 
and Pen-2 [40,41]. Additional S-palmitoylation of Nct and Aph-1 is observed [42]. 
1.3.3 Endoproteolysis of PS
It is not yet fully understood, how the  endoproteolysis  of PS takes place inside the membrane. 
However ε-, ζ-, and γ-like sites of endoproteolysis have been identified at amino acids 292/3 (minor), 
295/6, 298/9 (major) (Fig 1.6) [43]. The hydrophobic nature of the amino acids around the sites 
probably helps it to enter plasma membrane for a stepwise cleavage. It was shown that the cleavage 
occurs in successive interval of three amino acids each like in APP [44]. This helps in getting rid of 
the products from the catalytic pore which harbors the aspartates in TMD6 and 7 in NTF and CTF 
respectively. This stepwise cleavage was also found for APP which will be discussed in detail in the 
following paragraphs. However it is not clear how GS processes type-II membrane protein unlike the 
related SPP or SPPLs. Autoproteolysis of GS is necessary for its functionality. Mutation in one of the 
catalytic aspartates can block endoproteolysis  [21].  It has been proposed that exon-9 encoded 
autoproteolysis site actually keeps the GS in inactive form to prevent it from non specific substrate 
cleavage [45]. 
1.3.4 ER Retention Signals
ER retention signals are important for studying subunit interactions of GS. The rention signals are 
masked during GS complex formation by its subunit interaction which results in the secretion of 
mature GS complex. Uncomplexed GS members are retained in the ER in this manner. Presenilin 
C-terminus is required for binding to Nicastrin, ER retention and GS activity  [46].  Rer1p 
(endosplasmic retention factor 1p)  competes with APH-1 for binding to  the polar residues of 
nicastrin TMD and is involved in its ER retention [47]. These signals are different from RXR ER 
retention signals in ion channels [48].  
Only fully assembled complexes are transported from ER which retains the unassembled subunits. 
Pen-2 and TMD 4 of PS carry ER retention/retrieval signals. When both of them interact, the ER Introduction 26
retention signal is masked, and it allows surface transport of GS complex [41]. Unassembled TMD1 
of Pen-2 interacts with ER retention factor Rer1 to stay attached to the ER [40].Over expression of 
Rer1 retains unassembled Pen-2 in ER. ER retention/retrieval signals like RXR are found in many 
ion channels. ER retention factors like Rer1 interacts with the polar residues of the membrane 
proteins [48]. 
Recent studies indicate that during AD, PS is found in high amounts in subcompartment of the 
endoplasmic reticulum (ER) that is physically and biochemically connected to mitochondria, called 
mitochondria-associated ER membranes (MAMs).These finding explain including altered lipid 
metabolism and calcium homeostasis during AD [49]. 
1.3.5 Stoichiometry
The stoichiometry of the complex was determined to be 1:1:1:1 which is in agreement with the 
molecular weight of each component [50]. However the MW of it varies from 250 kDa to 2000 kDa 
in literature  depending on the method used for determining the MW, albeit agreeing the same 
stoichiometry [29]. But there are some evidences of dimeric GS with 2:2:2:2 stoichiometry [51]. 
1.3.6 Individual subunits of GS
All GS subunits are integral membrane proteins. 
Presenilin (PS): Presenilin is an integral membrane protein in type II orientation. N and C-termnal 
fragment of PS spans the membrane 6 and 3 times respectively [52,53].  Recent evidences suggest 
that from TMD4, only N204 interacts with Pen-2, D194, T197 and N204 is involved in ER retention 
and D194 is required for complex stability. Most of the mutations during FAD are linked to PS. 
Pen-2: Pen-2 is a 101 amino acid long double membrane spanning type 1 membrane protein which 
has both N and C-terminal facing the lumen [54]. It was identified in a genetic screen for modulators 
of PS activity in C. elegans [55]. In absence of Pen-2, APP and Notch can't be processed by PS. 
Pen-2 is involved in the endoproteolysis of GS as shown by RNA interference  [39].  There are 
N-linked glycosylation sites only in N and C-termininal loop of Pen-2.    Further glycosylated 
N-terminal of Pen-2 fails to bind to PS [54].  
Biochemical experiments indicated that residues 18-38 and 58-80 form TMDs. DYSLF domain of 
Pen-2 (residues 90-94) at C-termini is responsible for binding to PS [56]. Incorporation of FLAG tag 
in C-termini of Pen-2 increases Ab42/40 ratio  [57]. Furthermore, various GS modulators which 
lowers Ab42 were found to only bind to Pen-2. Cross-linking indicates that Pen-2 and PS1 CTF are 
in close proximity [58]. 
Aph-1  and  Nicastrin:  Glycoprotein  Nicastrin is the largest subunit of the complex in type I Introduction 27
transmembrane orientation.  However it has only one membrane spanning domain and it modulates 
presenilin mediated APP and notch processing [59]. Aph-1 interacts with Nct and PS CTF. Aph-1 
TMD 5 (H171), 6 (H197A) were demonstrated to be vital for GS complex formation and stability 
[60]. Residues 245-630 are important for APP and Notch processing. This region consists of DAP 
domain (DYIGS and peptidase; residues 261-502), that is homologous to a tetratricopeptide repeat 
(TPR) domain commonly involved in peptide recognition. Leu571 in the TPR domain is involved in 
substrate binding [61,62]. 
1.3.7 GS regulating enzymes
Transmembrane protein 21 (TMP21, a member of the p24 cargo protein family) [63] γ-secretase 
activating protein (GASP) (He et al. 2010) has been shown to regulate GS activity. GASP increases 
Aβ production by interacting with GS and APP. However it neither interacts with Notch nor affects 
its cleavage. Knockdown of GASP results in decreased  Aβ production in mouse.  Anticancer drug 
imatinib inhibits GASP to reduce  Aβ  formation in AD.  However  TMP21 and GASP  are not 
associated (does not form complex) with GS.
1.3.8 Stepwise substrate processing in the water cavity
Residues in the catalytic water pore
PS TMD 6 (NTF) and 7 (CTF) harbouring the catalyic aspartate dyad are implicated to be present in 
the water containing cavity in GS [64]. Additionally the GxGD and the conserved PAL (pro, ala, leu) 
motif of CTF which is in close proximity TMD 6 is water accesible [36,65,66]. Futher, TMD 1 and 9 
of PS1 has been implicated to be present in the water cavity. TMD 1 is in proximity to GxGS and 
PAL motifs of PS CTF [67].  PAL motif is required for normal active site conformation but not for 
ER retention and GS complex formation [66]. 
The aspartate in TMD 7 (CTF) is a part of GxGD motif which is also found in other proteases [68]. 
There are initial substrate binding sites in PS TMD2 and 6 [69]. TMD1 of PS1 is a part of the 
catalytic pore [67]. 
APP is cleaved by GS in stepwise fashion in short intervals to get rid of hydrophobic APP from the 
membrane. First the cleavage occurs in ε-site (Leu 49) which is very close to the membrane [70] (Fig 
1.6) which releases AICD. It is followed by the cleavage of the intramembrane Αβ49 at the ζ-site to 
generate Αβ46 [71]. Then GS cleaves at multiple γ-sites [72] giving rise to  Αβ43,  Αβ40, Αβ37 
where  Αβ40 is the major product. However these cleavages are hetergeneous giving rise to two 
product lines with 3 amino acid intervals major product line : Αβ49-37 (main product Αβ40) and 
minon product line Αβ48-39 (main product: Αβ42 and Αβ38 which are the causative agents of AD) 
[73].  Presence of the successive release of tri- and tetra-peptides from APP have been elucidated Introduction 28
[74]. It has been known that mutations at the GxxxG motif of APP decreases Αβ42 production. The 
GxxxG motif promotes APP dimerization,  Of late, it has been found that due to steric hindrance, 
stepwise cleavage of dimeric APP by GS stops at γ-42 unlike going to γ-38 site. Consequently, higher 
amounts of Αβ42 is produced [75]. 
This stepwise cleavage of APP at ε-, ζ-, and γ-like sites separated by 3 amino acids has been also 
founding during autoproteolysis of PS and cleavage of TNF-alpha by SPPL2b [44]. Similar type of 
step by step cleavage of Notch1 and APLP1 and CD44 has been detected [76]. Lately a coding 
mutation (A673T) in the APP gene was demonstrated to protect against AD. The mutation is to the 
aspartyl protease β-site of APP and reduces Ab production by 40% in vitro [77].
Fig 1.6 Stepwise cleavage of substrates by GxGD proteases. (Top) GS cleavage sites in the APP 
transmembrane domain (TMD) are shown in thick (major cleavage sites) and thin (minor cleavage 
sites) vertical arrows. The direction of the cleavages are given by horizontal arrows. The three step 
cleavage of APP from  ε49 –γ37  gives rise to Aβ40  as a major product. In the alternative three step 
cleavage from ε48 –γ38, Aβ42 emerges as a minor product. White letters indicate the GxxxG 
dimerisation motif in the APP which regulate if Aβ40/Aβ42 will be main product. (middle) Similar 
ε-, ζ-, and γ-like cleavage sites during PS autoproteolysis.  Numbers indicate amino acid number in  
PS  [44].(bottom)   GxGD   protease   SPPL2b   mediated   cleavage   of   TNFα.   In   case   of   PS 
autoproteolysis and  TNFα, the direction of the cleavage is just the opposite [448]. Grey highlight 
indicates predicted TMD. Figure obtained from [5]Introduction 29
Kinetic studies show that FAD mutations affect the production of Aβ species in three ways. FAD 
mutants don't show   -cleavage   ɛ unlike  GS inhibitors which also block Notch processing.    GS 
modulators  increases  carboxypeptidase-like (γ) activity  of GS.  These results could be useful in 
screening GS inhibitors [78]. 
1.3.9 Substrate recognition 
The mechanism of substrate recognition has not been elucidated in detail yet. However evidences 
suggest that the substrate binding site is different from the active site [79]. Glu 333 of Nct has been 
shown to bind to substrate and participate in GS activity [80]. However there are contradictory 
evidences suggesting that GS is functional in absence of nicastrin  [81]. Aph-1 has also been a 
candidate for substrate interaction prior to cleavage [82]. Another evidence suggest that the initial 
substrate binding site is located on presenilin near the active site [35]. Therefore, due to the close 
proximity of the docking site compared to the active site, any mutation near the active site i.e. in the 
GxGD motif has drastic effects on GS activity.  Also mutations in the PAL motif results in hampering 
of substrate cleavage  [66].  Further, the juxtamembrane, TMD and ICD can influence substrate 
processing by GS [83]. 
1.3.10 Effect of PS Mutations
The Aβ42/40 ratio is increased during FAD [84,85]. Even a negligible increase in the ratio can 
trigger AD by causing synaptic and cellular neurotoxicity. More than 180 mutations in PS1 and a few 
in PS1 has been related to FAD (http://www.molgen.vib-ua.be/ADMutations). Notch signaling is 
often severely affected by these mutations rather than increase in Aβ42 product line [86]. 
1.3.11Relationship with GPCRs and miRNAs
G protein-coupled receptors (GPCRs) mediate various signaling systems in neurons which are 
affected during AD . GPCRs   can modulate α-, β- and γ-secretases, proteolysis of the amyloid 
Fig 1.7: Sequence alignment of the GS substrates Notch, CD44 and APP showing cleavage sitesIntroduction 30
precursor   protein   (APP)   and   regulation   of   amyloid-β   degradation.   Moreove  Aβ   has   been 
demonstrated to rapture GPCR function. Therefore GPCRs can be potential targets for AD [87]. 
1.4 Structure of GxGD type protease
Members of the GxGD family includes preflagellin peptidase, type 4 prepilin peptidase, presenilin 
and signal peptide peptidase (SPP) and signal peptide peptidase like (SPPL). Recently the 6TM 
structure of preflagellin peptidase Flak from Methanococcus maripaludis was solved which shows 
similarity to PS1 CTF structure (PDB: 3S0X) [88]. 
The archaeal site 2 protease (S2P) also has 6 TMDs. The active site containing Zn atom coordinated 
by two histidines is located in the middle of the lipid bilayer 14 A up from the cytosolic surface [89]. 
(PDB ID: 3B4R) 
Fig  1.8  Structural 
Alignment   of 
PS1-CTF   with   Flak 
proteaseIntroduction 31
Table 1. List of selected RIP-mediated LPD signaling events (adapted from [7])
iCLiP
Substrate 
Protein RIP Stimulus LPD Signaling Function Refs.
Presenilin/γ- 
Secretase
APP TAG1 Nuclear signaling, suppression of 
neurogenesis
12
β2 Na channel ?, PMA ?, cell migration 22
CD44 Loss of cell contact, PMA Cell adhesion, nuclear signaling 45
CD74 ? Nuclear signaling via NF-kB  3
Fig 1.9 Structure of the S2P protease shown in 
cartoon   form   which   has   six   transmembrane 
helices. The zinc atom (shown in van der Waal's 
sphere) is coordinating with His54 and His58 
from helix α2 and Asp148 from the N-terminal end 
of helix α4-C.
Fig 1.10 Structure of the GlpG rhomboid protease (PDB ID: 2IC8) [13]. Its structural analysis 
reveals gating mechanism of substrate entry [15]. Introduction 32
iCLiP
Substrate 
Protein RIP Stimulus LPD Signaling Function Refs.
activation
CSF-1 CSF-1, PMA, TLR 
activation
? 17,6
7
E-Cadherin Calcium, apoptosis ?, β-catenin signaling 38,4
0
EpCAM EpCAM ectodomain Nuclear signaling, controls c-myc 
expression and cell proliferation 
37
EphrinB2 EphB Src activation and sprouting of 
endothelial cell
16
ErbB-4 EGF ligands (heregulin) Nuclear signaling, neurogenesis 47,5
3,55
IFNαR2 PMA, IFN-alpha Nuclear signaling 54
Fibrocystin/Po
lyductin
Calcium, PMA, 
Mechanosensation
? 19,2
1
Il-1R2 ?, PMA ? 25
LRP1 ? ?, association with adaptor proteins 42
LRP1B ? Tumor suppression, nuclear 
signaling?
33
LRP6 Wnt3a, PMA Wnt signaling 44
Megalin ?, PMA ?, gene expression 31,7
3
N-Cadherin NMDA receptor agonists Proteasomal-dependent degradation 
of CBP
39,5
2,72
Nectin-1α ?, PMA ?, remodeling of cell-cell junctions 23
Notch Notch-Delta Transcription factor 11
Delta 1, 
Jagged
Nuclear signaling via AP-1 27,5
7
p75 NTR MAG Rho activation, inhibition of neurite 
regeneration
13
RPTP Cell density Dephosphorylation of nuclear 
β-catenin, suppression of β-catenin 
transcriptional activity
1
Ryk Constitutive. Wnt 
stimulates nuclear 
accumulation
Nuclear signaling, neurogenesis 35
SorLA ?, PMA Possible nuclear function 5
Syndecan 3 bFGF, PMA, forskolin Regulation of CASK nuclear 
translocation
56
SPP HCV precore 
protein
? HCV precore protein processing 43,6
5
MHC ? HLA-E signaling 29
Pre-prolactin ? CaM-dependent signaling 66
SPPL2a, 
SPPL2b
TNF-α LPS Pro-inflammatory cytokine (IL-12) 
induction
14–1
5
Bri2(Itm2b) ? ? 41Introduction 33
iCLiP
Substrate 
Protein RIP Stimulus LPD Signaling Function Refs.
S2P ATF6 ER stress, unfolded 
protein
Nuclear signaling, activation of the 
UPR
70
CREB4 ? Nuclear signaling 58
CREBH ER stress, cytokines Nuclear signaling, activation of the 
UPR and APR
72
Luman/CREB
3
ER stress Nuclear signaling, activation of the 
UPR
32,5
0
OASIS ER stress Nuclear signaling, activation of the 
UPR in astrocytes
24,4
6
ER stress-induced bone formation
SREBP Cholesterol levels Nuclear signaling, cholesterol 
biosynthesis
6,51
Rhomboids Spitz, Gurken, 
Keren
? EGF signaling 28,6
2,63
PARL OPA1 ? Mitochondrial remodeling, 
anti-apoptotic
10
? Polycystin-1 ?, mechanosensation Nuclear signaling, JNK, Wnt, 
STAT6 signaling
9,34
• APP,   Alzheimer   precursor   protein;   bFGF,   basic   fibroblast   growth   factor;   CSF-1, 
colony-stimulating factor; EGF, epidermal growth factor; iCLiP, intramembrane-cleaving 
protease; HCV, hepatitis C virus; HLA-E, human lymphocyte antigen E; IFNaR2, type I 
interferon a receptor 2; ll-1R2; interleukin-1 receptor II; LPD, liberated protein domain; LRP, 
low-density lipoprotein-related protein; MAG, myelin-associated glycoprotein; MHC, major 
histocompatibility   complex;   NTR,   neurotrophin   receptor;   PARL,   presenilin-associated 
rhomboid-like; PMA, phorbol 12-myristate 13-acetate; RPTP, receptor protein tyrosine 
phosphatase; S2P, site-2 protease; SPP, signal-peptide peptidase; SPPL, SPP-like; SREBP, 
sterol   regulatory   element-binding   protein;   STAT,   signal   transducers   and   activators   of 
transcription; TLR, Toll-like receptors. 
Fig 1.11 Interactions of presenilin 1 
with various  proteins as found by 
StringDB  by text mining pubmed 
abstracts [449]Introduction 34
1.5 Amyloids and Amylome
Amyloids and prion proteins are thought to be culprits of various age related neurodegenerative 
diseases. However the strength and durability of specific forms of amyloids can be useful not only 
physiologically but also in nanotechnology. Aβ  peptides are  formed by sequential cleavage of 
Amyloid precursor protein (APP) by β and γ-secretase. The function of  APP is not clearly known but 
presumed to be involved in neuronal development.  The length of  Aβ monomer varies from 39-43 
amino acids. But Aβ40 and Aβ42 are most prevalent [90]. Aβ contains hydrophobic C-terminal 
domain which adopts beta-strand structure and the N-terminal region can exist as an alpha-helical or 
beta-strand conformation depending on the environmental condition (pH and hydrophobicity 
surrounding the molecule) [91].
Many proteins can convert into amyloid fibrils either to comply with the physiological needs or as 
part of a pathological scenario. To fight against pathological amyloid states and to stop growth of 
particular   amyloids,   the   prospective   inhibitors   of   amyloid   fibril   formation   may   be   helpful. 
Unfortunately, the structure-based drug design is hampered because amyloid proteins do not have 
defined structures. Nonetheless, in a recent paper [92], the Eisenberg and Baker groups described a 
structure-based design of such inhibitors. They demonstrated that a structure of a short segment 
directly engaged in fibril formation can be sufficient for the design of fibril formation inhibitors and 
that the computational methods may be successful in designing novel peptide–peptide interfaces. The 
inhibitory peptides were designed employing modeled structures of the so-called “steric zippers” 
which are dual β-sheets. One of the inhibitory peptides, consisting exclusively of d-amino acids, 
inhibited the formation of the tau protein tangles associated with Alzheimer’s disease [93]. Its target 
was a hexapeptide VQIVYK corresponding to tau protein residues 306–311. This fragment was 
shown to be important for fibril formation by the full-length tau protein [94,95], and fibrils formed 
by this fragment are similar to full-length tau fibrils. The researchers also designed a non-natural 
l-amino acid inhibitor of the amyloid fibril enhancing transmission of HIV. Its target was also a steric 
zipper structure of the GGVLVN peptide from a fragment of prostatic acid phosphatase [96]. The 
authors designed the specific and tight interface between the inhibiting peptide and the end of the 
steric zipper by maximizing the number of hydrogen bonds and hydrophobic interactions. 
Eisenberg also introduced the concept of amylome [97] defined as a large set of proteins capable of 
forming amyloid-like fibrils. It was suggested in this paper that the amyloid state is accessible to 
many more proteins that was originally thought—not only to those whose entire sequence is engaged 
in amyloid formation. In the classical view, in each disease of amyloid origin, one or two 
fibril-forming proteins were characterized, namely β-amyloid and tau proteins in Alzheimer’s 
disease, α-synuclein in Parkinson’s disease, huntingtin polyglutamine stretch in Huntington’s disease, 
prion protein in Creutzfeldt-Jakob disease and amylin in type II diabetes [98]. Aggregates of these Introduction 35
proteins are toxic, highly stable, and are producing polymer-like amyloids by recruiting normal, 
soluble proteins [99]. 
Eisenberg and coworkers [97] investigated the factors that enable a protein to acquire an amyloidal 
form. It turned out that the major factor responsible for amyloid formation is the presence of a 
segment in the protein that can form a tightly complementary interface with other mostly identical 
segments. Such interface between the segments was named “steric zipper.” It is usually created by 
self-complementary β-sheets that form the amyloid fibril. Another suggested factor is a sufficient 
conformational freedom of the self-complementary segment allowing for interaction with other 
identical   segments.   Eisenberg’s   group   examined   more   than   12,000   proteins   whose   folded, 
three-dimensional (3D) structures are already known. The predictions of an amyloid state were done 
by the modified 3D-Profile method [100] based on the crystal structure of the NNQQNY motif, 
known to form a steric zipper. They computationally examined proteins of three organisms: 
Escherichia coli, Saccharomyces cerevisiae, and Homo sapiens. The method identified protein 
segments with high tendency to form amyloid fibrils and demonstrated that a specific residue order is 
required for fiber formation. These segments were typically about six amino acids long and could be 
exposed for instance during thermal motion of the protein. It was found that 95% of the predicted 
amyloid-prone segments are buried within the protein, and those that are exposed are too twisted and 
inflexible to form a “steric zipper” with partner segments. Using bovine pancreatic ribonuclease A 
(RNase A) as a model system, they experimentally validated the accuracy of predictions and 
investigated the effect of sequence and residue composition. For instance, the FERQHM sequence 
was one of several segments predicted and experimentally confirmed not to form fibrils. However, 
when the residues of this segment were rearranged to QEMRHF, the energy of the rearranged 
segment fell below the formerly estimated threshold of −23 kcal/mol; QEMRHF was thus predicted 
to form fibrils, which was subsequently confirmed by EM images. On the contrary, the fibril-forming 
segments QANKHI and STMSIT were rearranged to IHKAQN and ISMTTS, respectively. The 
rearranged sequences were predicted not to form fibrils, and it was also confirmed by experimental 
methods. Such shuffling experiments suggest that the tendency to form amyloid-like fibrils is 
strongly sequence-dependent and relatively insensitive to amino acid composition. 
In earlier research it has also been shown [101,102] that many globular proteins can be converted to 
the amyloid state by a variety of denaturing processes, suggesting that conversion may generally be 
applicable   to   all   proteins.   The   self-association   of   peptides   and   proteins   into   well-ordered 
supramolecular structures is of central importance in normal physiological processes such as the 
assembly of collagen fibrils [103,104], actin filaments [105] but also in pathophysiological cases 
[106]. Integration of old and new techniques and development of novel methods of nanoscience can 
provide   powerful   opportunities   to   increase   our   understanding   of   processes   underlying 
amyloid-related disorders [107]. Until recently, it was commonly believed that amyloid formation is Introduction 36
a feature of only a tiny fraction of proteins. Not all proteins, however, form amyloids because in most 
cases these potentially harmful segments are hidden deep inside the protein structure and are kept 
under control. Such behavior can be of evolutionary origin suggesting that evolution treats amyloids 
as a fundamental threat. The presence of different kinds of amyloids have been confirmed in some of 
the most common age-related diseases, so one can suppose that the accumulation of amyloid is 
unavoidable during aging. Sometimes, the presence of amyloid deposits does not give rise to 
neurodegenerative symptoms, indicating that amyloid fibrils do not cause the onset of disease. 
Therefore, one of the hypotheses suggested that the oligomeric intermediates are the toxic species 
while the fibrils are detoxification products [108]. Fibrils are not the only shape taken by amyloids 
especially during the nucleation process. For instance, spheroidal oligomeric species have been 
demonstrated for α-synuclein—they are thought to be responsible for cytotoxicity towards the 
neuronal cells observed in Parkinson’s disease [109,110]. 
On the basis of current research, it was proposed by Eisenberg [97] that the amyloid state is more 
like a default state of a protein especially in the absence of specific protective mechanisms such as 
chaperoning. Proteins that are not correctly folded and less protected (by chaperoning and/or disposal 
mechanisms) are predisposed to become amyloids. The amyloid-associated diseases that are known 
so far probably involve only the most vulnerable human proteins. Many research groups try to find 
ways to supplement or boost the protective mechanisms, in the hope of treating or preventing the 
original cause of amyloid-linked diseases. Even a subtle pharmacological interference in the process 
of amyloidogenesis might have a major effect on the disease and even on ageing in general. On the 
other hand, one can enhance the natural protective mechanisms that stabilize a protein. A review of 
potential strategies for tackling protein aggregation and the toxicity associated with it has been 
published by Bartolini and Andrisano [111]. However, the complexity of the aggregation processes 
and other related events account for the fact that no effective treatments for these disorders are 
currently available. Studies of the structures of amyloids and mechanisms of amyloid formation 
should unveil new molecular targets for potential anti-neurodegenerative drugs. Although the three 
characteristic   stages   of  nucleation-dependent   fibrillation—seed  formation,  accelerated   fibrillar 
growth, and the stationary phase—have been examined separately, additional studies are required to 
unambiguously uncover the mechanism of amyloidogenesis. 
1.5.1 Molecular Structures of Amyloids 
Amyloid fibrils represent an energetically stable state of many proteins and peptides. Basically, 
amyloid fibers are a bundle of highly ordered filaments composed of ladders of β-strands that are 
placed perpendicular to the fiber axis and are arranged in hydrogen-bonded β-sheets [112]. Amyloid 
fibers have a diameter of about 7–10 nm and can be up to several micrometers long. In cross 
sections, amyloid assemblies appear as hollow cylinders or ribbons. The measurements of amyloid Introduction 37
fibers revealed that their strength is comparable to that of steel while their mechanical stiffness 
matches that of silk [113]. In general, amyloid structures attain their stability through non-covalent 
bonds, mainly hydrogen bonds stabilizing the β-sheets, but also through hydrophobic and π–π 
stacking interactions of the side chains. The frequent occurrence of aromatic residues in short 
amyloid-related peptides suggests that π stacking may play a role in speeding-up the self-assembly 
process by providing geometrical constraints that promote directionality and orientation of the 
growing   fibril.   The   importance   of   hydrogen   bonds   is   especially   seen   in   glutamine-   and 
asparagine-rich proteins which form amyloids. Extended sequences of repeated glutamine (or 
asparagine) units are related to several amyloidoses such as Huntington’s disease and spinocerebellar 
ataxia, and also to the aggregation of yeast proteins into prions. 
The three-dimensional structure of the fibrils comprising Aβ42 (Protein Data Bank code 2BEG) was 
obtained using quenched hydrogen/deuterium exchange NMR in solution, while the β-sheet 
arrangement was taken from previous solid-state NMR studies of this structure. Residues 18–42 form 
a β–strand–turn–β–strand motif while residues 1–17 are disordered and could not be detected. The 
parallel β-sheets are formed by residues 18–26 (β1 strand) and 31–42 (β2 strand). The repeating 
structure of a protofilament requires two monomers because of the salt bridge D23-K28 formed 
between adjacent monomers. This interaction pattern leads to the formation of partially unpaired 
β-strands at the ends of the Aβ42 fibrils (Fig. 1.12). Such unpaired ends explain the specific shape of 
these fibrils and could be a target for inhibitors of fibril growth [114]. The salt bridge and also the 
hydrophobic interactions of the side chains keep the structure rigid and compact despite the repulsion 
Fig  1.12  The structure of fragment of β-amyloid (Aβ42) obtained by NMR 
methods (PDB code 2BEG). The salt bridge K28-D23 is linking adjacent 
β-sheets, therefore, the residues K28 and D23 from terminal strands are 
unpaired (in yellow-green). Hydrogen bonds shown as dashed yellow cylinders. Introduction 38
between the charged residues E22, D23, and K28 from the adjacent β-strands. 
Amyloid fibrils can be formed by different proteins and usually contain a common cross-β spine. 
Glutamine repeats were first suggested to act as “polar zippers” joining monomeric units together 
and propagating the amyloid fibrils. The structure of the fibril-forming segment, GNNQQNY, of the 
yeast prion protein Sup35 has been recently revealed by crystallography [115]. It is formed by a pair 
of β-sheets, with the facing side chains of the two sheets locked together in an interdigitated way 
forming a so-called “dry steric zipper” (Fig. 1.14a). Eisenberg and coworkers [115] reported dozens 
of other segments from fibril-forming proteins that are able to form amyloid-like fibrils on their own. 
The segments from the β-amyloid and tau proteins, the PrP prion protein, insulin, islet amyloid 
polypeptide (IAPP), lysozyme, myoglobin, α-synuclein, and β-2-microglobulin were analyzed. The 
obtained structures are characterized by structural features that are shared, at the molecular level, by 
all the proteins studied but some variations in the atomic architecture of the amyloid-like fibrils can 
provide some clues on their origin and the mode of growth. In the GNNQQNY amyloid, the peptide 
strands are parallel, and the Asn and Gln residues form regular rows connected by hydrogen bonds in 
addition to the hydrogen bonds in the β-sheet. The hydrophilic character of these residues and their 
length make the steric zipper interface highly interdigitated. In the other amyloid formed from the 
AILSST peptide (Fig. 1.14b), the strands are antiparallel, and the steric zipper interface is formed 
mostly by hydrophobic residues Ile and Leu. The hydrogen bonds between side chains of serine 
residues are bridged by water molecules. 
According to [115] there are eight types of the steric zipper interfaces classified according not only to 
the orientations of their strands (parallel or antiparallel) but also faces (face-to-face or face-to-back 
Fig  1.13:   Different   forms   of   amyloids:   a   squared   plates,   b 
nanospheres, c hydrogels, d tubular structures—single-walled and 
multi-walled tubes, e fibrilsIntroduction 39
arrangement) and the up or down orientations of the edges of the strands. So identical peptides can 
form different polymorphic structures characterized by distinctive phenotypes. New polymorphic 
crystal structures of segments of the prion and other amyloid proteins [116] proved to be useful for 
elucidating the structural mechanisms of different modes of fibrillation. Additionally, β-sheets 
formed by the same segment of a protein can reveal alternative packing arrangements (polymorphs). 
Such polymorphism can be responsible for enduring conformations capable of “encoding” prion 
strains. Such transfer of protein-encoded information into prion strains involves sequence specificity 
and recognition by means of noncovalent bonds. 
Amyloid fibril formation is considered to be a signature of neurodegenerative processes. The exact 
processes leading to cellular degeneration remain unknown although several amyloid-involving 
mechanisms have been proposed [117]: 
• amyloids occupy the extracellular space and destroy the structure of cells and tissues,
• amyloid fibrils destabilize cell membranes,
• heavy metals incorporate into amyloids and generate reactive oxygen compounds which 
affect cellular functions,
• some proteins essential for cell survival are trapped in protein aggregates.
In a recent review, Zerovnik et al.  [118]  classified the mechanisms by which proteins undergo 
ordered aggregation into amyloid fibrils: 
• templating and nucleation;
• linear, colloid-like assembly of spherical oligomers,
• domain swapping.
The local environment and inter- and/or intra-molecular interactions may have a significant influence 
on the conformation of certain amino acid residues. Therefore, even small variations in pH, 
temperature, and ionic strength could induce changes in the conformational propensities of these 
residues (leading to a different secondary structure) including their ability to aggregate. 
Some proteins forming amyloids, for instance α-synuclein which contributes to the formation of 
intracellular Lewy bodies in Parkison’s disease [119], can exist without a defined structure. It was 
postulated that exogenous α-synuclein fibrils induce the formation of Lewy body-like intracellular 
inclusions [120]. Other proteins with an unordered structure are the IAPP in type II diabetes [121] 
and β-amyloid in Alzheimer’s disease [122]. Such an unfolded structure allows the protein to be 
rather easily self-assembled into fibrils. On the other hand, some amyloidogenic proteins preserve 
their   3D   structure   until   the   actual   fibrillation  [102].  This   group   of   proteins   includes   β-2 
microglobulin identified in dialysis-related amyloidosis [123], huntingtin in Huntington’s disease 
[124], immunoglobulin VL domain in light-chain amyloidosis  [125], lysozyme in hereditary 
systemic amyloidosis [126], prion protein in Creutzfeldt-Jakob disease [127], and transthyretin in Introduction 40
senile systemic amyloidosis [128]. However, regardless of the initial structure, the amyloid fibrils 
obtained from different amyloidogenic proteins and peptides are very similar and adopt a cross 
β-sheet conformation [101] even though these proteins and peptides share rather little amino acid 
sequence similarity. It was known that even all α (protein composed of α-helices only) or mixed α/β 
protein types can form β-sheet fibrils. Therefore, it was tempting to suggest that when elucidated for 
a given protein in a particular disease, the molecular mechanism of amyloidogenesis will apply to 
other proteins and amyloid-related diseases. However, it became gradually recognized that amyloid 
fibrils exist in multiple fibrillar forms and exhibit so-called fibrillar polymorphisms. Even a single 
amyloidogenic protein can create multiple forms of amyloid fibrils depending on the conditions in 
which fibrillation occurred. This may indicate that amyloidogenesis can proceed via multiple 
mechanisms. Various types of possible amyloids structures are shown on Fig. 1.13. 
The conversion and aggregation of proteins from their soluble states into well-organized fibrils is 
associated with a wide range of conditions, usually pathological, including neurodegenerative 
diseases and amyloidoses. Although a conformational change of the protein native state is generally 
necessary to initiate aggregation, it was shown that a transition across the large unfolding energy 
barrier is not essential and that the aggregation may be initiated from locally unfolded states that 
become accessible, for example, via thermal fluctuations occurring under physiological conditions 
[102]. Conformational states thermodynamically distinct from the native state, but structurally 
similar to it, can be easily accessed from the native state through thermal fluctuations. These states 
are separated from the native state by a relatively low energy barrier. They are therefore only 
transiently populated under physiological conditions, yet they can be sampled more frequently than 
the entirely unfolded state (global unfolding) or a partially folded state. The existence of such 
conformational states can be deducted from the observation that, under physiological conditions, the 
amide hydrogen atoms buried in the interior of a native protein can exchange with the solvent 
hydrogen atoms more rapidly than it could be expected from the rate of protein unfolding. The 
possibility of sampling of such partially unfolded states is also confirmed by long molecular 
dynamics simulations. 
Amyloid self-polymerization is also the basis of the “protein-only” hypothesis for the mechanism of 
prion infectivity. The infectious prion conformation replicates itself in a host by pairing with the host 
protein and forcing it into the infectious, fibrillar conformation. It was found that amyloids, including 
β-amyloid, can also be infectious like the PrPSc prion protein. Data showed that β-amyloid, which is 
associated with Alzheimer’s disease, behaved like an infectious agent when injected into the brain of 
a mouse. The same mechanism was suggested in the case of other diseases in which amyloid forms 
of proteins were detected [129]. A self-complementary “steric zipper” structure identified in protein 
fibrils allows them to tangle very tightly with an identical segment exposed on another protein. 
Several of these segments are needed to seed, or nucleate, an amyloid. Segments attach to one Introduction 41
another and form fibrils. As they grow, fibrils are fringed by the remnants of the host protein 
segments (Fig. 1.15). Eventually, this developing fibril breaks to form two smaller fibrils, each of 
which starts to grow at both ends again. The nucleation events are rare but once the fibril is formed 
its spreading is fast. Ohhashi et al. [130], based on mutational and biophysical analyses, proposed 
that before fiber formation, the prion domain (Sup35NM, consisting of residues 1-254) of yeast prion 
Sup35 forms oligomers in a temperature-dependent reversible manner. Experiments revealed that 
“non-native” aromatic interactions outside the amyloid core drive oligomer formation by bringing 
together different monomers, which leads to the formation of new amyloid cores. In this way, the 
transient non-native interactions in the initial nucleus are responsible for the diversity of amyloid 
conformations. 
1.5.2 Kinetics of the Growth of Amyloid Fibrils 
Using quantitative measurements of protein aggregation rates, Buell et al. [131] developed a kinetic 
model of a conversion of a protein from a soluble to a fibrillar form which shows that there is a 
single free energy aggregation barrier controlling the addition of protein molecules into amyloid 
fibrils. Other characteristics of the aggregation process are natural consequences of finite diffusion 
times. These findings suggest that this process does not follow a simple chemical mechanism, but 
rather operates in a way analogous to the multitrajectory (landscape) models of protein folding 
defined by stochastic dynamics on the surface of the potential energy of the system. Another kinetic 
study [132] was based on quantitative quartz crystal microbalance measurements of the kinetics of 
the growth of amyloid fibrils in crowded environments. Such environments strongly modify the 
association of components, through attractive entropic interactions such as the depletion pressure that 
results from the entropically favorable overlap of the regions surrounding two aggregating particles. 
The complex effects of macromolecular crowding on the growth of amyloid fibrils can be described 
on the basis of established physical principles using a combination of osmotic effects and entropic 
interactions. Within this framework, it was possible to predict the aggregation susceptibility of many 
proteins with different structural properties. Campioni et al. [133] described two types of oligomers 
formed   by   the   HypF-N   protein   (91-residue   N-terminal   domain   of   E.   coli   HypF)   that   are 
morphologically similar, as detected with atomic force microscopy and thioflavin T assays, though 
one is benign when added to cell cultures, whereas the other is toxic. They found that a lower degree 
of hydrophobic packing is correlated with a higher ability to penetrate the cell membrane and to 
cause an influx of calcium ions. It suggests that structural flexibility and hydrophobic exposure are 
primary determinants of the ability of oligomeric assemblies to cause cellular dysfunction and its 
consequences such as neurodegeneration. A broad review on aggregation kinetics and mechanisms of 
fibril formation was prepared by Morris et al.  [134]. By employing an extensive mathematical 
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amyloid intermediates. 
1.5.3 Specific Mechanisms of Fibrillation 
To   explain   the   process   of   α-synuclein   amyloidogenesis,   a   specific   mechanism   named 
double-concerted fibrillation, corresponding to the prevailing nucleation-dependent fibrillation 
model, was introduced  [135]. According to the double-concerted fibrillation, the amyloid fibril 
formation is achieved via two consecutive, concerted associations of monomers and the subsequently 
formed oligomeric granules. These newly formed oligomeric species act as units for fibril formation 
and subsequent growth in the absence of a template [117]. Template-dependent fibrillation requires a 
pre-existing fibril to which the incoming protein monomers or granules can attach if, due to a 
conformational change, they match the structure of the template. The fibril is extending, and the 
subsequent assembling step requires the exposure of the interactive domains of the protein to 
facilitate further molecular self-assembly. Template-dependent fibrillation is the most appropriate 
mechanism to study the infectivity of prion proteins. Prion protein (PrPC) is anchored to the cellular 
surface via the glycosylphosphatidylinositol moiety. Its conformational change into another structural 
entity (PrPSc) is associated with the occurrence of transmissible spongiform encephalopathies (a 
group of prion diseases). Exogenous PrPSc directs the conversion of PrPC into PrPSc conformation 
by acting as a template. In a template-independent fibrillation, the amyloidogenic conformations of 
building units are induced (by physical or chemical influences) before the main molecular assembly 
occurs. Polymorphism of amyloids, reflected by the existence of various types of amyloid fibrils, 
especially in the presence of specific ligands, is achieved via multiple pathways. The natively or 
partially unfolded amyloidogenic proteins are at a high-energy state, but increased conformational 
entropy could allow the self-interactive conformers to be stabilized. Initial stable seed formation is 
by no means privileged since the production of an oligomeric nucleus is an entropically expensive 
process which needs to be overcome by an enthalpic advantage [117]. 
Another mechanism, the 3D domain swapping, has been suggested to explain the development of 
protein oligomer assembly of cystatins and stefins [118]. These small globular proteins (11–13 kDa) 
are part of a large family of cysteine proteinase inhibitors which are also linked to amyloid diseases. 
The process of domain swapping is rate limiting for the initiation of amyloid fibril formation because 
of a high energetic barrier in this process. Nevertheless, it was suggested that, in principle, any 
protein is capable of oligomerization by 3D domain swapping  [136]. Guo and Eisenberg  [137] 
proposed the term “run-away domain-swapping” for a process of continuous domain swapping. 
Wahlbom et al. [138] used the term “propagated domain-swapping” to describe a similar process of 
continuous domain swapping in the formation of cystatin C prefibrillar oligomers and fibrils. 
Apart from the oligomeric species formed on the route to mature fibrils the off-pathway oligomers 
are also formed. They are the dead ends of an alternative folding pathway because they are incapable Introduction 43
of converting directly to fibrils and substantially slow fibril formation. The OFF model for amyloid 
formation was first described by Pallitto and Murphy [139]. In this model, denatured monomers are 
refolded into either stable monomers or dimers or less stable dimeric intermediates which can form 
non-fibrillar oligomeric forms. These initial steps are followed by a cooperative assembly of the 
fibril-prone dimeric intermediates into a nucleus from which the protofibrils originate. 
1.5.4 Conformationally Distinct Amyloid States 
Since it was known that the amino acid position specifically contributes to protein oligomerization, 
Maji et al. [140] performed amino acid substitution to determine the distribution frequency of the Aβ 
oligomer. The substitutions were done at positions 1, 10, 20, 30, and 40 (for Aβ40) or 42 (for Aβ42). 
The effects of these mutations were probed using circular dichroism spectroscopy, thioflavin T 
binding, electron microscopy, and other techniques. All peptides displayed a transition from a 
random coil to α/β and to all-β structure, but substitution-dependent changes in the kinetics of 
assembly and the complexity of conformers were observed. The ability of a single substitution (Tyr 
in position 1) to alter the Aβ assembly kinetics and the oligomer frequency distribution suggests that 
the N-terminus is also involved in the oligomerization process and that, most probably, there is a 
competition between the N- and C-termini to form a stable complex with the central hydrophobic 
cluster. Additionally, recent electron microscopy and AFM data for Aβ40 suggest that dimerization 
and subsequent monomer attachment are processes in which significant conformational changes 
occur in the monomer. It was also found that dimers were threefold more toxic than monomers, and 
tetramers were about 13-fold more toxic [141]. 
Fig  1.14  The crystal structures of amyloids (A) GNNQQNY (PDB ID: 2OMM) – 
adjacent β-strands are parallel, and (B) AILSST (PDB ID: 3FOD) – adjacent β-strands 
are antiparallel. Hydrogen bonds shown as dashed yellow cylinders. Introduction 44
Using mass spectrometry and ion mobility spectrometry, Bowers and coworkers [142] investigated a 
mixture of Aβ40 and Aβ42. A heterooligomer was formed composed of equal parts of both forms of 
Aβ. These mixed species comprise an oligomer distribution extending to tetramers, similar to the 
structures created by Aβ40, whereas Aβ42 alone produced longer oligomers (dodecamers) indicating 
that Aβ40 inhibits oligomerization of Aβ42. In solution, Aβ40 and Aβ42 adopted similar random coil 
structures; however, Aβ42 was significantly more neurotoxic and formed amyloid fibrils much more 
rapidly than the shorter form of Aβ. Although amyloid formation is triggered by a transient nucleus, 
the mechanism by which the initial nucleus is formed and allows the protein to acquire a specific 
amyloid conformation is still unclear. The observation that Aβ40 and Aβ42 self-assemble via 
different pathways put forward the Aβ42 dodecamers as candidate primary toxic species in 
Alzheimer’s disease [143]. 
If mutations in sequence or changes in environmental conditions elicit partial unfolding of the native 
state of a protein, the protein will tend to aggregate, sometimes into fibrillar structures. The 
metastable, partially unfolded states that precede the aggregated states of proteins are of special 
interest because of their specific features and especially because of increased toxicity. It was found 
that protein aggregation is favored by conditions that promote stable intermolecular interactions, 
particularly the hydrogen bond formation. Calamai et al.  [144]  showed that human muscle 
acylphosphatase is able to form both fibrillar and non-fibrillar aggregates with a high β-sheet content 
from partially unfolded states with very different structural features due to the use of different 
destabilization factors: urea or increased temperature followed by incubation in the presence of 
different concentrations of 2,2,2-trifluoroethanol (solvent that has been found to promote aggregation 
of other polypeptides, including the natively unfolded Aβ peptide). The same amino acid sequence 
can give rise to several conformationally distinct amyloid states. To address this puzzle, Ostapchenko 
et al. [145] studied two amyloid states of the prion protein (referred to as R- and S-fibrils). The 
obtained results suggested that the energy landscape for protein folding and assembly contains 
several close to global free-energy minima: one of which is occupied by the native state and the 
remaining ones by the amyloid states. The transmissible form of prion disease can be induced in 
wild-type animals by inoculation with R-fibrils while S-fibrils failed to induce the prion disease. 
Recently, an apparent generation of toxic prions (PrPSc) in normal brain tissue in the presence of 
metal (steel wires) has been discovered. The metal catalyzed de novo formation of PrPSc from a 
normal cellular prion protein  [146]. Alternatively, metal surfaces might concentrate the already 
existing PrPSc to the extent that it became quantifiable by the cell assay. 
1.5.5 Molecular Simulations of Amyloids 
The long time scale in which the aggregation takes place is prohibitive for molecular dynamics (MD) 
simulations. However, some structural and dynamic features of amyloids were investigated using Introduction 45
coarse grain protein models and specific MD or Monte Carlo procedures. Urbanc et al.  [147] 
elucidated the structural characteristics of oligomers of Aβ40 and Aβ42 and of their mutants. They 
simulated oligomer formation using discrete MD with a four-bead protein model (the backbone is 
represented by three beads corresponding to the amide, alpha-carbon, and the carbonyl groups; the 
side chain, with the exception of glycin, is represented by only one bead). For the peptides under 
study, the characteristic oligomer size distributions were obtained, which were in agreement with 
experimental findings. Aβ42 had a high propensity to form pentameric and hexameric structures that 
could self-associate into higher-order oligomers. Structural analysis revealed that the C-terminal 
region played a dominant role in Aβ42 oligomer formation, whereas Aβ40 oligomerization was 
primarily driven by intermolecular interactions among the central hydrophobic regions. The 
N-terminal region (2)AEF played a prominent role in Aβ40 oligomerization but did not contribute to 
the oligomerization of Aβ42 or the mutants. 
Studies conducted in vitro and in vivo suggest that administration of flavonoids, compounds 
naturally present in many foods including wine and tea, can prevent and reverse Aβ aggregation, but 
the mechanism of their action is unknown. Lemkul and Bevan [148] employing atomistic, explicit 
solvent MD simulations investigated the mechanism of Aβ fibril destabilization by morin which is 
one of the most effective anti-aggregation flavonoids. They used a model of mature Aβ and through 
the course of 24 simulations found that morin could bind to the ends of the fibrils to block the 
attachment of an incoming monomeric peptide and can penetrate into the hydrophobic core to disrupt 
the D23-K28 salt bridges. It also modified the backbone hydrogen bonding. 
The stability of Aβ42 fibrils and thermodynamics of peptide dissociation were investigated in [149] 
using all-atom molecular dynamics simulations and pulling one monomer from the pentameric 
protofibril of Aβ42. Results indicated that the presence of water molecules around the D23-K28 salt 
bridge is crucial to protofibril stability. The extent of packing between hydrophobic residues 
regulates the level of hydration in the core of the protofibril and thus rigidifies the D23-K28 salt 
bridge. Such studies explore the mechanism of destabilization of amyloid aggregates which may be 
important because numerous studies have found that the insoluble fibrillated form of the peptide also 
contributes to neurotoxicity, although the principal toxic species in Alzheimer’s disease are believed 
to be the soluble, oligomeric aggregates of Aβ. Membrane disruption and increased ion conductance 
have been observed in vitro in the presence of Aβ, and it is assumed that the same phenomena occur 
in the brain neurons of Alzheimer's disease patients. Simulations of Aβ in a membrane bilayer 
revealed how the peptide interacts with the surrounding lipids and to what extent it affects lipid 
behavior and contributes to membrane damage. The results showed that Aβ40 is capable of 
disordering the nearby lipids, as well as of decreasing the thickness of the membrane. During 
simulations the peptide unfolded and finally acquired a disordered, extended conformation allowing 
for extensive electrostatic and hydrogen bonding interactions with lipids [149]. The stability and Introduction 46
conformational dynamics of trimeric and pentameric full-length Aβ42 peptides were investigated by 
Masman et al. [150] for the purpose of defining structural elements influencing their stability. The 
N-terminal part not detected in NMR was treated as a disordered domain. The models of the 
oligomer were stable during 100-ns simulations while the β-strand acquired a characteristic twist 
which facilitated a compact packing of the side chains from the neighboring β-sheets. It seems that 
the hydrophobic core comprising the β2 fragment of the oligomer β-sheet is a stabilizing element in 
the process of Aβ aggregation. Destabilization of this crucial β-sheet fragment emerges as a 
prospective target for anti-amyloid drugs. 
1.5.6 Amyloid Can Be Beneficial for Cells and Also Convenient for Engineers 
Amyloid   fibrils   are   cross-β-sheet   structures   that   are   primarily   associated   with   several 
neurodegenerative diseases. However, amyloid is also a fundamental nonpathological protein 
structure (or conformation) utilized by organisms from bacteria to humans. The cross-β-sheet motif 
is composed of intermolecular β-sheets arranged along the fibril axis with the β strands aligned 
perpendicularly to the fibril axis. Amyloid fibril formation also provides biologically important 
entities termed functional amyloids [151] that are present in silkworms [152,153] and in mammalian 
skin [154]. It is also known that pituitary hormones are functioning in an amyloid state. Riek and 
coworkers [155] found that peptide and protein hormones in secretory granules of the endocrine 
system are stored in an amyloid-like conformation composed of cross-β-sheets. Thus, functional 
amyloids in the pituitary and other organs can contribute to normal cell and tissue physiology. The 
hormone amyloids are stored inside the granules, an “inert” membrane container, and the amyloid 
fibrils dissociate only upon secretion. Additionally, the amyloid aggregation of these hormones must 
be highly regulated. This regulation may include the processing of prohormones that aggregate more 
slowly than their hormone counterparts [156] or require the presence of helper molecules to induce 
aggregation; the latter was demonstrated for prolactin, which lacks a prohormone stage. 
Amyloid, a fibrillar quaternary structure, was first discovered in the context of human disease and 
tissue damage. Therefore it was long thought to be detrimental to the host. However, recent studies 
have identified functional amyloid fibers in bacteria, fungi, insects, invertebrates, and humans. 
Nevertheless, physiological amyloidogenesis requires tight regulation to avoid toxicity of the 
produced amyloids. Diverse physiological applications of amyloids can change our views on the 
potential treatment of amyloid diseases  [151].  The discovery of native amyloids in mammals 
provides a key insight into the molecular basis of both the physiological and pathological role of 
amyloids. 
The examples of useful amyloids include fungal prions, which are involved in prion replication, the 
amyloid protein Pmel17 which is involved in biosynthesis of the pigment melanin in mammals, and 
the factor XII protein of the hemostatic system which is activated by amyloid. The Pmel17 protein Introduction 47
forms amyloid fibrils that act as a template and accelerate the covalent polymerization of small 
reactive molecules into melanin—a critically important biopolymer that protects against a broad 
range of cytotoxic insults including UV and oxidative damage. The Pmel17 amyloid also appears to 
play a role in diminishing the toxicity associated with melanin formation by sequestering and 
minimizing diffusion of highly reactive melanin precursors [156]. The silkmoth chorion protein is 
also a natural protective amyloid. This is the major component of the eggshell, a structure with 
extraordinary physiological and mechanical properties. Other natural, protective amyloids are fish 
chorion, the hydrophobins, and the antifreeze protein from winter flounder. 
The phenomenon of the self-assembly of molecules is more and more frequently exploited to invent 
new   supramolecular   structures   and   materials   inspired   by   biological   systems   such   as   novel 
biocompatible polymeric structures with excellent physicochemical properties for new biomedical 
and industrial applications [153]. A variety of protein and peptide molecules with various amino acid 
sequences form highly stable and well-organized amyloid assemblies under diverse conditions. They 
display phase states ranging from liquid crystals to rigid nanotubes. The potential applications of 
these supramolecular assemblies can be broader than those of synthetic polymers since one can 
easily introduce biological function in addition to their mechanical properties [157]. Self-assembly is 
a powerful mechanism for organizing molecular binding blocks into complex structures and aromatic 
groups can facilitate this process  [158,159]. For example, the Phe-Phe dipeptide motif from 
Alzheimer’s disease β-amyloid protein was able to self-assemble into peptide-based nanotubes [160]. 
The Phe-Phe peptide is of special interest due to its ability to form ordered nano-assemblies of 
unique physical, chemical, and mechanical properties  [160,161]. It was shown that the thermal 
stability of diphenylalanine peptide nanotubes is significantly higher than that of a nonassembling 
dipeptide, dialanine. In addition to thermal stability, the peptide nanotubes were chemically stable in 
many organic solvents. Other aromatic dipeptides can also self-assemble into ordered structures such 
as   tubes,   spheres,   plates,   and   hydrogels  [161,162].  Moreover,   Phe-Phe   nanotube-based 
electrochemical biosensors have shown a large increase in their sensitivity upon the modification of 
the electrode surfaces with the forest-like nanotube arrays [163,164]. Such bio-inspired materials can 
be composed of chemically synthesized biomolecules. In the recent work [165], diphenylalanine 
nanotubes have been used to modify carbon electrodes, by physical vapor deposition of peptide 
nanotubes, of the electrochemical energy storage devices called supercapacitors. The structural motif 
of Phe-Phe forms discrete and stiff nanotubes that can be used for production of discrete nanowires 
with a long persistence length. The same dipeptide building block, made of d-phenylalanine, resulted 
in the production of enzymatically stable nanotubes [160]. It was shown that a non-charged peptide 
analogue, Ac-Phe-Phe-NH2, self-assembled into similar tubular structures as did diphenylalanine. A 
similar peptide, diphenylglycine, self-assembled into ordered nanospherical assemblies. Other 
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additional phenyl groups or by alteration of the phenyl groups and naphthyl groups, or by nitro 
substitutions, were also investigated. In all cases, the well-ordered nanostructures were formed in the 
shape of tubular, spherical, and two-dimensional structures  [161]. Peptide-based nanostructures 
represent nano-objects of particular interest, as they are biocompatible, can be easily synthesized in 
large amounts, decorated with functional elements, and used in various biological and non-biological 
applications. 
The significant thermal and chemical stability of the peptide nanotubes could be potentially useful in 
microelectronics   and   microelectromechanics   as   well   as   for   fabrication   of   functional 
nanotechnological devices [166]. Amyloids have unusual properties, for instance, rigidities varying 
over four orders of magnitude depending on the nature of intermolecular forces. The major 
contribution to their rigidity stems from a generic interbackbone hydrogen bonding network that can 
be modulated by the variability of side chain interactions [167]. Especially the aromatic residue, side 
chain interactions play a role in Phe-Phe and related peptide nanotubes and in biological processes 
such as collagen self-assembly which involves the hydrophobic interactions of Tyr and Phe residues 
within the C-terminal chain [82, 83]. Usage of bionanostructures in industrial applications requires 
precise control over self-assembly of monomeric units and the ability to scale up production of these 
materials. A significant challenge is to control the formation of large, homogeneous arrays of 
bionanostructures on macroscopic surfaces. The example is the self-assembly of large arrays of 
aromatic peptide nanotubes using vapor deposition methods. This approach allows controlling of the 
length and density of the nanotubes by supplying the building blocks from the gas phase. The 
nanotube arrays can be used to develop high-surface-area electrodes for energy storage applications, 
microfluidic chips, and also highly hydrophobic self-cleaning surfaces  [168]. Other interesting 
applications are supramolecular gels in nonpolar solvents which are composed of self-assembled 
nanowires. Such studies highlight the role of self-assembly and gelation in the electronic properties 
of semiconducting molecular gelators and opens the window for a new class of conducting materials 
which may find a wide application in organic electronic devices [159]. There was also a proposition 
of using amyloid fibrils as new nanoscale biomaterials to investigate cell adhesion, migration, and 
differentiation in vitro. Gras et al. [169][85] used peptides with an additional segment motif of the 
biological cell adhesion sequence (RGD) or a control sequence (RAD) at the C-terminus of an 
11-residue peptide taken from the amyloidogenic protein transthyretin. The fibrils containing such 
sequences are bioactive and interact specifically with cells via the incorporated sequences exposed 
on the fibril surface. Such functionalized fibrils can be systematically altered, so it could be possible 
to generate nanomaterials based on amyloids to promote interactions for a range of cell types. 
One of the most recent and striking examples of the usefulness of a potentially dangerous, 
fibril-forming protein was described in [170,171]. The protein is α-synuclein which participates in 
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nanoparticle (AuNP) arrangement into one-dimensional chain structures within the dielectric 
amyloid fibrils of α-synuclein. The assembly units composed of α-synuclein encapsulating AuNPs 
were manipulated by either hexane or the pH value to induce structural rearrangement within the 
protein coat. The method of encapsulation of noble metal nanoparticles within dielectric matrices is 
used to develop fast optoelectric response systems near the surface plasmon resonance frequency. 
Light energy can be transported through nanoparticles whose sizes are substantially smaller than the 
wavelength of the corresponding light. These AuNP-embedded amyloid protein nanofibrils exhibited 
photoconductivity   with   visible   light—such   property   is   crucial   for   the   development   of   a 
subwavelength size light-guiding nano-optics systems. 
Conclusions 
The genome-wide analysis revealed that self-complementary amyloidogenic segments are found in 
almost   all   proteins  [97];   however,   not   all   proteins   form   amyloids.   There   are   40–50 
amyloid-associated diseases identified so far, but only a few proteins were identified to be causative 
in such diseases. Such an observation may result from the fact that only the most vulnerable proteins 
convert into amyloids. There are protective mechanisms that shield other proteins from this 
dangerous behavior. About 500–600 genes/proteins protect young organisms from such diseases, but 
their role is diminishing with age, so the ultimate goal would be to find a way to restore their 
protective function. Amyloids can be devastating but also beneficial when kept under control by 
specific cellular systems. Finally, the unusual properties of amyloid—mechanical, electronic, and 
other—can be exploited in many industrial applications. These biological nanostructures do not cease 
to inspire new ideas on how to protect the organism against their detrimental effects but also on how 
to use them in practical devices.
Fig  1.15  A scheme displaying the process of amyloid formation resulting form 
instability of part of the protein structure (in yellow-green). The rest of proteins not 
participating in amyloidal β-sheet development are shown as blue ellipses. All 
figures were created in Yasara (YASARA Biosciences) [450]. Introduction 50
Part I: Cell-free Expression and Structural Studies of the γ-Secretase 
Components
2 Cell-free Expression of Membrane Proteins 
2.1 Overview
Cell-free (CF) expression has been proven to be an efficient way to express high amounts of not only 
soluble (cytosolic) but also functional membrane protein targets, which is impossible by traditional 
E. coli based in vivo expression system [172–176]. CF expressed proteins are suitable for structural 
and functional characterization as well as for high-throughput drug screening and in proteomics. CF 
is emerging as an important tool in synthetic biology which allows synthesis of biological building 
blocks and mimic their in vivo activity. 
Recently mathematical modeling of gene expression dynamics was used to engineer CF system for 
high yield, reproducibility and predictability [177]. Kuruma et al showed the artificial synthesis of 
phospholipids by two membrane proteins embedded in liposomes [178]. In recent times functional 
membrane proteins have been successfully associated into nanodiscs  [174,175,179].  Kim et al 
proposed the use of fructose-1,6-bisphosphate as an energy source in CF system to reduce the 
operating cost [180]. A myriad of membrane protein targets have been successfully expressed by CF 
system as described in our previous review [173]. 
Due to the openness of the CF system, it can be classified into three types depending on the type of 
external additives: P-CF (no additives and protein is expressed as precipitate), D-CF (addition of 
various Brij detergents in RM), and L-CF (addition of liposomes or bicelles or nanodiscs or 
Fig 2.1 Various Cell-free expression modes: P-CF (as precipitate), D-CF (in detergent) and L-CF (in 
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combination of lipid and detergent). This allows improved expression or functionality or direct 
incorporation of expressed proteins in micelles (D-CF) or lipid bilayers (L-CF) or expression as a 
precipitate.
2.2 Cell-free expressed membrane proteins
Over the years an efficient CECF expression system especially suitable for membrane protein 
synthesis has been set up. Since last few years, we have successfully expressed and purified and 
structurally   or   functionally   classified   various   membrane   protein   targets   such   as   GPCRs 
(bacteriorhodopsin   into   nanodiscs  [181],   solved   NMR   structure   of   proteorhodopsin  [182], 
aquaporins [183,184] endothelin A receptor [185] etc.), channels (PorA, PorH [186]), transporters 
(organic cation transporters OCT1 and OCT2 and rat organic anion transporter OAT1[187,188]), 
enzymes (MraY [189] , GNA1 [190]), tail anchored protein Get3 [191] etc. A collection of 134 
α-helical integral membrane proteins from E. coli inner membrane proteome mostly consisting of 
larger transporters were also expressed [188]. Furthermore we reconstituted the mitochondrial 542 
kDa ATP-Synthase complex, compriing 16 membrane embedded and 9 soluble proteins, in vitro and 
resolved its electron microscopic structure by single particle reconstitution which is almost identical 
to the in vivo expressed complex [192]. We recently did N-terminal tag variation before the start 
codon in order to improve the expression of several GPCR targets [193]. 
2.3 Solved membrane protein structures of CF expressed proteins
Presenilin 1 is the catalytics subunit of the γ-secretase complex which cleaves the amyloid precursor 
protein into amyloid beta peptides (Ab 37-43), that accumulate as senile plaques in Alzheimer's 
patients, affecting more than 30 million people worldwide. The structure of CF expressed Presenilin 
1 CTF in SDS micelles was solved using NMR spectroscopy [53]. Furthermore the structure of 
proteorhodopsin expressed in CF system was solved by NMR spectroscopy[182].  Other solved 
structures include multidrug transporter EmrE, voltage gated anion channel VDAC1 (expressed in 
D-CF mode).
Due to the emergence of multidrug resistant bacteria, new antibacterial targets are urgently quired. 
By means of CF, we reconstituted the bacterial peptidoglycan (cell wall) synthesis pathway involving 
MraY and MurA,..,G in vitro. In our system, adding substrate of MurA: UDP-GlcNAc yields Lipid II 
which is the product of  MurG.  MraY translocase is involved in the formation of Lipid I. CF 
expressed MraY [189] can be useful for throughput anti bacterial screening because it is easily 
accessible and contains ten transmembrane helices that can be easily targeted. Several members of 
Mur family and MurY are already being targeted by existing antibiotics. Our system would allow 
discovery of novel drugs against Mur family and MraY because it allows throughput screen of a 
single lead compound against all of these protein targets. 
Glucosamine 6-phosphate N-acetyltransferase (GNA1) is involved in UDP-GlcNAc biosynthesis 
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variety of diseases including aspergillosis and cancer. We proposed a novel CF expression strategy 
for functional and inhibition assay of human GNA1and GNA-sGFP in 96-well microplate format. In 
addition, we carried out inhibition assay of  GNA1 and  GNA1-sGFP  by Glucose-6-phosphate 
inhibitor. From molecular modeling, we suggested binding mode of Glucose-6-phosphate to GNA1 
and the differences to its original substrate and pathogenic Aspergillus GNA1 which could be helpful 
in novel lead design [190]. 
2.4 Expression of Membrane Proteins (MPs):
Membrane Proteins (MPs) represent 20-30% open reading frames of an genome and serve a myriad 
of functions including receptors, channels, transporters, enzymes, singnal transducers, cell adhesion 
etc. α-helical membrane proteins represent more than a quarter of all MPs in human genome. Unlike 
soluble proteins, it is not a trivial task to express membrane proteins. Integral membrane proteins are 
targeted to the membrane through endoplasmic reticulum (ER) and golgi apparatus (GB). The 
insertion of membrane proteins  into the lipid bilyer is  mediated by translocons  i.e. Sec61 
(eukaryotes) and SecYEG (prokaryotes). 
Rhodopsin is highly abundant in the retina of bovine eye. Such naturally evolved system specialized 
in producing high amounts of membrane proteins. However it is hard to express other proteins in 
such systems. 
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2.5 Cell-free expression of MPs
CF systems can easily be set up in biochemical laboratories due to the lack of requirement of 
advanced instruments. Initially the CF technique was employed to uncover the genetic code. Later it 
was used for analytical scale synthesis of soluble proteins. Preparative scale expression by means of 
CF was established in the 80s. In present time, CF systems are routinely used for expression and 
structural characterization of soluble proteins. 
Preparative scale CF expression of MPs was first reported by [194]. Because CF expression is an 
open system, it is subjected to modifications at any time point.  Furthermore, toxic and growth 
inhibitory effects of MPs in case of expression in vivo can readily be avoided. In cell-free extracts, 
cellular metabolism pathways are diminished. 
2.6 CF extract sources:
The most efficient way to obtain mg amount of protein from reaction mixture (RM) is by using 
prokaryotic E. coli or eukaryotic wheat germ extracts (WGE). However, the quality of WGE is 
dependent on the souce of the wheat seeds. Consequently, variations in expression can be observed 
from different sources of WGE, and it is also laborious and quite lengthy to prepare WGE.  However, 
due to the eukaryotic origin of the extract, post-translational modifications can be observed, and also 
the protein expression can last upto a week resulting in 10 mg/ml yield.
In case of  E. coli  extract, various strains BL21 derivatives or strains deficient in endogenous 
RNAases like A19 or D10 can be used to obtain S30 extract within a day. Also endogenous mRNAs 
and amino acids are removed during S30 extract preparation resulting in minimization of unwanted 
protein expression and also efficient amino acid labeling schemes can be used for NMR spectroscopy 
[195]. WGE and S30 extracts are equally efficient in producing large proteins [188]. 
Other eukaryotic systems which are based upon rabbit reticulocyte extracts (RRL), insect cells or 
parasitic protozoan Leishmania can only be used for analytical scale productions. Furthermore a 
hybrid CF extract called PURE (Protein Synthesis Using Recombinant Elements) have been 
constructed where purified recombinant components are used to make the  E. coli  translation 
machinery. It can be useful to study the kinetics of protein translation to name a few.Cell-free Expression of Membrane Proteins  54
Fig 2.2: Various modes of L-CF expressionCell-free Expression of Membrane Proteins  55
2.7 E. coli based CF expression system
In the continuous exchange CF (CECF) system, milligram amounts of protein targets can be 
synthesized within a few hours. CF system utilizing the E. coli extract retains its transcription and 
translational machinery of ribosomes and ER that allows proper folding of newly synthesized 
proteins as well as an open system. During CF expression, plasmid/operon of the target protein(s) is 
added to the reaction mixture (RM) containing all higher molecular weight compounds like tRNA, 
T7 polymerase etc and E. coli extract. RM is separated from the feeding mixture (FM) holding the 
lower molecular weight precursors such as amino acids, energy sources (nucleotides) by a 
semipermeable membrane. This allows diffusion of toxic chemicals and aminoacids/energy sources 
Fig 2.3 Flow-chart of HsGNA1-sGFP and HsGNA1 production by CECF expression and in vivo. A. 
CECF expression of HsGNA1-sGFP which only takes ~6 hours followed by measurement of its 
concentration and assay of activity each for 1 hour. The whole procedure can be completed in 8 
hours. B. In contrast, CECF expression of HsGNA1 alone followed by binding to Ni-NTA column 
and affinity purification, freeze drying, measurement of concentration and finally activity assay. The 
whole procedure takes around one day.  C. In-vivo expression of HsGNA1, followed by harvesting 
the cells, sonication, centrifigation, resuspending the pallet and binding to the Ni-NTA column 
followed by purification and activity measurement steps similar to CECF expression of HsGNA1. 
Here binding to the Ni-NTA resin takes around 3 hours, totally, while it takes 2 days at least to 
finish this process for HsGNA1 in the traditional way.[190]Cell-free Expression of Membrane Proteins  56
to  FM and RM respectively and thereby improving the expression yield. 
E. coli based CF expression systems are primarily based on T7 or SP6 polymerase coupling. So the 
target gene must contain T7 or SP6 promoter. This does not hold true for WGE CF syste because the 
optimum Mg
++ concentration is 15-18 mM in case of transcription but only 3 mM for translation. 
Also the translation efficiencies depend on the nature of 5' and 3' untranslated regions of mRNA. 
Therefore the 5' and 3' ends of the mRNA are replaced by AC rich sequences derived from tobaco 
mosaic virus and viral leaders found in plant virus genomes. 
CF extracts contain the translation machinery: ribosomes, aminoacyl-tRNA synthases, tranlation 
factors, acetate kinase etc. Additionally, transcriptional and translational precursors like amino acids , 
tRNAs, nucleotide triphophates (ATP, GTP, CTP, TTP or collectively NTPs), DNA template are 
supplied during the CF reaction. Amino acids concentrations can vary from 0.3 – 2 mM and unstable 
amino acids (R, C, W, M, D, E) are given in higher amounts. 
Commonly used component for ATP regeneration during CF reaction is phosphoenolpyruvate (PEP) 
and acetylphosphate (AcP) together with their enzymes. Protease inhibitors, ligands, stabilizers, 
chaperones and any compound which is benificial for the expression, folding and stabilization of the 
protein can be added to the CF system due to its open nature. Additional tRNAs can replenish the 
effect of heterogeneous codon usage during translation. Formation of disulfide bonds can also be 
prevented. Chaperone and microsomal extracts can improve folding of the target MP. Moreover, 
composition of the supplied amino acid can be modified according to their distribution in the target 
MP. Incorporation of isotope labelled amino acids in the expressed protein makes them suitable for 
NMR and diminishes scrambling backgrounds.
Fig 2.4: Pictures 
showing 
Mini(left)   and 
Maxi(right) 
cell-free reactors 
used   for 
analytical   and 
preparative 
scale   reactions 
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CECF reactions can be performed in  two ways. One is with small amount of RM (i.e.  30 -100µl) in 
order to optimize the expression by varying N-terminal tag of the target protein, vector type, Mg
++, 
K
+ ion, plasmid concentrations etc for maximum yield. This is called analytical scale CECF reaction. 
It is required for screening of various conditions for maximal expression with minimal chemical 
usage. However for >80% of the targets only varying Mg
++ ion concentration from 12-22 mM and 
keeping K
+ ion concentration at a fixed 290 mM. Separate optimization of K
+ ion concentration in 
RM is required for different cell-free extracts because they have different concentrations of  K
+ ion. 
After all required optimizations, one can proceed to CECF reactions in much higher scale up to 1-3 
ml of RM to obtain target proteins in mg amounts per ml which is suitable for further functional 
(protein purification, activity assay, circular dichroism, gel filtration etc), structural studies (NMR, 
crystallization) etc. 
Analytical scale reactions are usually carried out in 24 well plate trying 12 conditions in small 
mini-reactors (as shown in Fig 2.4) The membrane containing RM is manually sealed with a teflon 
ring and put into the well containing FM (note).  High throughput robotic system for analytical 
CECF reaction is still under development. The RM is separated by FM with membrane (MWCO <14 
kDa) so that all the toxic byproducts during protein synthesis can escape to the FM giving drastic 
improvements to expression yield in comparison to batch scale reaction.  The volume of FM is kept 
at 15-20 times more than RM and it primarily consists of low molecular weight compounds like 
amino acids, and energy sources like NTPs, AcP, PEP etc as shown in Table No. 2 One disadvantage 
of manual setup of mini reaction chamber is the chances of leakage of RM which can avoided with 
manual skill. Therefore the same reaction in mini reactors are done in duplicate to avoid error due to 
leakage of membrane. The reproducibility of analytical scale reaction in preparative scale reaction is 
quite high e.g. the conditions optimized in analytical scale can be used without alteration for 
comparable protein yields in  preparative scale reactions. During preparative scale reactions the maxi 
reactors (Side-A-Lyser, Thermo Scientific, USA with MWCO <10 kDa) are used and it improves the 
diffusion rate because the RM in contained in flat membrane in two sides. The concentrations of 
required chemicals in stock solutions and their final concentrations in FM and RM are given in table 
2. A pipetting scheme can be made using a spreadsheet softwares like proprietary MS Excel or free 
and opensource LibreOffice Calc or Gnumeric. Avoid air bubbles in the RM while pipetting it to 
mini or maxi reactors. Also carefully leak at any leakage from mini or maxi reactors containing RM.
2.8 Various CF expression modes for MPs
Only in CF, Mps can be expressed in three novel ways. In the simplest method, Mps can be 
expressed as precipitate (P-CF) mode without providing any hydrophobic environment. Further 
detergents can be added for ready incorporation of MPs as micelles (D-CF) or in lipid based (L-CF) 
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2.8.1 P-CF Mode 
In P-CF mode of CF expression, MPs precipitate just after translation because the CF extract lacks 
any amphiphilic or hydrophobic substance (only 50-100 µg lipid/ml of extract which might not be 
admissible to the MP). The P-CF precipitates can readily be solubilized in detergents within few 
hours. No extensive refolding mechanism is required like in inclusion bodies. The detergents which 
are often used for resolubilization include lipid like n-dodecylphosphocholine (Fos-12) , lyso- 
phosphoglycerols   1-myristoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)]   (LMPG)   and 
1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)]   (LPPG)   .   These   detergents   are 
suitable for sturctural investigation by NMR.
2.8.2 D-CF Mode
In D-CF mode the RM contains artificial amphiphilic environment comprising detergents in which 
the synthesized protein is inserted just after translation. As a result hardly any precipitate of 
expressed protein is obtained. However it requires to screen a variety of detergents to ascertain in 
which  detergent the protein solubility is maximum and functional. However some detergents like 
Fos-12 and  Cholamidopropyl)dimethylammonio]propanesulfonic acid (CHAPS) were found to 
inhibit protein expression despite being present in low concentration (<critical micelle concentration 
(CMC)) in the RM. In case of other well used detergents n-dodecyl-β-D-maltoside (DDM) or Triton 
X-100 were found to be efficient until 10 times of their respective CMCs. Having said that, most 
suitable   detergents   for   Mps   expression   in   D-CF   mode   are   Brij   family   which   are   mild 
polyoxyethylene-alkyl-ethers, and also the steroid derivative digitonin. In case of Brij, the tolerance 
exceeds 100 times of CMC [196]. 
Moreover, amphipols or flurinated surfactants can be used in the RM during D-CF expression. 
Unlike detergents, they don't disintegrate membranes and can promote partitioning of membrane 
proteins into lipid bilyers. In addition, various detergents can be combined (mixed micelles) or lipid 
and   detergent   mixture   (lipomicelles)   can   be   used   to   render   ideal   environment   for   proper 
solubilization and functiality of the nascent protein expressed in the RM.   Lipids might have 
beneficial effect to membrane protein folding and can work like chaperones. One advantage of D-CF 
mode is that the expressed proteins are not required to be resolubilized. So an important requirement 
to obtain MP s in soluble form can be achieved. 
2.8.3 L-CF Mode
Co-translational insertion of expressed MPs into supplied lipid bilyers can be achieved in L-CF 
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P-CF or D-CF expressed MPs can be integrated to the lipid bilayer in two different ways. One is 
post-translational reconstitution based on published protocols for the specific protein. The alternative 
is L-CF mode of expression. The charge of the lipid plays decisive role in determining the 
translational efficiencies of Mps e.g. cationic lipids inhibit translation. Lipids can can be added to the 
RM as preformed liposomes in defined compositions, isolated fractions of cell membranes, detergent 
solubilized lipo-micelles allowing mixed environment to the expressed MP, bicelles comprising 
planar bilayers surrounded by detergents, nano-lipid particles or nanodiscs providing highly soluble 
bilayer. Mechanism of co-translational MP translocation can be assessed by screened by all these 
options. In L-CF mode, the insertion of membrane protein to the lipid bilayer is more specific 
compared to the post-translational reconstitution in P-CF/D-Cf mode. 
Having said that, the L-CF mode of expression is still not well established method for MP expression 
and  currently  various  possibilities  are  being  investigated.  In 2007  Kalmback  et  al  showed 
co-translational insertion of bacteriorhodopsin in various lipids and lipid mixtures. What is more, 
cholate solubilized phosphatidylcholines can be mmied to the RM and can easily by dialyzed out to 
assist bacteriorhodopsin proteoliposome formation. Combining detergents to lipids in RM is useful in 
improving the functionality of the synthesized protein. Effect of chaperones, crude inner membrane 
vesicles and microsomes in MP integration to membranes have been reported.   But the added 
chaperones did not improve the post-translational insertion of aquaporin Z into synthetic liposomes. 
Expression of membrane proteins  can further be improved by means of variation of lipid 
composition, polarity of the lipid head group, alkyl chain length in order to change the lipid bilyer 
thinkness. Recently use of nanodiscs have become useful tools to improve MP integration to lipid 
bilayer in aqueous environment. Materials  60
3 Materials 
3.1 Laboratory equipments
Name  Source Company
0.22-μm polysulfone filters  Roth
10-liter fermenter  B.Braun
96F Nunclon Delta Black Microwell SI  Nunc, ON 137101
Äkta purifier  GE Healthcare Amersham
Autoclave  Getinge
Balance  Sartorius
Centrifuge 
Centriprep devices YM-10  Amicon
Cooled table top centrifuge 
Dialysis tubes type 27/32 MWCO 14 kDa  Spectrum, Rancho Dominguez
DispoDialyser 25 kDa MWCO, 
regenerated cellulose Spectrum,  Rancho Dominguez
French press / Cell disrupter 
Gel imager  Biometra
Glass vials  e.g., Rotilabo vials; Roth
Heating block  VWR
ITHACO electrometer  ITHACO, NY, USA
Lumi Imager P1  Roche Diagnostics
Maxi PCR Purification Kit Machery & Nagel
MicroDispoDialyser 25 kDa MWCO, 
regenerated cellulose  e.g., Roth
Microwave  Alaska
Midi DNA preparation kit  e.g., Qiagen
Mini-extruder  Avanti lipids
Nanodrop 100  peqlab
Ni-NTA Superflow resin  Qiagen
pH-meter PHM 210  Radiometer
Pipettes  Abimed, Gilson
Plate Centrifuge Rotana 46RSC-Robotic  Hettich
PS-microplate 96well V-shape ON 651101  Greiner bio-one
QIAquick gel extraction kit  Qiagen
QIAquick PCR purification kit  Qiagen
Rolling device  e.g., Frö Labortechnik
SDS-polyacrylamide gel electrophoresis system BioRad
SEC columns: Superdex200 3.2/30 
Shaker  Heidolph
Shaking incubator  New Brunswick
Slide-A-lyzer dialysis cassette 10 kDa MWCO  Pierce
Sonifier Labsonic U  B.Braun
Temperature-controlled shaking incubator 
Thermocycler  Bio-Rad, Eppendorf
UV/Vis spectrometer  Cary
Vacuum pump  Abm
Vortexer Reax 2000  Heidolph
Waterbath 
Western blotting system  BioRadMaterials  61
3.2 Chemicals
Chemicals were purchased from Roth   (Darmstadt) unless otherwise  stated. Molecular biology 
enzymes were obtained  from NewEngland Biolabs (Frankfurt,Germany). 
1,4-Dihydrobutane dihydrochloride (Putrescine) (Sigma) 
1,4-Dithiothreitol (Roth) 
2-Mercaptoethanol (Sigma Aldrich) 
2x yeast tryptophan peptone glucose (YTPG) medium (see Buffers) 
Acetyl phosphate lithium potassium salt (Sigma Aldrich) 
Adenosine 5-triphosphate disodium salt trihydrate (Roche Diagnostics) 
Amino acids (Sigma Aldrich) 
Antibodies: anti-biotin peroxidase conjugate (Sigma); anti-gree fluorescent protein from rabbit 
(Calbiochem); anti-mouse IgG HRP conjugate from goat (Sigma Aldrich); anti-penta His IgG from 
mouse (Qiagen); goat anti-rabbit IgG (Calbiochem); T7 tag antibody HRP conjugate (Novagen) 
Antifoam Y-30 emulsion (Sigma Aldrich) 
Bactotryptone (Roth) 
Benchmark protein ladder (Invitrogen) 
Coenzyme A sodium salt hydrate (Sigma) 
Complete protease inhibitor mix (Roche Diagnostics) 
Cytidine 5`triphosphate disodium salt hydrate (Fluka Sigma Aldrich) 
Detergents (Sigma Aldrich, Anatrace, Avanti Polar Lipids, Glycon): Brij-35, polyoxyethylene-(23)- 
lauryl-ether; Brij-56, polyoxyethylene-(10)-cetyl-ether; Brij-58, polyoxyethylene-(20)-cetyl-ether; 
Brij-72, polyoxyethylene-(2)-stearylether; Brij-78, polyoxyethylene-(20)-stearyl-ether; Brij-97, 
polyoxyethylene-(10)-oleyl-ether; Brij-98, polyoxyethylene-(20)-oleyl-ether; β-OG, 
n-octyl-β-glucopyranoside; FG, n-Heptyl-β-D-Glucopyranoside; 
NG, n-Nonyl-β-D-Glucopyranoside; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1- 
propansulfonat; DHPC, 1,2-diheptanoyl-sn-glycero-3-phosphocholine; diC6PC, 1,2-dihexanoyl-sn- 
glycero-3-phosphocholine; diC8PC, 1,2-dioctanoyl-sn-glycero-3-phosphocholine; DM, n-decyl-β- 
maltoside; DDM, n-dodecyl-β-D-maltoside; NM, n-Nonyl-β-maltoside; DMPC, 1,2-dimyristoyl-sn- 
glycero-3-phosphocholine; DPC, dodecyl-phosphocholine; LMPG, 1-myristoyl-2-hydroxy- 
snglycero-3-[phospho-rac-(1-glycerol)]; LPPG, 1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-rac- 
(1-glycerol)]; Lauryl-MNG, 2,2-didecylpropane-1,3-bis-β-D-maltopyranoside; Decyl- MNG, 2,2- 
dioctylpropane-1,3-bis-b-D-maltopyranoside; C6F-TAC, C6F13C2H4-S- 
poly[tris(hydroxymethyl)aminomethane; C8F-TAC, C8F17C2H4-S-poly[tris(hydroxymethyl); 
SDS, sodium dodecylsulfate; Triton X-100,; Tween 20, polyoxy-ethylene sorbitan monolaurate 20; 
Tyloxapol. E. coli A19 (E. coli Genetic Stock Center) 
Ethidiumbromide (Roth) 
Folinic acid calcium salt (Sigma Aldrich) 
Gene ruler 1kb DNA ladder (Fermentas) 
Glucose monohydrate (Roth) 
Guanosine 5`triphosphate disodium salt hydrate (Fluka Sigma Aldrich) 
Hemin (Sigma) 
HEPES (Roth) Imidazole (Roth) 
3.3 Software 
Gemini 4.2.17.304 
Tecan Magellan 5.03 
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3.4 Buffers and Media for S30 extract and T7 polymerase preparation: 
40 x S30-A/B buffer: 400 mM Tris-acetate, pH 8.2, 560 mM Mg(OAc)2, 2.4 M KCl. 
Supplement 1 x S30-A buffer with 6 mM ß -mercaptoethanol. 
Supplement 1 x S30-B buffer with 1 mM DTT and 1 mM PMSF. 
40 x S30-C buffer: 400 mM Tris-acetate, pH 8.2, 560 mM Mg(OAc)2, 2.4 M KOAc. 
Supplement 1 x S30-C buffer with 0.5 mM DTT. 
2x YTPG medium: 22 mM KH2PO4, 40 mM K2HPO4, 100 mM glucose, tryptone 16 g/l, yeast 
extract 10 g/l, NaCl 5 g/l. 
LB medium: Peptone 10 g/l, yeast extract 5 g/l, NaCl 5 g/l. 
Buffer T7RNAP-A: 30 mM Tris-HCl, pH 8.0, 50 mM NaCl, 10 mM EDTA, 10mM 
ß-mercaptoethanol, 5% glycerol. 
Buffer T7RNAP-B: 30 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1 mM EDTA, 10 mM 
ß-mercaptoethanol, 5% glycerol. 
Buffer T7RNAP-C: 30 mM Tris-HCl, pH 8.0, 1 M NaCl, 1 mM EDTA, 10 mM β-mercaptoethanol, 
5% glycerol. 
Buffer T7RNAP-D: 10 mM K2HPO4/KH2PO4, pH 8.0, 10 mM NaCl, 0.5 mM EDTA, 1 mM DTT, 
5% glycerol. 
20% streptomycin sulphate. 
3.5 Reagents for CF reaction: 
All stock solutions should be prepared with  MilliQ  ultrapure water and stored at -20
oC if not 
otherwise stated. 
50 x Complete® protease inhibitor cocktail (Roche Diagnostics) 1 tablet per 1 ml of MilliQ water. 
Amino acid mixtures containing 4 mM or 8 mM of each of the 20 natural amino acids. 
RCWMDE mixture containing 16.7 mM of each amino acid. 
1 M acetyl phosphate lithium potassium salt (AcP) (Sigma-Aldrich), adjusted to pH 7.0 with KOH. 
1 M phospho(enol)pyruvic acid K+ salt (PEP) (Sigma-Aldrich), adjusted to pH 7.0 with KOH. 
NTP mixture containing 90 mM ATP, 60 mM CTP, 60 mM GTP and 60 mM UTP, adjusted to pH 
7.0 with NaOH. 
Pyruvat kinase (Roche Diagnostics), 10 mg/ml. 
RiboLock® RNAse inhibitor (Fermentas), 40 U/μ l. 
Total E. coli tRNA (Roche Diagnostics), 40 mg/ml. 
Folinic acid, Ca2+ salt, 10 mg/ml (Sigma-Aldrich). 
Polyethylene glycol 8000 (PEG 8000), 40% (w/v). 
4 M potassium acetate (KOAc). 
2.4 M Hepes/ 20 mM EDTA, pH 8.0 adjusted with KOH. 
500 mM 1,4-dithiothreitol (DTT). 
E. coli S30 extract, store frozen at -80oC 
T7-RNA polymerase (T7RNAP), store frozen at -80oC 
Template DNA (plasmid DNA or linear PCR products) 200-500 ng/μl 
Reaction container: Analytical and preparative scale reaction container; D-tube containers, 12-14 
kDa MWCO (Merck Biosciences); Slide-A-Lyzer, 10 kDa MWCO (Pierce); dialysis tubes, 14 kDa 
MWCO. 
10   x   Premix:   15   mM   putrescine,   15   mM   spermidine,   2.5   M   K+-glutamate,   100   mM 
NH4+-glutamate, 
100 mM Mg2+-glutamate, 40 mM Na+-oxalate, 330 mM Na+-pyruvate, 340 μg/ml folinic acid, 10 
mM DTT, 5.3 mM NAD+. 30 mM CoA-Na+. 
GFP assay buffer: 20 mM Tris, 150 mM NaCl, pH 7.8. 
1000× Ampicillin stock: Dissolve 100 mg/ml Na+-Ampicillin salt in 50% H2O and 50% EtOH. 
Store at -20° C. 
1000× Kanamycin stock: Dissolve 30 mg/ml kanamycin sulfate in H2O. Store at -20° C. Materials  63
all other chemicals are from Sigma-Aldrich if not otherwise stated. 
3.6 SDS-gel buffers: 
Stacking gel buffer: 0.4% (w/v) SDS, 0.5 M Tris-HCl, pH 6.8. 
Separating gel buffer: 0.4% (w/v) SDS, 1.5 M Tris-HCl, pH 8.9. 
5× SDS-PAGE sample buffer: 25% (w/v) glycerol, 25% (v/v) β-mercaptoethanol, 7.5% (v/v) SDS, 
0.05% (w/v) bromphenol blue, 300 M Tris-HCl, pH 6.8. 
Running buffer: 0.025 M Tris-HCl, pH 8, 0.1% (w/v) SDS and 0.2 M glycine. 
Tricine-SDS- PAGE buffers: 
10× Anode buffer: 1.0 M Tris-HCl, pH 8.9 
10× Cathode buffer: 1.0 M Tris, 1.0 M Tricine, 1.0% (w/v) SDS, pH ~8.25 
3× buffer: 3.0 M Tris-HCl, 0.3% (w/v) SDS, pH 8.45 
3.7 Gel 
Coomassie brilliant blue-staining solution for SDS gels: 
50% (v/v) ethanol (96%), 10% (v/v) acetic acid (100%) and 0.1% (w/v) Coomassie Brilliant Blue 
G250 + R250. Dissolve in H2O and store at RT in a dark bottle. 
Western-blotting buffer (Towbin): Dissolve 25 mM Tris, 192 mM Glycin, 3.5 mM (1%) SDS, 15% 
MeOH in H2O and adjust to pH 8.3 by HCl. Store at 4° C. 
ECL1: 100mM Tris (pH 8.5), 2.5 mM Luminol, 0.4 mM p-cumaric acid. Store at 4° C. 
ECL2: 100mM Tris (pH 8.5), 0.0183% H2O2. Store at 4° C 
3.8 Sequencing primers for pET-Vectors 
T7-promotor : 5’ TAA TAC GAC TCA CTA TAG GG 3’  TM= 53.2 °C  
T7-terminator:  5’ GCT AGT TAT TGC TCA GCG G 3’  TM= 56.6 °C  
3.9 Materials for Nanodisc Preparation
pET28b vector (Merck, Germany)
1 M IPTG in H2O
30 mM kanamycine
500 mM phenylmethanesulfonylfuoride (PMSF) in 100% ethanol
Syringe filter, sterile, 0.45 µm (Roth)
Buffer MSP-A: 40 mM Tris, pH 8.0, 300 mM NaCl, 1% TritonX-100 (v/v). 
Buffer MSP-B: 40 mM Tris, pH 8.9, 300 mM NaCl, 50 mM cholic acid.
Buffer MSP-C: 40 mM Tris, pH 8.0, 300 mM NaCl.
Buffer MSP-D: 40 mM Tris, pH 8.0, 300 mM NaCl, 50 mM imidazol. 
Buffer MSP-E: 40 mM Tris, pH 8.0, 300 mM NaCl, 300 mM imidazol.
Buffer MSP-F: 40 mM Tris, pH 8.0, 300 mM NaCl, 10% glycerol (v/v). 
Buffer ND-A: 10 mM Tris, pH 8.0, 100 mM NaCl 
Strep-buffer: 20 mM Tris-Cl, pH 7.5, 100 mM NaCl
Sodium cholate (Carl Roth)
D-desthiobiotin (IBA)
Strep-elution buffer
3.10 Materials for Tag Variation Screen and Template Preparation 
PCR purification kit (Qiagen)
Plasmid DNA purification kit (Machery-Nagel)
Vent polymerase (New England Biolabs)
Agarose (Rotigarose, Carl Roth).Materials  64
3.11 Microbial Strains
3.12 Oligonucleotides
All primers were ordered from MWG Biotech AG or Biospring unless otherwise stated. Methods 65
4 Methods
4.1 Cell-free Expression of GS Components 
4.1.1 S30 extract preparation 
In order to obtain highly efficient cellular extracts, cultivation of the cells in a fermenter with good 
aeration is recommended. Growth curve of selected strain should first be determined in the 
individual facility and an efficient chilling of the broth after fermentation should be ensured. A brief 
summary of S30 extract preparation is listed in the following table, detailed protocols can be found 
in previous reports [197].
Protocol Step Comments
Cell fermentation Inoculation 100 ml freshly E. coli overnight culture into 10 liters of 
sterilized medium in a fermenter.
Incubation 37oC with intensive aeration and stirring
Chilling Start to chill the cell broth before the cells reach mid-log 
phase (OD600 3-5) (see Note 6).
Harvesting Harvest the cells at 18oC by centrifugation at 7,000 x g for 
15 min at 4oC.
Storage Keep the cell pellets at 4oC for the following steps or 
freeze the cell paste in -80oC for later processing.
Cell extraction Washing Gently but completely resuspend the cell pellet with 300 
ml pre-cooled S30-A buffer. Centrifuge at 7,000 x g for 10 
min at 4oC. Discard the supernatant and repeat washing 
step twice.
Cell 
disruption
Resuspend the pellet in 110% (v/w) pre-cooled S30-B 
buffer and disrupt the cell by high pressure, e.g, French 
press at 1,000 psi (see Note 7).
Lysate 
clearing 
Centrifuge the lysate at 30,000 x g for 30 min at 4oC. 
Transfer the supernatant to a fresh tube and repeat the 
centrifuge step.
Removal   of 
endogenous 
mRNA
Harvest the supernatant and adjust to a final concentration 
of 400 mM NaCl. Incubate at 42oC for 45 min in a water 
bath (see Note 8).
Dialysis Dialyse the turbid extract overnight against 100-fold excess 
of   pre-cooled     S30-C   buffer   (12-14   kDa   MWCO 
membrane) with two changes of dialysis buffer.
Harvesting Centrifuge the extract at 30,000 x g for 30 min at 4oC. 
Harvest the supernatant and transfer to a clean plastic 
tubes.
Storage Aliquot into small reaction tubes, shock-freeze in liquid 
nitrogen and store at -80oC.Methods 66
Pre-preparation
Make pre-culture in 100ml LB medium from LB plates prepared the previous day.
5L 2xYTPG:
2xYPTG: 160g Tryptone, 100g Hefeextract, 50g NaCl to 5L (gets autoclaved in fermenter)
2L Phosphate: 29.9g KH2PO4, 91.3g K2HPO4 to 2L (autoclave separately) pH 7
1M Glucose: 198g to 1L (filter separately)
2L DH2O: autoclave separately to add later
S30 buffers (50x) 
A/B (50x): 60.6g Tris, 150.1g Mg(OAc)2, 224g KCl to 1L (adjust pH to 8.2 with acetic acid)
C (50x): 60.6g Tris, 150.1g Mg(OAc)2, 294g KOAc to 1L (adjust pH to 8.2 with acetic acid)
2M DTT
1.54g in 5ml H2O
100mM PMSF
34.8mg in 2ml EtOH
Other preparations
Chill two 5L beaker of ddH2O
Autoclave necessary glassware
Collect six 1L centrifuge tubes
Collect ten 35ml centrifuge tubes
Collect two 500ml centrifuge tubes (pre-weigh one of these)
Preparation of S30 extract
First day
1. Drain water from fermenter and rinse once more with dH2O
2. Pour media in fermenter (w/o glucose and phosphate; they ppt out if autoclaved) and add 2L 
of H2O (to a total volume of 7L)
3. Turn fermenter on with green switch and press Ack to disengage alarm
4. Set fermenter switch to sterilization position
5. Re-attach third pipe from the left to remove dirty water.
6. Turn on the water and make sure small black faucet at on top of metal tubing is open 
(otherwise the water cannot enter) and press thermostat fill a couple of times
7. Close off the pressure sensor, close off the compressor (black knob to the side) and open the 
Aeration valve.  Turn on compressor and wait until the meter is at 8-10 bar.  At this point 
open both the pressure sensor and compressor, and close the aeration valve until a pressure of 
1.6 bar is reached
8. Close metal cage, go to batch and sequence F1, then press 1 and enter to activate autoclave 
sequence (at this point, the ball at top of the pressure sensor should drop down)
9. Leave the room while autoclaving
10. After autoclaving, turn water off (once temperature comes back down)
11. Leave compressor on O/N (sterilization mode and stirring) so that nothing grows meanwhile
Second day
1. Put fermenter in fermentation position
2. release the pressure valve and open one of the openings to fermenter
3. place in glucose (filtered 0,2u) and phosphate buffer (should make it up to 10L)
4. place in antifoam for excessive foaming (usually 2ml)
5. release pressure and close opening
6. Go to batch control and begin stirring (~500rpm)
7. Add bacterial culture and take “0” sample for OD
8. Take samples every 0.5h for O.D (595nm).
9. When reaching about 2.4-2.8 O.D., the temp is set to ~ 0°.  Once a temp of ~ 20° is reached, 
the water bath is filled with ice water and connected to fermenter (switch on top button of 
bath, not bottom). You then wait for the temp to reach less than 15° and take one last O.D.Methods 67
10. Drain the bacteria into centrifuge flasks (six of these so you refill each once).
11. Centrifuge (Ludwig Lab’s) at 6500rpm for 15 min
12. Pour supernatant again into fermenter and autoclave
13. Take pellet and stir with glass rod.   At this step, add buffer A (20ml 50x stock, 420ul 
β-mercapto to 1L H2O)
14. After uniform, add ~ 10ml buffer A
15. Pour contents into centrifuge flask (weighed) and top up with buffer to 300ml.
16. Wash 2x at 8000xg for 10min and the last time for 30min
17. Weigh the pellet and add 1.1x buffer B (2ml 50x stock, 50ul (2M stock) DTT, 100ul (100mM 
stock) PMSF in 100ml H2O)
18. re-dissolve pellet in buffer B and take for cell disruption
19. use french press as described
-assemble french press upside down, place in nozzle and nob
-make sure the opening is closed before placing it on apparatus
-place so that knob and nozzle face outward and that the handles do not collide
-turn on pump, place switch on high until up to platform roof and the press on 
medium.
-turn the knob slightly so that pressure does not fall below 1000 and collect lysate
-after bubbles come out, close knob and refill
20. Alternatively, use the cell-breaker (Glaubitz)
-Turn machine on, set pressure to 0.5 kbar, and press start to wash apparatus:
-wash once with water, 2x with NaOH, and 2x with water (pressure 0.5 kbar)
-pour in cells, press stop, change pressure to 1.5-1.7 kbar, and press start
-run cells 2-3x through in order to get complete lysis
-after finishing, wash machine as before (above)
21. Take the supernatant and spin it at 30xg for 30min
22. Take supernatant and transfer to another container
23. Spin again at 30xg for 30min.  
24. Collect supernatant and add from a 5M NaCl stock to final conc of 400mM, and incubate at 
42° for 45min; meanwhile dialysis tubes:
-add the tip of NaH2PO4 to 500ml H2O and microwave for 2min
-add 1ml 0.5M EDTA to 500 ml H2O and microwave for 2min
-rinse several times with water (if needed, store in 30% EtOH, 4°)
25. Place extract inside membrane and let equilibrate in buffer C (100ml 50x stock, 1.25ml (2M) 
DTT in 5L H2O) a few hours.  Then exchange buffer (another 5L) and let exchange O/N.
Third day
A. Take out dyalized lysate and centrifuge at 30xg for 30min at 4°
B. Collect supernatant, transfer to eppendorf tubes, freeze in liquid nitrogen, and store at -80° 
4.1.2 Production of T7RNAP
T7RNAP is produced by conventional overexpression in  E. coli  cells in Erlenmeyer flasks. On 
average, approximately 20,000 - 40,000 units can be isolated out of one liter culture. A summary of 
the expression protocol is given in . 
Protocol Step Comments
Fermentation Inoculation  Inoculate on liter of LB medium 1:100 with a fresh 
overnight   culture   of   strain   BL21   (DE3)   Star   x 
pAR1219.
Incubation   and 
induction
Incubate at 37oC until OD600 of 0.6 – 0.8 and induce 
with 1 mM IPTG. Continue to grow at 37oC.
Harvesting Harvest the cells by centrifugation at 8,000 x g for 15 
min at 4oC after inducing for five hours. Cell pellets Methods 68
can be stored at -80oC for later usage.
Purification Cell disruption Resuspend the cell pellet with 30 ml of T7RNAP-A 
buffer. Disrupt cells by French press at 1,000 psig or by 
sonication. Remove cell debris by centrifugation at 20, 
000 x g for 30 min at 4oC.
Precipitation of 
DNA
Adjust the supernatant to a final concentration of 4% 
streptomycin sulphate. Mix gently, inoculate on ice for 
5 min and centrifuge at 20,000 x g for 30 min at 4oC.
Ion   exchange 
chromatography
Load the supernatant on a 40 ml Q-sepharose column 
equilibrated  with  T7RNAP-B  buffer  and  wash  the 
column with the same buffer extensively. Elute the 
T7RNAP with a gradient from 50-500 mM NaCl using 
T7RNAP-C buffer for 10 cv. Collect the fractions and 
analyze by SDS-PAGE (see Note 9).
Concentration Dialysis  Pool T7RNAP containing fractions and dialysis against 
T7RNAP-D buffer overnight.
Concentration Adjust to a final concentration of 10% glycerol and 
concentrate   the   T7RNAP   pool   to   a   total   protein 
concentration of 3-4 mg/ml by ultrafiltration (see Note 
10). Adjust to a final concentration of 50 % glycerol 
and store aliquots at -80oC.
4.1.3 CECF reaction preparation for 1 ml RM and 16 ml FM
Table 3
Compound Stock Final concentration Volume
a
[µl]
RFM-Mix
RCWMDE 16.7 mM 1 mM 1,020 
Amino acid mix  25 mM 0.5 mM 374
Acetyl phosphate (Li
+, K
+) 1 M 20 mM 340 
Phospho(enol)pyruvic acid (K
+) 1 M 20 mM 340 
75 x NTP mix 90 mM ATP 1.2 mM 226.7 
60 mM G/C/UTP 0.8 mM
1,4 Dithiothreitol 500 mM 2 mM 68 
Folinic acid (Ca
2+) 10 mg/ml 0.1 mg/ml 170 
Complete® protease inhibitor 50 x 1 x 340 
Hepes/EDTA buffer 24 x 1 x 623.3 
Mg(oAc) 1 M 11.1 16, mM
b 274 
KOAc 4 M 110, 270, mM
b 382.5 
PEG 8000 40% 2% 850 
NaN3 10%  0.05% 85
MilliQ water 1,963.5 
                            Total:  7,057
RM-Mix
Master mix RFM 415 µl
Pyruvat kinase 10 mg/ml 0.04 mg/ml 4 µl
t-RNA (E. coli) 40 mg/ml 0.5 mg/ml 12.5 µl
T7RNAP 1.4 mg/ml 0.05 mg/ml 35,7 µl
Ribolock 40 U/µl 0.3 U/µl 7.5 µlMethods 69
DNA template 0.2 - 0.5 mg/ml 0.015 – 0.03 mg/ml 60 µl
E. coli S30 extract 1 x 0.35 x 350 µl
MilliQ water 115.3 µl
                            Total:  1 ml
FM-Mix
Master mix RFM 6,642 µl
S30-C Puffer 1 x 0.35 x 5,600 µl
Amino acid mix 4 mM 0.5 mM 2,000 µl
MilliQ water 1,758 µl
                            Total:  16 ml
a Calculated for 1 ml RM and 16 ml FM = 17 ml RFM master mix.
b Subject to optimization. Volumes are calculated for final total concentrations of Mg
2+ of 16 mM and 
K
+ of 270 mM as additional amounts of 4.9 mM Mg
2+ and 160 mM K
+ are contributed by other 
compounds.
4.1.4 Template Production and Yield Optimization by Tag Variation Screen
CF system using  E. coli  extract require either circular plasmids or linear DNA as template for 
expression.   No   or   insufficient   expression   of   proteins   is   usually   caused   by   an   inefficient 
translation/transcription process. Rational template design is therefore important for successful 
protein synthesis. 
4.1.5 General Template Design
High level protein production in the E. coli CF system is usually directed by standard T7 regulatory 
sequences. T7 promoter as well as T7 terminator must be present in the DNA template. Suitable 
vectors containing the T7 promoter sequence include the pET (Merck Biosciences) and pIVEX 
(Roche Diagnostic) series. In addition, few further parameters regarding template design should be 
considered. (I) Purification tags. The presence of small tags at the C-terminal of the target protein is a 
valuable tool for the detection of expression and for full-length protein purification. Poly(His)10-tags 
or StrepII-tags may be used for protein detection by immunoblotting or for efficient membrane 
protein purification. (II) Expression monitoring. Fusion with reporter proteins such as GFP allows 
the fast monitoring of expression and may accelerate the optimization of the reaction conditions for 
improved protein target production. (III) Codon usage. In rare cases, cluster of non-frequent codons 
or the formation of unfavorable secondary structures within the coding sequence may cause amino 
acid misincorporation or premature terminations of the protein product. Such problems should be 
addressed by expression of synthetic genes. (IV) Expression tags. In most cases, inefficient initiation 
of translation is the reason for low expression efficiency. This problem is addressed by the tag 
variation screen (see Subheading 3.3.3) by fusing small tags to the N-terminus of the target protein. A 
small set of templates containing different optimized tags is synthesized by a two step PCR approach 
and the generated linear PCR products are directly screened in CF reactions.Methods 70
4.1.6 DNA Template Preparation
High quality and purity of the plasmid or linear DNA is crucial for efficient CF expression. As the 
vectors do not replicate during the reaction, specific selection markers or are not of importance. The 
final template concentration for optimal expression efficiency should be determined for each new 
target with an initial concentration screen in the range in between 0.1 and 20 ng/µl of reaction 
mixture. 
4.1.7 Plasmid DNA
1. Inoculate 100–200 mL of LB medium supplemented with the specific antibiotic with the E. coli 
strain containing the desired plasmid and incubate overnight at 37°C on a shaker. 
2. Purify the plasmid using commercial available kits  like “Midi” or “Maxi” kits. “Mini” 
preparations are not suitable due to the low quality of the purified DNA.
3. Dry the DNA overnight and dissolve it into MilliQ water. Optimal concentration of stock DNA 
solution is in between 0.2 and 0.5 mg/ml. DNA stocks can be stored at -20°C. In case of 
precipitation due to freezing/thawing cycles, the DNA concentration must be checked again.
4.1.8 Linear DNA
If the target gene is already present in a suitable vector under control of T7 elements, fragments 
containing the T7 regulatory sequence and the target gene can be amplified by standard PCR and 
directly   used   in   the   CF   reaction.   If   the   target   gene   is   not   under   T7   control   or   if 
expression/purification tags or expression monitors have to be attached, a multistep PCR strategy 
such as for the tag variation screen can be applied.
1. For the PCR two primers are needed: a forward primer annealing at the T7 promoter and a 
reverse primer annealing at the T7 terminator.
2. The reaction can be performed in 50 µl volume with 20 ng of plasmid DNA as template, 0.4 µM 
each of the forward and reverse primers, 200 µM of dNTPs, 0.5 units of Vent DNA polymerase 
(NEB) and 1x ThermoPol reaction buffer. The PCR program has 2 min denaturation step at 94 °C 
followed by 32 cycles of denaturation for 15 s at 94°C, primer annealing for 30 s at 55°C and 
extension for 2.5 min. at 72°C. A last step of final elongation is performed for 10 min. at 72°C.
3. PCR products should be purified using standard PCR purification kits (e.g. Qiagen).
4.1.9 Tag variation screen for improved expression
Small expression tags comprising 6-12 codons are fused to the translational start site of the target 
coding sequence by an overlap PCR approach. The expression tags are optimized in suppressing 
secondary structure formation which may prevent the initiation of translation. As secondary 
structures also depend on the individual target sequence, it is recommended to empirically screen a Methods 71
mini library of optimized tag fragments (Table 5). The whole tag variation screen can be performed 
in one day. The finally identified most efficient expression tag may further be modified [193]. The 
small expression tags have only minimal impact on structure and function and can usually remain on 
the target protein. 
4.1.10Primer Design
Four different primers are needed for the first step of the PCR reaction in order to generate a library 
of tags fragments and a target fragment. 
Primer 1 (P1): A universal forward primer annealing upstream of the T7 promoter.
Primer 2 (P2): Reverse tag-specific primer, for each tag a specific P2 primer is needed. P2 anneals at 
the ribosome binding site and contains a 5-prime linker with a specific tag sequence followed by an 
PCR overlap region. For the PCR overlap region, protease cleavage sites e.g. for TEV or PreScission 
protease could be used, allowing the option to remove the tags after protein purification. 
Primer 3 (P3): This primer is target gene specific annealing at the start of the coding sequence and 
carrying a 5-prime linker with the PCR overlap region.
Primer 4 (P4): A universal reverse primer annealing downstream of the T7 terminator.
4.1.11Linear DNA Template Preparation for  Tag Variation Screen
1. First a tag fragment library is produced by PCR using a vector containing the T7 promoter as 
template and the primers P1 and P2.
2. Second a linear target fragment is produced by PCR with the primers P3 and P4 and with a vector 
carrying the coding sequence of the target protein under T7 control.
3. All synthesized PCR fragments are purified using standard PCR purification kits (e.g. Qiagen).
4. In the overlap PCR step, the linear target fragment is mixed with the individual fragments from 
the tag library in equal molar ratios using 200 ng target fragment and corresponding amounts of 
tag fragments. The overlap PCR is performed with the primers P1 and P4. The resulting PCR 
fragments are purified and analysed for purity and integrity on a 1% agarose gel. The purified 
PCR fragments can be directly added into the CF reaction as templates. Expression tags may be 
removed after CF expression and purification of the target protein by taking advantage of the 
protease recognition site used as overlap region. Alternatively, identified beneficial expression 
tags may be further modified by truncations.
5. Expression tags for tag variation screen
Name  Nucleotide sequence  Amino acid sequence AT (%)
AT AAATAT TATAAATATTAT KYYKYY 100
SER AAATCATCATCATCATCA KSSSSS 72
H AAACCATACGATGGTCCA KPYDGP 55
G AAAAGTAAAGGAGAA GAA KSKGEE 72Methods 72
4.1.12General Setup of CF Expression Reactions
Analytical scale CECF reactions are suitable for any kind of screens such as Mg
2+ optimization 
screens, tag variation screens or ND lipid screens and can be performed in Mini-CECF reactors or in 
suitable D-tubes (Merck Biosciences) with RM volumes of 50-100 µl. The identified optimal 
reaction parameters can then be scaled up in a 1:1 ratio into preparative scale CECF reactions with 
RM volumes of several ml and by using Maxi-CECF reactors. Mastermixes of common compounds 
of RM and FM should be prepared in order to minimize variations in between identical reactions. 
Nevertheless, reactions should be always prepared at least as duplicates. We recommend a RM : FM 
ratio in between 1:15 and 1:20.
4.1.13Analytical Scale CECF Reactions
1. Calculate the individual compound volumes according to the desired number of  reactions 
and design an appropriate pipetting scheme using standard software packages such as MS Excel, 
LibreOffice Calc or Gnumeric.
2.  Prepare standard 24-well microplates and appropriate numbers of Mini-CECF reactors and 
pieces of dialysis membrane with a MWCO of 14 kDa.
3. Prepare a common master mix RFM for the RM and FM and mix by vortexing (Table 2). 
4. Reconstitute RM and FM with the appropriate volumes of RFM and complete by addition of 
MilliQ water. Mix FM by vortexing and the RM by gentle shaking.
5. Fill RM and FM aliquots into reaction containers. A: Mini-CECF-Reactors [172] with RM 
volumes of 30 - 100 µl can be used in combination with standard 24-well  microplates holding 
FM volumes of up to 1.5 ml in their cavities. A piece of fresh dialysis  membrane is  fixed to the 
Mini-CECF-Reactors with a Teflon ring. Avoid air bubbles or residual water in the container and 
check for leakage. B: Commercial D-tube  dialyzers (Novagen) for RM of 100 µl can be used in 
combination with suitable tubes (e.g. 2 ml  Eppendorf tubes) holding the appropriate volume of FM. 
6.  CECF reactions are incubated over night at temperatures in between 20 - 30°C with gentle 
shaking or rolling in order to ensure efficient substance exchange between RM and FM. 
4.1.14Preparative Scale CECF Reactions
For preparative scale CECF reactions, commercial Slide-A-Lyzer devices (Pierce) with a MWCO of 
10   kDa  and   holding  up   to   3   ml   RM   volumes   may   be   used.  As   FM   container,   either 
Maxi-CECF-Reactors [197] or small suitable plastic boxes or beakers may be used. Alternatively, 
suitable sized D-tube dialyzer or appropriate pieces of dialysis tubes sealed at both ends by knots 
may be used as RM container in combination with 15 - 50 ml Falcon tubes as FM container.Methods 73
4.1.15Quantification of Target Production by 
35S-Met Incorporation
If exact determination of expression efficiency is necessary, the labelling with 
35S methionine is 
recommended. Refer to [197] for details.
4.1.16Preparation of NDs as Supplement for CF Reactions
NDs are highly water soluble and stable. Different diameters of NDs are possible depending on the 
selected type of MSP [198,199]. Most frequently used are MSP1 (9.7 nm with POPC) fitting MPs 
containing at least up to 21 transmembrane segments [181] and MSP1E3 (12.1 nm with POPC). 
Essential for the efficient solubilization of CF expressed MPs are highly concentrated and 
homogenous ND stock solutions. The preformed NDs can be filled with a large variety of different 
lipids and the selected type of lipid can have crucial effects on the solubilization efficiency of 
individual MPs. We describe the basic protocol for MSP1 production containing an N-terminal 
His6-tag cleavable by the TEV protease. The protocol can also be applied to the preparation of the 
larger MSP1E1, MSP1E2 and MSP1E3 constructs.
MSP1 Expression
1. For   high  yield   expression  transform   the  MSP1-gene   containing   pET28b-plasmid  (Merck 
Biosciences) into BL21 Star (DE3) cells (Invitrogen). Inoculate 4 x 600 ml sterile LB medium 
supplemented with sterile filtrated glucose (0.5%; w/v) in 2 liter Erlenmeyer flasks with 50 ml of 
fresh LB overnight cultures. 
2. Grow cells at 37°C and induce expression with 1 mM Isopropyl-β-D-thiogalactopyranoside 
(IPTG) at OD600  = 1. Incubate cells for 1 h at 37°C and then reduce temperature to 28°C for 
additional 4 hrs. Harvest cells by centrifugation (10 min, 6,000xg). The pellet can be stored at 
-20° C.
MSP1 Purification
1. Thaw pellet of 2.4 liter fermentation on ice and resuspend in 50 ml buffer MSP-C  supplemented 
with one tablet Complete
© protease inhibitor cocktail (Roche) and 1 mM freshly prepared PMSF. 
Add Triton X-100 from 10% (v/v) stock to a final concentration of 1% (v/v). 
2. Disrupt cells by ultrasonification (3x 60 sec and 3x 45 sec) with equal cooling times in between 
each cycle. Centrifuge at 30,000xg for 20 min. The supernatant is filtered through 0.45 µm prior 
further purification.
3. Equilibrate ion metal affinity chromatography (IMAC) column (10 ml bed volume, Sepharose 6 
FF, GE Healthcare) with 5 column volumes (CV) buffer MSP-A. Load the filtered supernatant of 
cell disruption onto the column and wash the column with 5 CV buffer MSP-A, 5 CV buffer 
MSP-B, 5 CV buffer MSP-C and 5 CV buffer MSP-D. 
4. Elute MSP1 with buffer MSP-E in 1 ml fractions. Pool MSP1 containing fractions and Methods 74
immediately set to 10% glycerol (v/v) to prevent precipitation. Dialyze pooled fractions over 
night at 4°C against 5 liters MSP dialysis buffer (40 mM Tris-HCl, pH 8.0, 300 mM NaCl, 10% 
glycerol (v/v)) with one buffer exchange after 2 hrs. MSP concentration is determined using A280 
with the molar extinction coefficient ε = 24,750 L*mol
-1*cm
-1 and MW = 25.3 kDa. MSP1 is 
aliquoted and frozen at -80°C for long time storage.
ND Assembly
The assembly of empty NDs requires extensive optimization if homogenous samples are required. As 
the MSP associates with a fixed number of lipids, the MSP to lipid ratio needs to be adjusted for each 
MSP/lipid combination. 
1. Lipid stocks are prepared by suspending lipids in water to a final concentration of 50 mM 
supplemented with sodium cholate (Roth) for complete solubilization. For each individual 
lipid specific final concentrations of sodium cholate may be required in order to obtain a clear 
suspension.
2. For analytical assembly, combine MSP with lipids and detergent in a final volume of 100 µl. 
MSP (25 µM), lipids (e.g. 2 mM with MSP1 and DMPC) and detergent (e.g. DPC 0.1% w/v) 
are mixed and incubated for 1 h at room temperature. Induce ND assembly by dialysis 
against a large volume (e.g. 5 liters) of disc formation (DF) buffer (100 mM NaCl, 10 mM 
Tris-HCl, pH 8.0) at room temperature for 12 hrs (10 kDa MWCO, Slyde-A-Lyzer, 
ThermoFischer). Refresh buffer and dialyse for further 24 hrs at 4°C. Centrifuge supernatant 
(20 min, 22,000xg) and apply to SEC analysis.  
3. Load supernatant of the assembly reaction to a suitable SEC column (e.g. Superdex 200 
3.2/30). Equilibrate the column with buffer ND-A. At optimal MSP to lipid ratios, the SEC 
elution profiles should show evenly shaped elution peaks indicating homogeneous ND 
populations. 
4. For preparative scale ND assembly, reaction volumes can be scaled to 3 ml. Larger volumes 
(e.g. 10 ml) might require extended dialysis time and more frequent buffer changes.
ND Concentration, Storage and Stability
1. Equilibrate Centricon filter devices (10 kDa MWCO, Millipore) with buffer ND-A and 
concentrate at 4°C to the minimal volume of 200 µl as recommended by the manufacturer. 
After concentration centrifuge the ND stock for 10 min at 22.000xg. The final protein 
concentration is determined by the Bradford assay.
2. For short time storage (< 12 hrs) the ND stock can be kept on ice. Long time storage (up to 
weeks) can be achieved by flash freezing in liquid nitrogen and storage at -80°C. Avoid 
extensive numbers of freeze-thaw cycles as this will destroy the NDs. Thaw ND stock 
solutions on ice.Methods 75
3. Stability depends on the type of generated ND. While MSP1-DMPC NDs can be stored at 
4°C for weeks, other types will start to precipitate after a few days. Stability generally 
decreases with increasing numbers of double bonds in the lipid chains (e.g. DMPC NDs are 
more stable than DOPC NDs) and with increasing MSP size. 
Co-translational Formation of MP/ND Complexes
A protocol for the co-translational association/insertion of CF expressed MPs with NDs is described. 
Solubilization with detergents or the initial precipitation of the MPs can thus be avoided. NDs are 
highly tolerated by CF systems and usually do not have inhibitory effects on the expression 
efficiency. C-terminal fusion-constructs of MPs to sGFP allow a fast initial monitoring of the 
co-translational solubilization of MPs with the NDs, although the folding of sGFP may not always be 
completely correlated with the folding of the N-terminal MP fusion. 
Quantifying sGFP
1. After expression, centrifuge the reaction mixture (10 min, 22,000xg) and use supernatant for 
fluorescence assay.
2. Add 3 µl of the supernatant in 300 µl of GFP-assay buffer (20 mM Tris-HCl, pH 7.4, 150 
mM NaCl). Measure fluorescence intensity of each reaction by at least triplicates and convert 
into protein concentration by a calibration curve with purified sGFP.
CF Production of MP/ND Complexes
1. The synthesized MPs and the NDs must be present at least in stoichiometric amounts in order 
to improve the sample homogeneity. In addition, the type of lipid in the NDs can strongly 
affect the efficiency of complex formation with individual MPs. Initial ND concentration 
screens should therefore be performed for each new MP/ND combination in order to 
determine conditions for best solubilization. The MP is quantified in the soluble and 
non-soluble   fraction   after   reactions   with   increasing   amounts   of   supplied   NDs.   For 
quantification, either MP-sGFP fusions, detection of immuno-tags after western blotting or 
35S-Met incorporation can be used.
2. Prepare duplicate CF reactions for each ND concentration. A recommended initial screen 
would comprise final ND concentrations of 0 µM, 20 µM, 40 µM, 60 µM, 80 µM, 100 µM 
and 120 µM in the RM.
3. After reaction, centrifuge the reaction at 22,000xg for 10 min. to separate soluble and 
insoluble fractions and quantify the expressed MP in supernatant and in the pellet fraction. 
4. If sufficient solubilization of the MP cannot be achieved, the effects of different ND types 
and/or different lipids should be analysed.Methods 76
Purification of MP/ND Complexes
1. For functional analysis in most cases purified MP/ND complexes are required. For optimal 
sample homogeneity, the NDs are usually added in access to the CF reaction and empty NDs 
might need to be removed. Providing unique affinity tags at the MP, e.g. a Strep-II-tag, is 
therefore recommended. 
2. Centrifuge reaction mixture after expression at 22,000xg for 10 min. Apply 5-fold diluted 
supernatant in Strep-buffer to Strep-Tactin resin (IBA) equilibrated in Strep-buffer. Perform 
binding in batch setup with 500 µl Strep-Tactin resin (IBA) for each 1 ml supernatant of 
reaction mixture. Incubate for 12 hrs at 4°C with slightly shaking. 
3. Load binding solution on an empty gravity flow column. Wash resin with 5 CV Strep-buffer. 
Elute   protein   with   Strep-elution-buffer   (Strep-buffer   supplemented   with   2.5   mM 
desthiobiotin). Apply 1x 0.5 CV and 4x 1 CV of  Strep-elution buffer  and collect main 
fractions. 
Fig 4.1  Strategy for the tag variation screen. Two subsequent PCR steps are illustrated. 1: 
The tag fragment(s) with primers P1/P2 and the target fragment(s) with primers P3/P4 are 
generated with appropriate overlap sites. 2: Corresponding tag fragments and target 
fragments are fused by an overlap PCR reaction using primers P1/P4. The products are 
suitable as CF expression templates for the tag variation screen.
4.2 Protein Purification
Samples were separated on 16% (w/ v) acrylamide/bisacrylamide gel and stained with Coomassie 
blue or used for immunodetection via Western blotting and by using mouse penta-His antibodies Methods 77
(Qiagen, Hilden, Germany). The CF expressed GS components were purified by immobilized metal 
chelate affinity chromatography (IMAC). 1 ml RM with expressed HsGNA1-His6 was mixed with 
300 ll of Ni2+-NTA resin (Qiagen, Hilden, Germany), 10-fold equilibration buffer (20 mM 
phosphate buffer, pH 7.2, 300 mM NaCl, 20 mM imidazole) and incubated overnight at 4 °C with 
gentle shaking. The mixture was then poured into an empty column and washed with 10-fold col- 
umn volumes of equilibration buffer supplemented with 60 mM imidazole. GS components were 
then eluted with equilibration buffer supplemented with 300 mM imidazole. 
For analysis by size exclusion chromatography (SEC), IMAC purified GS samples were loaded on a 
Superdex 75 30/ 100 column (GE Healthcare, Munich, Germany) with a bed volume 
of 24 ml pre-equilibrated with SEC-buffer (150 mM NaCl, 20 mM Tris–Cl, pH 8.0) at a flow rate of 
0.4 ml/min. 
4.3 SDS-PAGE and Western Blot:
The soluble fractions in CF expression system were harvested by centrifuging the reaction solution 
for 10 min at 13,000 rpm and precipitated with the addition of 10 time cold acetone. Then it was 
redissolved in 25 µl sample loading buffer  after centrifugation, air drying and heated for 10 mins at 
95 °C. About 15µlsamples were loaded onto a 16% (w/v) acrylamide/bisacrylamide gel and stained 
with Coomassie blue. For western blot analysis, proteins were then transferred to a Immobilon-poly 
(vinylidene difluoride) membrane (Millipore GmbH, Schwalbach, Germany) by electroblotting for 
30 min at 350 mA. The membrane was blocked with 4% milk in PBST (0.137 M NaCl, 0.003 M 
KCl, 8 mM Na2HPO4 and 1.5 mM KH2PO4 and 0.05% (v/v) Tween 20) and probed with mouse 
Penta·His Antibody (Qiagen GmbH, Hilden, Germany) followed by HRP-conjugated goat antimouse 
IgG (Santa Cruz biotechnology, Inc., Santa Cruz, CA, USA). The protein bands were visualized with 
the Western Blotting Luminal Reagent (Santa Cruz biotechnology, Santa Cruz, USA) and developed 
using an luminescence detection system Lumi-Imager F1™ (Roche Diagnostics, Mannheim, 
Germany).Methods 78
4.4 Laser-induced liquid bead ion desorption-Mass spectrometry (LILBID)
LILBID is a novel mass spectrometry method that allows an exact mass determination of single 
macromolecules dissolved in droplets of solution containing an adequate buffer, pH, ion strength, 
etc., as described previously [1]. Briefly, droplets of solution of analyte are ejected by a piezo-driven 
droplet generator and transferred into a high vacuum. There, they are irradiated droplet by droplet (Φ 
= 50 μm, V ~65 pl, 10 Hz) by a pulsed IR laser tuned to the stretching vibration of water at 2.9 µm. 
By laser ablation the droplets explode, ejecting preformed biomolecular ions into the vacuum. The 
total volume of solution required for the mass determination is only few µl in typically µM 
concentration. The method is ideal for studying biomolecules of low availability [1]. The amount of 
energy transferred into noncovalent complexes by the IR desorption/ablation process can be 
controlled in a wide range, starting from ultrasoft to harsh conditions, just by varying the laser 
intensity [2]. At ultrasoft conditions large macromolecules can be detected in their native 
stoichiometry. The complexes are detected in different charged states, preferentially as anions. The 
number of charge states observed increases with the size of the molecules but is less than those 
observed in electrospray ionization and considerably more than in MALDI. For buffer exchange 
Zeba Spin columns were used following the standard procedure.
4.5 Blue Native PAGE
Gel-chamber,  4-16% Bis-Tris gels (NativePAGE Novex 4-16%, 1.0 mm, 10 well) and native marker 
(NativeMark) also from invitrogen were used. 
Anode-buffer: 50 mM Bis-Tris/HCl, pH 7 
Cathode-buffer 1:  50 mM Tricine , 15 mM Bis-Tris/HCl, pH 7 , 0.02% Coomassie 
Cathode-buffer 2:  50 mM Tricine , 15 mM Bis-Tris/HCl, pH 7 , 0.002% Coomassie
The gel was run for 1 h at 100 V with cathode buffer 1 containing 0.02% Coomassie and 1 more hour 
at 400 V with cathode buffer 2 containing 0.002% Coomassie
4.5.1 Silver Staining
The following protocol was used from [200]Methods 79Results 80
5 Results
5.1 Cell-free Expression of GS Operon
γ-secretase is an intramembrane cleaving protease that provides the final cut to Amyloid Precursor 
Protein to form Amyloid beta peptides (Aβ 37-43) that are stored as plaques in the brains of 
Alzheimer's patients. Therefore γ-secretase can be an important drug target but is there is no way to 
measure its activity in vitro and assay   inhibitors or modulators. A γ-secretase operon carrying T7 
poromoter, Pen-2, PS1, Aph1-(His)10,  Nicastrin, T7 terminator respectively connected by linkers 
was synthesized and cell-free expression protocol was optimized to express it. After initial Mg
2+ ion 
concentration optimization, the operon was expressed as precipitate (P-CF), in detergent micelles 
(D-CF), and in nanodiscs (L-CF). All proteins of the complex were pulled down and purified by 
Ni2+ metal-chelate affinity chromatography. Expression yield and solubility in various detergents 
were measured and compared. The presence of Aph-1 was confirmed by western bloting with Anti 
His antibody and other subunits were detected mass spectrometry. Electron microscopy analysis 
reveals the presence of heterogeneous complexes although blue native PAGE resulted in smearing. 
Currently further optimizations and in vitro activity assay is in progress. 
Cell-free Expression of GS
 
Synthesized GS operon comprises T7 promoter, Pen-2, Presenilin 1, Aph1-His 10, Nicastrin, T7 
terminator respectively from N- to C-termini. Each protein is separated by linkers. Assuming only 
monomers in the final γ- secretase complex, it gives a molecular weight of (13.6 + 52.7 + 28.8 + 
13.7) = 108.8 kDa. Two constructs with Ampicillin Resistance (pTriEx1.1 vector- 8145 bp) and 
Kanamycin Resistance (pMK-RQ-Bb vector- 5328 bp) were made. The sequences of the operon 
were verified by sequencing with T7 promoter and terminator primer respectively. In P-CF mode 
expression, first the Mg2+ ion concentration was optimized from 12-22 mM (Fig. 5.2) for both of the 
constructs. A clear lane was visible at the same level of Pen-2 control. Western blotting (WB) with 
anti-His antibody indicated the highest expression of Aph-1 at 20-22 mM Mg2+ ion concentration 
Fig 5.2  Mg
++ Screen of GS operon Fig 5.1 Western blot of pallet of unpurified 
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for the operon with Kanamycin resistance (Fig. 5.1). 20-22 mM Mg2+ concentration was further 
used for expression and purification of the complex. 
Purification of GS Operon
After preparative scale P-CF expression of 1 ml, GS was resolubilized with 0.5 % LMPG. It was 
incubated overnight to Ni-NTA column at 4°C with 150 mM NaCl, 20 mM HEPES pH 7.0, 2 mM 
beta Mercaptoethanol, and 20 mM Imidazole. Thereafter the resin was poured into an empty column 
and the flow through due to gravity was discarded. It was wasted with 10 column volumes of the 
same buffer supplemented with 20, 40, 60 & 80 mM Imidazole and 0.05 % LMPG respectively. The 
protein was eluted at 300 mM imidazole. The obtained protein concentration detected by Bradford 
assay was  (0.15 mg/ml) 
Because the amount of purified protein was low, Invitrogen's SilverQuest Silver staining kit was used 
to stain the 16 % SDS-PAGE gel. It is ~30 times more sensitive than coomassie G-250 staining. The 
purified protein migrates at 4 different MW i.e. two around 15 kDa and two around 50 kDa (Fig. 
5.3). 
In order to verify the presence of GS components, WB was carried out with anti-His antibody with 
recognizes the His tag. Since Aph-1 only contains His tag, clear bands in the WB indicates that 
Aph-1 is present in the expression. A thick band is missing in WB where Pen-2 migrates in 
SDS-PAGE of purified GS. So one can purify Pen-2 along with Aph-1. However in SDS-PAGE 
membrane proteins don't run at the same level of their molecular weight. 
We did not attach His-tag to any other GS component because it might inhibit their activity. Pen-2 
and PS1 should be also expressed because they are situated before Aph-1 in the operon. Still it is not 
clear whether we have all components of GS complex expressed well. Also during washing with 80 
mM Imidazole there is no signal in WB whereas in the first elution fraction one can see strong signal 
indicating that the proteins of the GS complex could be pulled down by Aph-1 (Fig 5.4, 5.3). 
Presenilin-1 could show up in the WB because it has several histidines and if they come close during 
folding, antibody would bind to it. Western blotting with PS1, Pen-2 and Aph-1 antibodies was 
undertaken without any signal probably due to the fact that the antibodies were raised against 
endogenous protein. However Pen-2 control expressed by cell-free expression gives signal. 
  
Fig 5.4 Fig 5.3Results 82
In order to further verify the presence all components of the GS complex in the pull-down, 
Laser-induced Liquid Bead Ion Desorption-MS (LILBID) was undertaken. LILBID is a novel mass 
spectrometry method that allows an exact mass determination of single macromolecules dissolved in 
droplets of solution containing an adequate buffer, pH, ion strength, etc. 
LILBID was performed on the elution fractions after dialysis to 50 mM NaCl. Before the experiment 
buffer was exchange from HEPES/LMPG into TRIS/DDM. Desalting in HEPES/LMPG gave no 
signals. Desalting in Tris/DDM gave signals, but only at harsh conditions - i.e. most likely breaking 
any complexes. Softer condition gave worse signals.  So the LMPG to DDM transition was only 
partially successful. However in harsh conditions singnals were better (Fig. 5.5). 
In order to identify the existence of GS complex after pull down, EM images were taken after 
Fig 5.5: LILBID mass spectra of expressed GS components. (left) In medium condition showing 
only the Presenilin 1 (right) in harsh condition showing Presenilin 1 and Aph-1.
Fig  5.6: (left) Electron Microscopy (EM) of GS showing presence of heterogeneous particles. 
(right) Blue Native Page of expressed GS. Lane 2: Invitrogen BN-marker, 4: GS LMPG 5: 0.05% 
DDM GS 6: 0.02 % DDM GS 7: Invitrogen BN-marker 8: c-ring (91 kDa)  Results 83
negative staining (Fig.5.6). In the EM images, many seem to be single particles and they seem to lie 
in different orientations on the grid, which is good if one is aiming for 3-D reconstruction. But also 
larger objects (dimer and trimer) can be seen. One has to take many more images of highly purified 
protein and do single particle analysis.  However the sample needs to be optimized, which is still 
heterogeneous. 
Also blue native page was carried out (Fig. 5.6) to identify the presence of complex after pull down. 
However only a smear was obtained in case of GS solubilized in DDM and LMPG. So it needs to be 
optimized and need to be performed just after purification. 
Furthermore, GS operon was expressed in D-CF mode with detergents like Brij 58, 78 etc and in WB 
of pallet had similar pattern like in P-CF expression mode. 
Conclusions and outlook
• GS operon consisting of Pen-2, Presenilin 1, Aph1-His10, Nicastrin was expressed and 
purified by continuous-exchange cell-free expression strategy. 
• Presenilin 1 and Aph1 proteins were identified by LILBID-MS and Pen-2 by SDS-PAGE and 
WB. 
• Activity assay of the purified complex is required to establish its enzymatic activity in vitro. 
Further Electron Microscopy needs to be performed for single particle reconstitution. Results 84
5.2 Structural Investigation of Pen-2
Presenilin enhancer 2 (Pen-2) is a structural subunit of the γ-secretase complex. Pen-2 is 101 amino 
acid long integral membrane protein with two membrane spanning helices and both N-terminal and 
C-terminal facing extracellularly. It regulates the endoproteolytic cleavage of Presenilin 1 into 
C-terminal and N-terminal fragments required for its functioning. Recent studies show that Pen-2 
and Presenilin 1 are able to cleave the substrates in vitro.
Methods:
Expression and Purification of Pen-2: Human gene of Pen-2 was cloned into the pET21a(His)10 
vector.   PCR   based   N-terminal   tag   variation   of   Pen-2   followed   by   Mg
2+  ion   concentration 
optimization was performed in order to improve its expression.
Quality and Stability assay of Pen-2 and NMR: Homogeneity of purified Pen-2 in various detergents 
was checked by Superdex 200 3.2/30 column and stability was checked performing Circular 
Dichroism (Secondary Structure and Melting Curve) experiments. 
NMR studies from Pen-2 expressed in P-CF mode:  Pen-2 was expressed as precipitate in 3 ml 
reaction mix of continuous exchange cell free (CECF) expression mode. It was resolubilized in 2% 
Fos-14 and bound overnight to Ni-NTA column with 20mM Tris-HCl pH 7.0, 300 mM NaCl, 20 mM 
β-Mercaptoethanol and 20 mM Imidazole.  The column was washed gradually with the same buffer 
and 10 column volume of  20 mM, 40 mM and 60 mM Imidazole and eluted with 5 column volume 
of 300 mM Imidazole. Purified Pen-2 was dialyzed to 20 mM sodium acetate buffer pH  5.0 and 5 
mM β-Mercaptoethanol and concentrated before recording [
15N,
1H] TROSY spectra of uniformly 
[
15N,
1H] labeled Pen-2.
  Fig 5.7: Scheme for Tag variation . 
The scheme of tag-variation is shown above where the N-terminal tag of the gene which is preceded 
by T7-promoter, epsilon enhancer, ribosome binding site and start codon respectively and followed 
by Gene of Interest, C-terminal tag, stop codon and terminator respectively. This N-terminal tag was Results 85
varied in order to boost the expression of Pen-2.
 
Fig 5.8: Tag variation screen of 
Pen-2.    The   expression   with 
sHis   tag   was   the   highest 
compared to T7, AT, GC, A-GC 
tag.    sHis  tag consists  of  6 
Serine residues (DNA sequence: 
TGA   TGA   TGA   TGA   TGA 
TGA ). Final sequence of Pen-2 
is as follows:M S S S S S S L E 
V L F Q G P M N L E R V S N 
E E K L N L C R K Y Y L G G F 
A F L P F L W L V N I F W F F 
R E A F L V P A Y T E Q S Q I 
K G Y V W R S A V G F L F W 
V I V L T S W I T I F Q I Y R P 
R W G A L G D Y L S F T I P L 
G T P L E H H H H H H H H 
H H
Fig 5.9 Optimization of Mg
++ ion concentration. From 16-18 mM 
of Mg
2+ the expression of Pen-2 was the highest. Moreover optimal 
K+ ion concentration was 290 mM. The results were confirmed by 
western blot.Results 86
Fig 5.10:  Purification of Pen-2. NiNTA elution profile of Pen-2 : After purification Pen-2 
gives band below 18 kDa.
116kD 
    66kD 
    45kD 
    35kD 
    25kD 
    18kD 
M  FT       80mM     100mM     120mM      150mM     180mM     300mM
Fig 5.11 In order to check the homogeneity and stability of the purified Pen-2 
sample in various detergents, size-exclusion chromatography was carried out 
after keeping it at room temperature for two days. First Gaussian like peak at 
1.6 ml elution volume corresponds to Pen-2 micelle. Running Buffer of 0.05% 
Fos-14, 20 mM β-Mercaptoethanol, Superdex 200 3.2/30 column was used for 
separation. x-axis: elution volume (ml) y-axis: blue line- absorbance at 280 nm 
(arbitrary units), red line: - absorbance at 260 nm (arbitrary units)Results 87
[
15N,
1H] TROSY HSQC Spectra of Pen-2 in various detergents:
All the spectrum show an overall distribution of the 
peaks from 7 
1H/ ppm to 10.5 
1H/ppm which is of 
good resolution. NMR spectra was also measured at 
313 K but it does not improve the spectra. Adding 
additional detergent in the NMR sample worsen the 
quality of the recorded spectrum and diminishes the 
number of peaks. However similar spectra were 
Fig 5.12 2% Fos-14 Fig 5.13 0.4% Fos-16
Fig  5.15  [
15N,
1H]   TROSY   spectra   of 
uniformly   [
15N,
1H] labeled 0.2 mM Pen-2 
resolubilized in 2% Fos-14 , 0.4% Fos-16 
and  1% LDEAO, 20 mM sodium acetate 
buffer pH  5.0 and 5 mM β-Mercaptoethanol 
recorded   at   303K   in   600   MHz   Bruker 
spectrometer. For Fos-14, Fos-16, & LDAO 
9, 5,6 glycine and 5, no & 6 tryptophan peaks 
are visible respectively.
Fig 5.14: 1% LDAOResults 88
obtained for 1% starting concentration of Fos-14 although with around 4% the spectra were little bit 
worse.  Spectra for Fos-14 at pH 6.5 did not provide any improvement. 
The possibility of degradation and oligomerisation of Pen-2 was addressed by adding 1x Complete 
protease inhibitor and TCEP bond breaker respectively without any change in recorded spectra. 
However all the recorded spectra are not quite well resolved and lack homogeneous peaks.
Conclusions and Perspectives
• Pen-2 can be highly expressed in P-CF, D-CF and L-CF mode of cell-free expression.
• Among various detergent conditions, best [
15N,
1H]−TROSY spectra  were observed at  600 
MHz with Pen-2 dissolved in 2 % Fos-choline-14. However it needs further improvement 
before starting 3D experiments. 
5.3 Aph-1 tag variation
N-terminal tag of Aph-1 was varied to different tags as given the figure below. However no 
expression was detected in the western blot after analytical scale CF reaction.
Fig  5.16: Agarose gel electrophoresis of linear Aph-1 constructs after 
N-terminal tag variationResults 89
Part II: Molecular Modeling of the interactions of γ-Secretase Components 
6 Introduction
6.1 Molecular Dynamics (MD) Simulations
MD simulations are used to describe time evolution of a system containing protein(s), DNA/RNA, 
water, ions etc by numerically solving Newton's equations of motion for all atoms in the system. 
However, MD simulations have the following approximations:
• Born-Oppenheimer   approximation   where   the   wave   functions   describing   nuclear   and 
electronic motions are decoupled
• Nuclei is treated classically by Newtonian mechanics
• Interactions of particles are described by empirical force field (FF)
6.1.1 Born-Oppenheimer approximation 
Dynamical time dependent evolution of a system can be described by time dependent Schrödinger 
equation:   where the reduced Planck's constant   = h/2π ,  ℏ i is the imaginary unit,  ω is 
the wave function,   is the Hamiltonian operator describing the total energy of the wave function. It 
takes various form depending on the system.  In three dimensions, it becomes   
where ∇
2  is laplacian and position of the particle is r = (x, y, z), V(r) is the potential energy of the 
particle and m is the mass.
In the Born-Oppenheimer approximation , the wave functions representing the fast motion of the 
electrons are separated from the slow moving nucleus. So the total wave function can be expressed 
as multiplication of electronic and nucleus wave function:
  to be more precise:  
where R and r   denotes the coordinates of nuclei and electrons respectively. Due the separation, 
movement of nucleus in the potential energy surface can be given by solving time independent 
Schrödinger equation for the electrons:  
6.1.2 Classical Newtonian Mechanics of Particles
Despite separating nuclear and electronic wavefunctions, solving Schrödinger equation for each 
nucleus in a macromolecule of protein/DNA/RNA is still computationally too expensive. Therefore 
an additional approximation that nucleus obeys Newton's equations of motion has been taken:Introduction 90
 where Fi is the force on atom i, mi is its mass, Ri its coordinates. The force on the 
atom i is given by the negative distance derivative of the potential energy.     The 
acceleration   results in the change in velocity an position of the atom. ∆t is chosen in such a 
way that fastest motions in the system can be captured which arise from the bond and angle 
vibrations. The bond vibrations due to light hydrogen atoms occur in femtosecond(fs) timescale 
limiting the ∆t to 1 fs. To extend the timestep, algorithms like SHAKE [201] and LINCS [202]  were 
developed to constrain the bond length. A parallel version of LINCS called P-LINCS has been used 
throughout the text [203]. 
Leap-frog integration algorithm was used for numerical integration of Newton's equations of motion:
[204] It uses positions r at time t and velocities v at time t- ∆t /2 and it updates positions and 
velocities using the forces F(t) determined by the positions at time t using the following equations:
                          
6.1.3 Force Fields (FF)
Although Born-Oppenheimer approximation provides a way to express electronic wave function as a 
function of nuclear coordinates, still the solution of time-independ Schrödinger equation to obtain 
electronic wave function is computationally too expensive. Therefore the potential energy of the 
system is expressed in terms of the following functions:
        
In case of AMBER force-field, Introduction 91
Limitations
In a force field, the electrons are at ground state, force fields are pair additive, the boundary of the 
system is periodic (using periodic boxes of different shapes like cubic, rhombic dodecahedron , 
truncated octahedron etc), the long range interactions are cut-off.Introduction 92
6.2 Reduced Representation of the system
Length of simulation that can be achieved by all-atom or united atom (no non-polar hydrogens) MD 
simulations is limited only to few µs range. However, most of the biological processes take place in 
much longer time scales like protein folding which happens in millisecond time scale, whereas 
membrane protein folding can take up to a second. Also dynamics of large protein complexes and 
assembly of protein molecules are also very computationally demanding. This issue can be addressed 
by two ways:
• Coarse graining : by reducing the degrees of freedom of the system by representing a set of 
atoms by one grain (i.e. one grain for 4 atoms or 1:4 mapping like in Martini FF)
• Implicit Solvation: by removing the water which often require up to 70% of all atoms in the 
system by implicit solvent (e.g. in IMM1 or EEF1 FF
Here such FFs for membrane protein simulation in lipid bilayer will be explained. 
6.2.1 Coarse-graining
Martini
Martini is a popular coarse grained force field used in biomolecular simulations involving membrane 
proteins in lipid bilayer [205–207] In It is parametrized by reproduction of partitioning free energies 
between polar and apolar phases of many chemical compounds.  Martini, the coarse-graining is 
achieved by mapping 4:1 which means that 1 grain substitutes 4 heavy (not hydrogen) atoms with 
total 20 beadtypes. Such mapping is applied for all parts of the system: protein, water molecules (one 
Fig 6.1 Mapping between the chemical structure and the coarse 
grained model for DPPC, cholesterol, and benzene. The coarse 
grained bead types which determine their relative hydrophilicity 
are indicated. The prefix “S” denotes a special class of CG 
sites introduced to model rings.Introduction 93
water grain is formed from 4 all-atom water molecules) and phospholipids or detergents. This 
approach reduces the number of building blocks which results in faster computation, longer timestep 
and much longer overall time of simulation compared to all atom simulations (even three orders of 
magnitude). Therefore, MARTINI is an excellent method to investigate processes occurring at a 
timescale of microseconds or higher. It has been implemented in leading MD packages like Gromacs 
and  NAMD. MARTINI was primarily developed to study the behavior of large biological membrane 
systems. Using this method a range of processes have already been investigated including vesicle 
fusion [208,209], membrane domain formation [210] and also formation of micelles and membranes 
from randomly distributed lipid or detergent molecules [211]. In recent times, it has been utilized to 
investigate the syntaxin-1A sequestering by ionic protien-lipid interactions [212] and mechanism of 
opening of mechano-sensitive MscL channels embedded in liposome [213]. 
Therefore, in Martini coarse grained forcefield :
• Four heavy atoms are represented by a single interaction center (including the water 
molecules as the solvent is explicit in this model) 
• There are four main types of interaction sites: polar (P), nonpolar (N), apolar (C) and charged 
(Q) 
• A shifted Lennard Jones 12-6 potential energy function has been used to describe the 
non-bonded interactions. The value of ε ranges 
from 5.6 kJ/mol to 2.0 kJ/mol, σ=4.7Å 
• The charge groups (type Q) bear a full charge qij interacting 
by Coulombing potential energy function. Coulombic energy 
function εrel = 15 for explicit screening 
• The bonded interactions are given by weak harmonic potential similar to the one explained 
before.
See Fig 6.1 and  Fig 6.2 for the diagram of Martini representations of lipids and proteins respectively.Introduction 94
6.2.2 Implicit Solvation
Effective Energy Function for Proteins in Solution (EEF1) 
EEF1 [214] is based upon the CHARMM19 polar hydrogen force-field with modification in the 
implicit solvation terms (interactions of the atoms with solvent):
  or more simply 
ΔG
solv is the solvation free energy of atom atom, rij is the distance between i and j. ΔGislv is the 
solvation free energy of the atom fully exposed to solvent, f(r) is the solvation free energy density 
which is modeled as a Gaussian function :   where Ri is the 
van der Waals radius of i (one half the distance to the energy minimum in the Lennard–Jones 
potential), λi is a correlation length (3.5 Å for most atoms), and αi is a proportionality coefficient.
The distance dependent dielectric constant (ε=r) was used for representing electrostatic interactions. 
Implicit Membrane Model 1 (IMM1) 
In the IMM1 model [215],  the membrane is positioned as parallel to the xy plane with its center at 
z=0. The solvation parameters ( ) of the atoms depend on the vertical direction z or z' 
= |z|/(T/2) where T is the tickness of the nonpolar core of the membrane (20-30 Å ) depending of the 
type of lipid. 
Fig  6.2: Coarse-grained representation of all amino acids. Different colors 
represent different particle types.Introduction 95
  where the function f(z') describes the 
phase transition.   , n controls the stepness of the transition. For example, n=0 gives 
the region of 6 Å over which the environment goes from 90% nonpolar to 90 polar. 
The electrostatic interactions are represented by a modified distance dependent dielectric screening 
in order to strengthen the electrostatic interactions in the membrane: ε = r
fij where fij depends on the 
position of the interacting atoms with respect to the membrane which is given by an empirical model:
 Far from membrane fij=1, and ε=r. In the membrane fij is equal to a, and 
empirically that value was set to a=0.85. 
6.3 Analysis of MD Trajectories
6.3.1 Root Mean Square Deviation (RMSD)
RMSD of specific atoms in a molecule with respect to a reference structure can be obtained by 
least-square fitting the structure to the reference structure (t2=0) and calculating RMSD by 
Fig  6.3:   The   IIM1   model,   red   is   the 
hydrophobic   core   and   cyan   blue   is   the 
implicit water. The transition between polar 
to nonpolar environment is given by the 
Gaussian curve.
Fig 6.4: Matrix of RMS DeviationsIntroduction 96
 where   and ri(t) is the postion of 
the atom I at time t. Fitting does not use the same atoms for calcultion since the fitting is usually 
obtained by using backbone atoms (N, C-alpha, C) although the RMSD is calculated for the whole 
protein or other atoms than backbone. 
6.3.2 Secondary Structure 
The change in secondary structure 
content   (Helix,   Beta   Sheet,   Coil 
etc)   during   simulation   can   be 
obtained   by   the   DSSP   program 
[216]  .  The DSSP output assigns 
each residue a letter according to its 
secondary   structure:   H   =   alpha 
helix   ,   B   =   residue   in   isolated 
beta-bridge , E = extended strand, 
participates   in   beta   ladder,   G   = 
3-helix (3/10 helix) , I = 5 helix (pi 
helix) , T = hydrogen bonded turn , 
S = bend
Fig 6.5: Time evolution of RMSD for two group of atoms (green and 
blue)
Fig  6.6: Change in secondary structure content over 40 ns 
simulationIntroduction 97
A Ramachandran plot is the projection of the structure between two residues on the two dihedral 
angles φ and ψ of the protein backbone (φ : C−N−CA−C, ψ : N−CA−C−N).
6.3.3 Root Mean Square Fluctuations (RMSF)
RMSF is defined as :     where T is the total time over which 
average will be taken,   is the reference position of the particle i which is often the time averaged 
position of the particle i. 
In case of RMSF, the average is 
calculated over time. In case of 
RMSD,   the   average   is 
calculated over particles giving 
rise to time dependent values. 
RMSF  is useful  for checking 
the   flexibility   of   the   protein 
especially at the active site and 
then   color   the   structure 
according to b-factor 
6.3.4 Solvent Accessible Surface 
Area 
Solvent accessible surface area around 
protein  (both  hydrophobic   and 
hydrophilic) can be calculated.
6.3.5 Principal   Component 
Analysis (PCA)
Cavariance analysis or PCA or essential 
dynamics   is   used   to   find   correlated 
motions   of   atoms.   It  approximate   the 
Fig 6.7: RMS Fluctuations
Fig  6.8: Solvent accesible surface areas and free energy of 
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motion of the complex into a set of eigenvectors with corresponding eigenvalues after matrix 
diagonalization. Then first two or following eigenvectors can be plotted for information on Gibbs 
free energy, entropy landscape etc. 
It uses the covariance matrix C of the atomic coordinates:
   
where M is a diagonal matrix containing 
masses of atoms in case of mass-weighted 
analysis or unit matrix in case of non-mass 
weighted analysis. C is a symmetric 3N x 
3N matrix which can be diagonalized by an 
orthonormal transformation matrix R:
  where 
 the columns of R are 
eigenvectors   and are called principal or 
essential nodes.  Now the trajectory can be 
projected   on   the   eigenvectors   to   obtain 
principal component pi(t)
  The 
eigenvalue λi is the mena square fluctuation of the principle component i.  
The collective motion of the system can be 
represented by the first few eigenvectors. 
For example, the trajectory can be fitted to 
the   eigenvector   i   by: 
 
In   order   to   get   rid   of   rotational   and 
translational   motion   of   the   molecule, 
least-square fit can be performed on the reference 
structure during the simulation. However care must 
be taken to choose the reference structure since it 
influences the covariance matrix. 
In order to find out if the eigenvectors or the 
principle components actually don't represent noise 
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or random motion, cosine content has to be  determined. It has been shown that the principal 
component of random diffusion are cosines with number of periods equal to the half of the principal 
component index [217]. The eigenvalues are proportional to the index to the power -2. The cosine 
content is defined as:
  when   the   cosine   content   of  the   first  few   principal 
components is ~ 0, the largest fluctuation is actually random diffusion.  
6.3.6 Change in radius of gyration (Rg) 
Rg is used to check how compact or loose is the structure during the simulation. 
 where mi is the mass of the atom i, and ri is the position of the atom I with 
respect to the center of mass of the molecule. Rg is really useful in characterizing proteins (see PS1 
CTF simulations.)
6.3.7 Interaction   energies   plotted 
over time.
Lennard-Jones and Coulombic interaction 
energies can be plotted over time between a 
pair of atoms throughout the simulation.
6.3.8 Hydrogen bonding pattern 
Hydrogen bonds can be analyzed between 
all possible donors and acceptors using 
the   geometric   criteria   of   maximum 
distance of 0.35 nm and angle of 30°. 
Using   the   average   of   autocorrelation 
function   of the 
existance function (either 0 or 1) of all H 
bond at time t, the lifetime of hydrogen 
bond   can   be   calculated   by 
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6.3.9 k-means or hierarchical clustering of trajectories 
6.3.10Free energy 
Biomolecular processes such as folding or aggregation can be described as molecule's free energy:
  where kB  is the Boltzmann constant, P is the probability 
distribution of the molecular sytem along coordinate R in which Pmax gives the maximum which is 
substracted to make sure that ΔG=0 for the lowest free energy minimum.  R (order parameters) can 
be defined by various order parameters like Rg, RMSD, no. of h-bonds etc. The reduced free energy 
surface can be obtained by plotting tw such oder parameters.
The Gibbs free energy can be obtained 
from  the  potential of mean force   or 
thermodynamic   integration   or   free 
energy perturbation. In order to obtain 
absolute free energy, a reference state 
is required whole absolute free energy 
is known (state B) i.e. in ideal gas. 
This   can   be   achieved   by   using   a 
parameter λ to  similate the transition 
between small molecules (state A with 
λ=0 ) and non-interacting particles in 
harmonic wells (state B with λ =1) 
whose absolute free energy is known. 
The   free   energy   difference   can   be 
expressed   as: 
 where the total Hamiltonian of the system at any particular value of λ is 
H= (1 – λ ) HB +  λHA
A myriad of other analysis can be conducted depending on the research problem. 
Fig  6.10:   Free   energy   surface   projected   along   principle 
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6.4 Modeling Membrane Proteins
6.4.1 Membrane proteins
Before starting the discussion of membrane protein modeling, a brief overview of membrane protein 
will be projected. Membrane proteins are classified into integral, peripheral and lipid-anchored 
proteins. Integral membrane proteins stay permanently attached to the lipid bilayer of plasma 
membrane (i.e. GS, GPCRs).  Peripheral membrane proteins  (e.g. phospholipase A2 or C, )  are 
temporarily attached to the lipid bilyer by non-covalent interactions. Lipid anchored proteins are 
covalently attached to the fatty acids like myristate/pamitate or glycosylphosphatidylinositol (GPI) 
which is a glycolipid that attaches to the C-termini during posttransalational modifications [218] (e.g. 
G proteins, kinases). 
Integral membrane proteins can further be classified into 3 groups depending on their localization:
• type I single-pass transmembrane domain with cytoplasmic C-termini (like amyloid precursor 
protein, CD44, cadherins, Notch and other substrates of GS )
• type II single-pass transmembrane with extracellular C-termini
• multipass transmembrane  (e.g. transporters: ABC transporters, ATPases, enzymes (GS, 
MraY), receptors (GPCRs), channels: porins, Na+/K+ channels). 
In order to adapt to the hydrophobic nature of the lipid bilyer, the integral membrane proteins have 
characteristic  ~  11-25 residues long patches of hydrophobic amino acids in the transmembrane 
domin. It is thermodynamically favorable as it minimizes the insertion and interaction energy 
between the protein and plasma membrane. Structurally the multipass transmembrane proteins can 
be subdivided into two categories- transmembrane helical and beta barrels. To collect the information 
of membrane proteins, various databases have been created. For instance, the orientation of proteins 
in membrane (OPM) database provies the calculated location of the membrane proteins with crystal 
structures in the hydrophobic core of the lipid bilayer. As of Nov, 2012, it consists of 660 
transmembrane proteins and 1086 peripheral proteins (http://opm.phar.umich.edu/ [219]) Is is based 
on minimization of free energy for transferring the protein from water to the lipid bilayer.  Apart 
from that, several databases on GPCRs, have been developed (http://www.gpcr.org/7tm)Introduction 102
6.5 Protein-Protein and Protein-ligand Docking
7 Methods 
7.1 Structure building and simulations of GS components
N-terminal Fragment of PS  1 (NTF),  Aph-1, Nicastrin and  PEN-2 were modeled using Rosetta 
Membrane   Ab-initio method  [220–222]  due to lack of homologies.  The  long (82 amino acid) 
N-termini  of  PS  1 (NTF) was modeled separately using Rosetta Ab-initio tool.  Prediction of 
membrane topology was obtained from OCTOPUS server which uses hidden Markov models and 
artificial neural networks [223].  
Threading in HHpred was used to find out distant homologies and models were built using Modeller 
with/ without secondary structure constrains [224,225]. Also models were generated from automated 
server I-TASSER [226,227]. Then all models were compared, clustered in various topologies and 
scored using Prosa 2003, ProQ [228,229], Rosetta Scores [230].   4-8 good scoring models from 
various scoring programs were selected for MD simulation in implicit and explicit membrane 
environment using IMM1[215]   in CHARMM  [231] and G53A6 forcefield [232]in GROMACS 
[233,234] respectively.
7.1.1 Modeling of Pen-2
Models of Pen-2 were constructed using the following 3 methods:
Rosetta ab-initio membrane 
The following options were used to generate 1000 models by rosetta ab-initio membrane program 
[220,221] available at: 
http://www.rosettacommons.org/manuals/archive/rosetta3.1_user_guide/app_membrane_abinitio.htm
l
3 and 9 amino acids long fragment databases were obtained from Robetta server [230].  Location of 
helices found by octopus server is used here: 19-39 and 57-77.
Options:
-in:file:fasta ../pen2.fasta
-in:file:frag3 ../aat000_03_05.200_v1_3
-in:file:frag9 ../aat000_09_05.200_v1_3Methods  103
-in:file:spanfile pen2.span
-in:file:lipofile pen2.lips4
-abinitio:membrane
-membrane:no_interpolate_Mpair
-membrane:Menv_penalties
-out:nstruct 1000
-database  /opt/gromacs/rosetta/rosetta_database/
HHSearch and Modeller
The following sequence alignment obtained from HHSearch [225] for distant homologs was feed 
into Modeller [235] to build homology models. 
>P1;pen2
sequence:pen2:   1: : 101: :: : 0.00: 0.00
MNLERVSN--EEKLNLCRKYYLGGFAFLPFLWLVNIFWFFREAFLVPAYTEQSQIKGYVWRS--
-AVGFLFWVIVLTSWITIFQIYRPRWGALGDYLSFTIPLGTP*
>P1;1qzmA
structureX:1qzm.pdb: :A: :A:ATP-dependent protease LA; oligomerizationdomain, AAA+ protein, 
hydrolase; 1.90A {Escherichia coli} SCOP c.37.1.20:Escherichia coli:1.90:0.18
------TE--DEKLNIAKRHLL------------------------------------------------------------------------------
------*
>P1;1zrjA
structureX:1zrj.pdb: :A: :A:a.140.2.1 (A1-37) Heterogeneous nuclear ribonucleoprotein U-like 
protein 1 {Human (Homo sapiens) [TaxId9606]}:Human (Homo sapiens) [TaxId 9606]:-1.00:-1.00
MDVRRLKV--NELREELQR---------------------------------------------------------------------------------
------*
>P1;3emlA
structureX:3eml.pdb: :A: :A:Human adenosine A2A receptor/T4 lysozyme chimera; caffeine, GPCR, 
membrane protein, LCP, mesophase, structural genomics, PSI-2; HET ZMA STE; 2.60A {Homo 
sapiens}:Homo sapiens:2.60:0.20
-------------VSLAAADIAVGVLAIPFAITISTGFCAACHGC--------LFIACFVLV---LTQSSIFSLLAI
A----------------------------*
>P1;1ppjD
structureX:1ppj.pdb: :D: :D:f.23.11.1 (D196-241) Cytochrome c1 subunit of cytochrome bc1 
complex (Ubiquinol-cytochrome c reductase), transmembrane anchor {Cow (Bos taurus) [TaxId Methods  104
9913]}:Cow (Bos taurus) [TaxId 9913]:2.10:0.33
------------------------------------------------------------RK---RMGLKMLLMMGLLLPLVYAMKRHKW
SVL-------------*
>P1;1di1A
structureX:1di1.pdb: :A: :A:Aristolochene synthase; sesquiterpene cyclase, isoprenoid biosynthesis, 
lyase; 2.50A {Penicillium roqueforti} SCOP a.128.1.4 PDB 1dgp_A:Penicillium roqueforti:2.50:0.25
AEESKLGI--PATKRVLWSMTRE---------WETVHDEIVAEKIASPDGCSEAAKAYMKGLEYQMS
GNEQWSK-------------------------- ------*
>P1;2fwkA
structureX:2fwk.pdb: :A: :A:b.38.1.1 (A24-115) U6 snRNA-associated sm-like protein LSM5 
{Cryptosporidium parvum [TaxId 5807]}:Cryptosporidium parvum [TaxId 5807]:2.14:0.31
---------------------------------------------------------------------------------------------GNNVAML
VPGGDP*
I-Tasser Server
3 models of Pen-2 were obtained from the fully automated I-Tasser server [227]. 
The models obtained from Rosetta, distant homology modeling, I-Tasser etc look pretty similar with 
the only difference in the location of transmembrane helices and orientation of N-terminal and 
C-terminal loops. These models are classified into two topologies with customized script which take 
into account the span of the TM helices. Topology 1 gives TM region: 21-40 and 60-80 which is 
similar to the predictions of TM region made by servers  (HMMTOP, TM-HMM, Octopus etc). 
However topology 2 gives TM region: 17-41 and 54-80 which is different from servers. Final models 
of Pen-2 were chosen by rosetta energy, proQ and prosa 2003 scores, statistics for rosetta results and 
some database search performed [236] namely: inter helical distance (7-10 Angs.); crossing inter 
helical angle (from -130 to -160 and from 148 to 168); type of contacting residues at the helical 
interface (small amino acids, rather polar: Gly, Ser, Leu, Ile, Ala) and by visual inspection. We chose 
3 models for topology 1 and 5 for topology 3. The models are sorted by rosetta energy. The 
remaining scores which could be useful for membrane proteins: pair potential and lennard-jones 
attraction potential. The N and C-termini were a bit unfolded in some of the models. Therefore MD 
Simulations were performed. 
All the models were subjected to both 20 ns implicit and 80 explicit solvent simulation in IMM1 and 
g53a6 forcefield respectively. The disadvantage of explicit solvent is slower convergence to final 
structure whereas in implict solvent it is achieved quite fast in absence of friction since the effect of 
solvent is represented by free energy of solvation. However, the atomistic interactions between the Methods  105
solvent the protein can not be probed. It is possible in explicit solvent.
MD Simulation:
8  best models were optimized by molecular dynamics simulations in all atom POPC bilayer in 
Gromacs (Gromos96 53a6  force-field) (van der Spoel 2005) and implicit membrane model 1 
(IMM1) (Lazaridis 2003) in CHARMM. Formation of lipid bilayer from random orientation of lipid 
and Pen-2 was simulated in coarse-grained forcefield Martini (implemented in Gromacs). 
The following procedure was followed for simulation in POPC bilayer: 0. Starting with minimized 
Pen2 in g53a6 FF with frozen backbone, 1. Inflategro [237] was used for inserting protein into 
membrane with strong position restraints so that RMSD change is close to zero. 2. adding water 
(Single Point Charge (SPC) model  [238]) , ions  to neutralize the system  with gromacs tools 
(increasing the vdwradii of C to 0.4 so that water is not inserted inside membrane) 3. l-bfgs and 
steepest descent minimization  for geometry optimization with g53a6 FF and modified Berger 
parameters   for   POPC   from  Prof.  Tielmann's  website  (http://moose.bio.ucalgary.ca/index.php?
page=Structures_and_Topologies ). 5. 100 ps MD with frozen backbone atoms of the protein, and 
with no pressure coupling (isochoric-isothermal (NVT) ensemble with temperature controlled by the 
Berendsen weak coupling algorithm [239]). After the simulation, checking the system to ensure no 
water molecules are present in membrane part of the system. If it’s necessary, remove them 6. once 
again, l-bfgs + steep for geometry optimization. Following annealing, 1 ns of NPT equilibration was 
performed using the Nosé–Hoover thermostat [240,241]  and Parrinello–Rahman barostat [242,243]. 
Secondary structure were assigned using DSSP algorithm  [216].  From this point, all the MD 
simulations are conducted with pressure coupling (npt), 7.   2 ns MD with position restraints only on 
transmembrane helices. 8. 80 ns production run 
7.2 Modeling of Bilyer Formation with Pen-2
Pen-2 models were converted to coarse grain representation. Secondary structure constraints were 
derived from DSSP and topology was generated with elastic restraints. Pen-2 was centered in a  6.4 x 
6.4 x 10 nm
3  box and ions were added to make the system neutral. The system was minimized with 
steepest descent algorithm, 128 POPE  molecules were added and the system was minimized again, 
2000 water molecules were added the system was minimized again. Then 50 ns of MD simulation in 
NVT ensemble followed by another 50 ns NPT was carried out during which bilyer was formed in 
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7.3 MD Simulations of PS1-CTF 
7.3.1 Coarse-grain (CG) simulations 
CG simulations were conducted using Gromacs software  [233,234]  and MARTINI force field 
[205,206]. Two types of phospholipids were used DPPC (dipalmitoylphosphatidylcholine) containing 
4   hydrophobic   grains   in   each   chain   and   DLPC   (dilauroylphosphatidylcholine)   containing   3 
hydrophobic grains. The starting systems contained NMR structure of protein, randomly distributed 
phospho lipids (ca. 460 molecules) and water (ca. 10000 grains). The necessary number of 
counterions (sodium cations) were added to ensure the electric neutrality of the system. Prior to the 
simulation the system was minimized, shortly equilibrated (about 1 ns) and minimized again. During 
the equilibration the protein structure was frozen. The productive simulations were run at a constant 
temperature 300 K and pressure 1 bar. The initial dimensions of the periodic box were 12 nm x 12 
nm x 10 nm. The isotropic pressure coupling was used with Berendsen coupling constant 0.2 ps. 
Timestep 20 fs was applied. Ten simulations with DPPC and ten with DLPC phospholipids were run 
for 1 μs each. Selected simulations where proper bilayer was formed were extended for another 1 μs. 
For micelle generation one CG simulation with 200 DPC (dodecylphosphocholine) detergent 
molecules was conducted for 1 μs with initial random distribution of detergent. 
7.3.2 Implicit Membrane Simulations
Replica Exchange and Molecular Dynamics simulations in continuous environments were performed 
using the program CHARMM [231](Brooks 1983). A united-atom forcefield, CHARMM19 [244] 
was used with a method IMM1 (Implicit Membrane Model)  [215]. Two different values of 
hydrophobic core thickness were chosen 2.6 nm and 3.0 nm. Twenty Replica Exchange (REx) 
simulations were conducted starting from ensemble of twenty NMR structures. Each Replica 
Exchange simulation was running in eight temperature windows with a temperature range 300 K and 
the lowest window had temperature 300 K. Selected structures were simulated using Molecular 
Dynamics method at a constant temperature 300 K and pressure 1 bar. In both methods the 
temperature was controlled with Langevine thermostat (friction coefficient was set to 5 ps-1). The 
bonds involving hydrogen atoms were constrained using the SHAKE algorithm, allowing an 
integration time step of 2 fs. 
7.4 Simulations in Amber FF
Prior to MD simulations, the complex was centered in an 8 nm
3 cubic periodic box, the system was 
solvated using TIP3P water model [245]. Counter ions were added to neutralize the system (150 mM 
NaCl). The system was minimized in Gromacs 4.5.5  using the Amber99sb Force Field [246] and a 
steepest descent algorithm [247] followed by L-BFGS [248,249] with harmonic restraints (force Methods  107
constant: 1000 kJmol
-1K
-1) applied to the backbone atoms of the protein. The same restraints were 
applied in the following 100 ps NVT and 100 ps NPT equilibration. The final MD runs were carried 
out for 80 ns with the NPT ensemble without any restraints. 
During all simulations a 2 fs integration time step was used, the temperature was maintained at 300 
K with the V-rescale algorithm and the pressure was coupled at 1 bar by isotropic pressure coupling 
utilizing the Parrinello-Rahman algorithm (time constant 10 ps, isothermal compressibility of water: 
4.5e
-5  bar
-1). Long-range electrostatics was calculated by fourth order particle mesh Ewald (PME) 
[250,251] algorithm with a grid spacing of 0.16 nm. All bonds were constrained using a fourth order 
P-LINCS algorithm [202,203]. Electrostatic and van der Waal's interactions were cut-off at 1 nm and 
a   dispersion   correction   was   applied   to   account   for   it.   Periodic   boundary   conditions   were 
implemented in three dimensions. Initial atomic velocities, prior to NVT equilibration, were obtained 
from Maxwell's distribution at 300 K. Water molecules were constrained by SETTLE  [252]. 
Neighbor lists for nonbonded interactions were updated at every 5th step.   Images were prepared 
using PyMOL [253] and Visual Molecular Dynamics (VMD) program [254].
7.5 Modeling of GPCRs (CB1,CB2 and β1AR) 
Molecular models of human cannabinoid receptors CB1  and CB2  were prepared by a combined 
strategy joining Modeller [235], Rosetta-ab-initio [230] and Rosetta-loop-modeling [255]. In the 
first stage, we performed multiple sequence alignments of sequence derived from cannabinoid 
receptors and available from the GPCR template structures: bovine rhodopsin, human β2-adrenergic 
receptor, turkey β1-adrenergic, human A2A adenosine receptor (protein codes from Protein Data Bank: 
1U19, 2RH1, 2VT4, 3EML, respectively). Multiple sequence alignments were prepared by two 
commonly used tools: MUSCLE [256] and CLUSTALW (version 2.0) [257]. Both methods gave 
similar results. The highest pairwise sequence score according to CLUSTALW (based on normalized 
identity) was achieved for: CB1-A2AR pair (24%), CB2-β1AR (22%) and also for CB1-β1AR and 
CB2-A2AR (21%) pairs. Pairwise sequence score with rhodopsin was very low, 15% (CB2) and 13% 
(CB1), the same with β2AR: 18% (CB2) and 14% (CB1). Consequently, we decided to chose these two 
receptors structures: A2AR and β1AR, both bound to antagonists in their crystal structures, as 
templates for homology modeling of CB1 and CB2. Alignment input for Modeller was prepared 
automatically by MUSCLE and adjusted manually in the Seaview editor [258] to preserve important 
functional motifs and disulfide bridges. Both CB1 and CB2 receptors have single disulfide bridge 
located in the loop EC2 (both cysteins are within this loop: 257-264 in CB1 and 174-179 in CB2) 
[259] so the sequences of cannabinoid receptors were manually aligned with templates A2AR and 
β1AR within the EC2 area to put cysteine residues in proximity. The final alignments for both Methods  108
templates are shown in Fig. 7.1. For transmembrane parts of modeled receptors we chose the DOPE 
(Discrete Optimized Protein Energy) option [260] in Modeller with subsequent MD-slow refinement 
of short loops. The mean DOPE score for 10 generated models was: -43281.0  (CB1 based on A2A), 
-42440.2 (CB1 based on β1AR), -38421.2 (CB2 based on A2A) and -37946.3 (CB2 based on β1AR). 
These scores reflect primarily the interactions within the bundle of transmembrane helices which are 
responsible for stabilization of the receptor. As the models based on A2AR were scored much better, 
we chose them for further docking studies. Subsequently, the Rosetta-loop-modeling protocol was 
used for remodeling the longest loop (IC3 – between helices TH5 and TM6): residues 300-335 in 
CB1 and residues 217-234 in CB2. Additionally, the N- and C-terminal parts of receptors, which are 
located outside the membrane, were modeled separately by the Rosetta-ab-initio protocol and joined 
with the rest of the protein by Modeller. The two final models of each receptors characterized with 
the highest scores according to the DOPE measure were subjected to further analysis. We used these 
two conformations per each CB receptor to assess whether the choice of the model from the 
Modeller generated ensemble influences the docking results to any extent.  
To refine the CB1 and CB2 structures obtained from homology modeling we used Implicit 
Membrane Model (IMM1) method [215] in the program CHARMM [231](2). It gives a possibility 
for fast convergence to final structure. The implicit solvent or continuous environment (CE) method 
reduces the number of degrees of freedom which are necessary for the evaluation of energy and force 
allowing more efficient sampling of phase space compared to explicit solvent methods. The 
water/membrane/water system in IMM1 is achieved by changing the parameters of the system along 
the perpendicular axis of the membrane. In the layer 0.6 nm thick between water and membrane 
environments the properties are changing smoothly according to a sigmoidal function so at the 
hydrophobic border of this layer 90% of the environment derives from the hydrophobic core while at 
the   water   border   90%   of   the   environment   derives   from   bulk   water   properties.
The value of hydrophobic core thickness chosen for molecular dynamics simulation was 3.2 nm. The 
CB1 and CB2 structures were simulated for 1ns with an integration time step of 2 fs at a constant 
temperature of 300 K and pressure of 1 bar. Constant temperature was achieved with Langevine 
thermostat by setting friction coefficient to 5 ps-1. The bonds involving hydrogen atoms were 
constrained using the SHAKE algorithm.
We conducted five simulations for CB1 and six for CB2 each time using different structures being 
the best scored receptor models based on the A2AR template from Modeller. The RMSD on C-alpha 
atoms was 0.27 nm for the transmembrane part of CB1 and 0.18 nm for CB2 on average. The 
representative plots of χ1 angle for residues in the rotamer toggle switch were found to be stable in 
most cases.  In some cases, the changes reflecting the spontaneous action of the switch were 
observed. This indicates that the models of CB1 and CB2 receptors we used were functional at least 
in the area of the binding site which is enough for ligand docking.Methods  109
For the CB1 and CB2 receptor models, which were based on A2AR template, we performed further 
studies, involving flexible docking of two antagonists (AM630 and NESS-0327) and two agonists 
(anandamide (AEA) and (-)-Δ
9-THC). Input conformations of ligands were prepared using the 
LigPrep protocol from the Schrodinger Suite [261]. To sample different protonation states of ligands 
in physiological pH we used the Epik module  [262]. From our set of ligands of CB1  and CB2 
receptors, only AM630 was used in the protonated state (protonated nitrogen atom in morpholine 
ring) based on pKa  calculations (6.2±0.6). However, literature data  [263]  provide unequivocal 
evidence on this protonation, therefore we decided to dock both forms of AM630. The obtained 
poses were similar, however, the protonated AM630 poses were characterized with higher energy 
values. Docking of all ligands were performed by Autodock 4.2 [264] using the genetic algorithm 
(GA) procedure. The following parameters for GA were used: 1.9 nm-large (50 grid points) search 
box, 150 individuals (poses - ligand/receptor conformations) in each population, 20 independent 
populations per each analyzed system (ligand-receptor complex), 2,500,000 energy evaluations per 
single evolution run, post-docking cluster analysis and other default settings. Some amino acids were 
set flexible during the docking. For this we chose amino acids with bulky residues close to the 
potential binding site (based on literature data): L3.29
(193), V3.32
(196), F3.36
(200), F268 (EC2 loop), 
E5.37
(273), F5.42
(278), T5.47
(283), W6.48
(356), L6.51
(359), L6.52
(360), C7.42
(386)  for CB1, and T3.33
(114), 
F3.36
(117), F183 (EC2 loop), D5.38
(189), S5.42
(193), I5.47
(198), F5.51
(202), W6.48
(258), V6.51
(261), L6.52
(262), 
M6.55
(265)  for CB2  receptor. Numbers of residues according to Ballesteros-Weinstein numbering 
scheme [265] in which x.50 denotes the most conserved residue in each helix).
Building of the complete structure of β2AR was done on the basis of the crystal structure of human 
β2ART4 lysozyme fusion protein with bounded carazolol (PDB ID: 2RH1) [266]. Modeling of N- 
and C-terminal domains of the receptor (residues Met:1 to Glu:30 and Cys:341 to Leu:413 
respectively) was conducted using ITASSER server [226,227]. The structure of the longest second 
intercellular loop of the receptor (residues Leu:230 to Leu:266) was predicted using CABS program 
[267]. Single palmitoyl chain was added to Cys:341 at the end of the cytoplasmic helix H8. Obtained 
β2AR model was  inserted into equilibrated palmitoyl-oleoyl-phosphatidylcholine (POPC) cell 
membrane model by means of Inflategro procedure [237]. Model of β2AR embedded in POPC lipid 
bilayer was then solvated with water molecules and ions were added. Energy minimization was 
conducted applying 2000 steps of the steepest decent algorithm followed by 2000 steps of the 
L-BFGS algorithm. Then, the molecular dynamic (MD) simulation lasting 40 ns was performed 
using  GROMACS   (v.  3.3)  program  [233].  All   calculations   were   conducted   using   modified 
GROMOS96 force field (ffG53a6 parameters set)  [232]  with additional parameters for POPC 
molecules [268]. SPC water model [269] was used and the PME procedure [250] was applied for 
treatment  of the  long-range  electrostatic  interactions.  All bonds   with hydrogen  atoms  were 
constrained by the LINCS algorithm [202]. MD was performed at the temperature of 310 K, pressure Methods  110
of 1013 hPa, and simulation time step was set 1 fs. 
To obtain (R,R)- and (S,S)-fenoterol isomer structures and force field parameters for MD simulation 
the PRODRG server [270] [41] was used. The ligands were inserted in the middle of the binding site 
of the β2AR model to preserve the interaction between D3.32
 and the protonated amine nitrogen of 
ligands. To investigate differences in binding of (R,R)- and (S,S)-fenoterol isomers similar starting 
structure of two receptor-ligand complexes were generated during restrained MD simulation lasting 
200 ps. Protein backbone atoms were constrained to their initial positions using “freeze” option and 
weak harmonic distance restraints (the distance was 0.3 nm) were imposed on three receptor-ligand 
atom pairs (pair 1: C atom of D3.32 residue and protonated nitrogen atom of ligand; pair 2: oxygen 
atom of hydroxyl group of S5.42 and oxygen atom of first hydroxyl group of 1,3-benzenediol 
moiety; pair 3: oxygen atom of hydroxyl group of S5.46 and oxygen atom of second hydroxyl group 
of 1,3-benzenediol moiety). Finally, two step MD simulation of receptor-ligand complexes was 
preformed. During the first step, lasting 2 ns, weak harmonic position restraints were imposed on 
backbone atoms of transmembrane helices of the receptor only and ligand-receptor distance restraints 
were released. In the second step the production run was conducted lasting 5 ns with no restraints. 
The described above two step MD simulation scheme was repeated 22 times applying random 
starting velocities for every atom, 11 times for receptor-(S,S)-fenoterol complex and also 11 times for 
receptor-(R,R)-fenoterol complex. Simulation parameters were identical to those used for MD 
simulation of unliganded β2AR model.Methods  111
Fig 7.1 The alignment of human CB1 and CB2 receptor sequences with A2AR (a) and β1AR 
(b)  templates. Transmembrane helices of templates are encircled (red dashed line), the 
conserved esidues (x.50) in each helix are in blue and cysteine residues forming disulfide 
bridge are in yellow. Conserved sequence motifs in cannabinoid receptors are underlined. Methods  112
7.6 Molecular modeling of FPR1
7.6.1 Homology modeling and refinement of FPR1
The homology models of FPR1 were obtained by Modeller 9v8   using the crystal structure of 
chemokine receptor type 4 (CXCR4, PDB code: 3OE0)  which shares the highest homology (31.0% 
identity, 53.8% similarity) with FPR1 according to Discovery Studio Visualizer . They are located in 
the same the  γ  branch of phylogenetic tree of GPCRs (gpcr.scripps.edu). Since the region 
corresponding to helix H8 at cytoplasmic side of CXCR4 is unfolded in the crystal, the crystal 
structure of human β2-adrenergic receptor  (PDB Code: 2RH1) was used as the second template for 
the H8 regions of FPR1. The sequence alignments were performed automatically in MUSCLE  and 
adjusted manually in Discovery Studio Visualizer   for proper aligning of conserved motifs and 
disulfide bridge. The 1500 models of initial FPR1 receptor were generated in Modeller with fully 
annealed protocol, and the optimal model was chosen according to DOPE (Discrete Optimized 
Protein Energy) score . Low homology regions of loops between transmembrane helices were 
constructed with loop refinement protocol in Modeller and the lowest DOPE score model from 1000 
generated models was selected for further study. To obtain the proper orientation of the receptor in 
the membrane the refined model of FPR1 was aligned with CXCR4 crystal structure (PDB code 
3OE0) taken from OPM (Orientations of Proteins in Membranes) database . The hydrogen atoms 
were added to the FPR1 structure according to the physiology pH environment. To remove 
unfavorable steric contacts and to release strain among amino acid residues the model was submitted 
to Prime (Schrödinger 2011 suite)   for backbone constrained truncated-Newton minimization 
refinement, using the OPLS_2005 force field  and implicit membrane model. 
7.6.2 Receptor model equilibration in explicit membrane
Using the builder tool for Desmond  in Maestro 9.2 program  the FPR1 model was embedded into 
pre-equilibrated   POPE   (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine)   lipid   bilayer 
solvated with water and NaCl to make the system neutral and set ionic strength 0.15 M. The total 
number of atoms was approximately 54,000 including 28 Na
+ and 40 Cl
− ions, about 10,000 water 
molecules, and 161 POPE molecules. The periodic box dimensions were about 6.8 nm × 7.2 nm × 
9.4 nm. Equilibration of the system was performed at constant pressure and temperature (NPT 
ensemble; 310 K, 1 bar) and Berendsen coupling  scheme with one temperature group. All bond 
lengths to hydrogen atoms were constrained using M-SHAKE . Van der Waals and short-range 
electrostatic interactions were cut off at 1.0 nm. Long-range electrostatic interactions were computed 
by the particle mesh Ewald (PME) summation scheme . A RESPA (time-reversible reference system Methods  113
propagator algorithm) integrator   was used with a time step of 1.6 fs. Long-range electrostatic 
interactions were computed every 4.8 fs. Harmonic positional restraints on the protein were tapered 
off linearly from 10 to 0 kcal/mol
-1A
-2 over 16 ns.
7.6.3 Ligand preparation and docking
Both ligands fMLF and tBoc-MLF were built in Maestro program. Ligand preparation utility was 
used to optimize the geometry of initial structures. Systematic conformational search was performed 
in MacroModel  and the top five conformers with the lowest potential energy were kept for docking. 
The docking procedure was performed using Glide  (Schrödinger 2011 suite). Ligand molecules were 
initially placed in the binding pocket with a random pose. Cubic boxes centered on the ligand mass 
center with a radius 1.5 nm for both fMLF and tBocMLF defined the docking binding regions. 
Flexible ligand docking was executed in all cases. Twenty poses per ligand out of 2000 were 
included in post-docking energy minimization. Top three scored poses were similar to each other, 
thus only one the best scored pose per each ligand was chosen as the initial structure for MD 
simulations. 
7.6.4 Molecular Dynamics
To obtain the non-standard residues (-CHO and tBoc-) the force field parameters for MD simulation, 
the partial atomic charges for the ligands were obtained in GAUSSIAN 09 program  via obtained 
Hartree-Fock 6-31G* electrostatic potential (ESP) and then using the fitting procedure performed by 
the R.E.D. tool . The membranous system was built and equilibrated as mentioned above. Three 40 
ns MD simulations with no restraints were conducted employing CHARMM36 full-atom force field 
for Apo-FPR1 as well as its complexes with agonist fMLF and antagonist tBocMLF. Data analysis 
was done using Desmond utilities and the molecular figures were made in VMD  and Pymol . 
7.7 Homology Modeling of Human CXCR4 and Dopamine D3 Bound to Ligands
7.7.1 Homology Modeling
The   CXCR4   and   DRD3   protein   sequences   were   aligned   with:   bovine   rhodopsin,   human 
β2-adrenergic 
receptor, turkey β1-adrenergic, human A2A adenosine receptor (protein codes from Protein Data 
Bank: 1U19, 2RH1, 2VT4, 3EML, respectively) by MUSCLE  [256]  and CLUSTALW2  [257] 
software. CLUSTALW2 scores were used to choose the most appropriate template (2VT4). Methods  114
Additionally, MUSCLE-derived multiple sequence alignments were prepared from BLAST[271] 
hits for each target protein sequence. The protonation state of the ligands and placement of disulfide 
bridges were confirmed by literature search [272–275]
Automatic alignments were manually adjusted to remove gaps inside the TM helices and to preserve 
disulfide bridges detected experimentally. The homology modeling was performed using the DOPE 
modeling option in Modeller, followed by slow MD refinement of loops [235]. The best scoring 
models (according to the DOPE score  [260]),  three per each target, were subjected to further 
analysis. The ligands conformations were prepared by Ligprep [261] and Epik [262] protocoles from 
the Schrodinger Suite. The docking was performed in two ways. First, using the Glide approach 
[276], and second, using the Autodock 4.2 [264] with Gasteiger charges assignment. The top scoring 
poses (according to the glide score and the Autodock free energy of binding) were refined in Glide 
and scored again. The five top scored complexes per each target were submitted. All of them were 
originally prepared in Glide docking procedure, not in Autodock. 
7.7.2 Criteria for prediction analysis, scoring and ranking: 
The DOPE (Discrete Optimized Protein Energy) and the DOPE scoring profiles, Glide score, 
Autodock free energy of binding and visual inspection were used in the assessment. 
7.7.3 PS1 CTF: APP simulations in implicit membrane
The proteins are treated in atomic detail while the effect of water and membrane was represented by 
adding an extra term in energy function. Implicit membrane model (IMM1) energy function can be 
expressed as Wimm1  = E +ΔGsol  where  E is the intramolecular energry from CHARMM19 polar 
hydrogen forcefield and ΔGsol is the solvation free energy which varies depending on the position of 
the atom relative to the membrane. Simulations were conducted in membranes containing 30% 
anionic lipid with area per lipid of 0.7 nm
2, salt concentration of 0.1 M, the valence of the electrolyte 
+1, and the position of the plane of smeared charge according to Gouy-Chapman theory relative to 
the nonpolar/polar interface was set to 0.3 nm.Results and Discussion  115
8 Results and Discussion 
8.1 MD Simulation of NMR Structure of PS1-CTF  
PS1 belongs to intramembrane proteases  (I-CLIPs)  which process its substrates inside the lipid 
bilayer [6,9]. Many of the mutations linked to the Early-onset Alzheimer's Disease is linked to PS1. 
During activation PS1 is proteolytically cleaved into N-terminal (NTF) and C-terminal fragments 
(CTF) each containing one catalytic aspartate residue [21]. Although the topology of the NTF is well 
accepted, it is somewhat controversial for CTF although the 3 transmembrane topology is mostly 
accepted  [52,277,278]  . Here we have validated the first structure of CTF obtained from NMR 
studies  [53]  in SDS micelles by performing molecular dynamics (MD) simulations in detergent 
micelles and lipid bilayer.
8.1.1 PS1-CTF MD Simulations in Detergent
The structure of CTF in SDS micelles determined by NMR Spectroscopy was characterized by lack 
of typical transmembrane part. To investigate further the 3D structure of CTF in lipid bilayer, we 
used molecular modelling methods, and especially simulations in water/lipid environments. To 
clarify which regions of CTF structure divide into hydrophobic and hydrophilic parts, we conducted 
MD simulation of CTF immersed in random mixture of detergent and water molecules. To achieve a 
reliable simulation time needed for micelle formation, and extensive sampling of conformational 
space we chose a coarse-grain approach. 
Simulations in DPC micelles
For micelle simulations, we used 2 00 DPC (dodecylphosphocholine) coarse-grain molecules in 
periodic box 12 nm x 12 nm x 10 nm filled with water grains. The coarse-grain CTF was placed 
centrally, and it was frozen for the first part of simulation lasting 50 ns. Several micelles were created 
and the central one formed around the protein contained about 60 molecules of detergent. Its 
representative structure is shown in Fig 8.1. It is striking that detergent molecules are grouped mainly 
around helix 8 and other regions of proteins are in contact with water. For the following 1 μs of 
simulation the CTF was unfrozen and adopted a more compact structure mainly by rearrangement of 
its N-terminal part and changing the position of helices 9a and 9b. During such process, a number of 
detergent molecules in this micelle diminished to about 50. They were still grouped around helix 8 
but also h7. A representative structure of this micelle is shown in Fig. 8.1D. Placement of helical 
elements is similar in both structures although a range of variability of angles between helices is high 
what can be seen in Fig.8.1E. By the end of 1 μs simulation with movable CTF, the angles between 
helices h7/h8 and h9a/h9b were both close to 125◦ . They are similar to analogous angles in ensemble 
of NMR structures where they are 120◦ ±3◦ for h7/h8 pair and 108◦ ±6◦ for h9a/h9b pair. During Results and Discussion  116
coarse-grain simulations, all helical segments were restrained what is an internal feature of this 
method because otherwise the secondary structure elements have tendency to unfold. However, a 
number and position of helical segments is determined by NMR experiments so employing of such 
restrains is justified. 
Fig 8.1 MD Simulation in DPC detergent: A-D. Evolution of randomized detergent molecules and 
initially frozen CTF structure in course of time: A (initial), B (50 ns), C (1 µs), D (3µs). E. Evolution 
of the angles between helices 7 and 8 (black) and helices 9a and 9b (red) and their distributions. F. 
Radius of gyration of the protein (Upper) and number of detergent molecules close to the protein 
(Lower). Incorporation of more DPC molecules from adjacent micelles at about 1.5 μs results in 
increasing angles between helices (they become more anti-parallel) and an increasing radius of 
gyration (protein becomes more elongated). Coloring scheme: helix α in cyan, helix β in blue, helix 
7 in green, helix 8 in yellow, helix 9a in orange, and helix 9b in red. The catalytic residue D385 is 
shown as purple spheres and the PAL (proline, alanine, leucine) motif [36,66] as blue spheres. 
Structures of CTF – they differed mainly in shape and location of N-terminal part. Starting from 
random distribution of lipids was necessary because lack of explicit transmembrane segment of CTF 
precluded placement of CTF into already equilibrated bilayer. Selected simulations in which a 
proper bilayer was formed were extended for another 1 or 2 μs when necessary to achieve stability. 
8.1.2 MD Simulations in Lipid Bilayers
We also investigated a dynamics of CTF in membrane bilayers. Two types of membrane were used 
differing with their thickness: one was composed of DLPC phospholipids (dilauroylphosphatidyl- 
choline) containing 3 hydrophobic grains in each chain and the second membrane was composed of 
DPPC   phospholipids   (dipalmitoylphosphatidylcholine)   containing   4   hydrophobic   grains.   The 
distance between phosphorous grains (and also between nitrogen grains) from both layers of the 
membrane was 3.6 nm for DLPC and 4.0 nm for DPPC. The starting systems contained NMR 
structure of protein, randomly distributed phospholipids (ca. 460 molecules) and water (ca. 10000 Results and Discussion  117
grains). The necessary number of sodium cations were added to ensure a neutral charge of the 
system. The periodic box was the same as in micelle dynamics. Ten simulations with DPPC and ten 
with DLPC phospholipids were run for 1 μs each starting from different NMR 
In some simulations, the lipid discs were created, and in such cases CTF resided primarily close to an 
edge of the disc what altered the structure of protein, and had an influence on values of angles 
between helices. A representative structure of CTF in DPPC membrane is shown in Fig 8.2. There is 
a hydrophobic mismatch between the longest helix 8 and the membrane resulting in large angle about 
50◦ to the membrane normal. The CTF structure was stable during the 2 μs extension of CG 
simulation. The value of h7/h8 angle was focused around 130◦ ±10◦ whereas h9a/h9b angle 
stabilized around 90◦ with much broader range of variability similar to that in a micelle simulation. 
Initially the latter value was about 60◦ but it was shortly changed to 90◦ after about 0.5 μs of 
simulation. The whole N-terminal part of CTF was located out of the hydrophobic part of the 
membrane and both helices hα and hβ resided in hydrophilic part of the membrane. The catalytic 
residue Asp385 and PAL motif on the loop between helix 8 and helix 9a were located just beneath 
the hydrophilic part of the membrane and close to one another. A short loop between helices 7 and 8 
as well as a short segment beyond helix 9b were not crossing the membrane/water border but they 
preferred to reside close to internal membrane border between its hydrophobic core and hydrophilic 
layer. 
Fig 8.2 Structure of Coarse Grained CTF in DPPC membrane after 3 μs simulation, following a 1 μs 
simulation with random distribution of lipids. Evolution of angles between helices 7 and 8 (black), 
helices 9a and 9b (red), and helix 8 with a normal to the plane of the membrane and their respective 
distributions . 
This is against the hydrophobic mismatch of CTF in this membrane and a tendency of helix 8 to 
adopt a position perpendicular to the membrane. However, a tryptophan residue Trp404 in this loop Results and Discussion  118
prevents it from crossing the membrane/water border regardless of presence of adjacent Asp and Asn 
residues. Additionally, the segment beyond helix 9b is ending with a hydrophobic motif FYI  which 
efficiently prevent this part of CTF structure from going into bulk water and attaches it into internal 
membrane border. In fact these both segments resided close together in nearly all CG simulations. 
The similar situation is for the thicker membrane composed of DPPC lipids. 
Although there is nearly no hydrophobic mismatch of helix 8 (30◦ of the angle between helix 8 and a 
normal to the membrane plane) both segments are residing between hydrophobic core of the 
membrane and its hydrophilic part (Fig. 8.2). The catalytic Asp residue is close in space to the PAL 
motif and they both are residing in the opposite hydrophobic/hydrophilic internal border of DPPC 
membrane. The helices 7 and 8 are more antiparallel (160◦ ±10◦ ) than in a case of DLPC membrane 
(130◦ ) whereas a distribution of an angle between helices 9a and 9b is similarly broad as in 
simulation in DLPC although mean value was changed from 90◦ to about 120◦ toward more 
antiparallel orientation of helices 9a and 9b. 
8.1.3 MD Simulations in Implicit Lipid Bilayer
To perform simulations with atomistic representation of protein, but retaining a possibility for fast 
convergence to final structure, we employed Implicit Membrane Model (IMM1) method [215] in the 
program CHARMM [231]. The implicit solvent (or in other words continuous environments – CE) 
method reduces the number of degrees of freedom that are necessary for the evaluation of energy and 
force, which allows for more efficient sampling of phase space than explicit solvent methods. The 
water/membrane/water system in IMM1 is achieved by changing the parameters of the system along 
the line perpendicular to the membrane. In the layer 0.6 nm thick between water and membrane 
environments the properties are changing smoothly according to a sigmoidal function so at the 
hydrophobic border of this layer 90% of the environment derives from the hydrophobic core while at 
the water border 90% of the environment derives from bulk water properties. Two different values of 
hydrophobic core thickness were chosen 2.6 nm and 3.0 nm. For the former we performed twenty 
Replica Exchange (REx) simulations (each REx was run in eight temperature windows ranging 300 
K) starting from twenty different NMR structures. Such parallel simulations of copies of the system 
(replicas) in different temperatures allowing exchanges of replicas at regular intervals of time with 
acceptance ratio dependent on probability based on Metropolis-Hastings criteria [279]: 
improves convergence of the protein structure to the near global optimum solution. Because the Results and Discussion  119
bilayer is already organized in this method the orientation of the initial structure of CTF had an 
influence on the final state. We oriented the NMR structures in such a way that helix 8 was entirely 
immersed in the membrane and parallel to the membrane normal. However, in many REx 
simulations the N-terminal part of CTF stayed divided between two parts of the membrane. Such 
structures were removed from subsequent MD simulations. 
The representative structures taken from simulations in 2.6 nm and 3.0 nm hydrophobic cores 
membrane are shown in Fig. 8.3. Similarly to CG simulations the helices hα and hβ are outside the 
membrane but close to water/membrane interface with exception of hβ in case of thicker membrane. 
The angle of helix 8 with normal to the membrane plane is about 15◦ for thinner membrane and 10◦ 
for thicker one. In both membranes the helices 7 and 8 stay antiparallel and an angle between them is 
160◦ (thinner membrane) and 150◦ (thicker). The big difference is for helices 9a and 9b because they 
are nearly parallel (30◦ ) in thinner membrane and anti-parallel in thicker one (165◦ ). However, in 
both membranes they are residing inside the membrane. Such different orientation of helix 9a (helix 
9b is oriented in the same way in both structures) denotes how easily the helices may adopt different 
conformations in the absence of explicit solvent if there is enough space in the thicker membrane for 
flipping the helix. A short C-terminal segment beyond helix 9b is close to the loop between helices 7 
and 8 as in was in CG simulations. 
.
Fig 8.3 Structure of CTF in implicit membrane after MD simulation with  hydrophobic core 
thickness of 3.0 nm. Red dashed lines indicate the hydrophobic core of the membrane and white 
dashed lines denote the border of the bulk water. The evolution of angles between helices 7 and 8 
(black), helices 9a and 9b (red), and helix 8 with a normal to the plane of the membrane and 
their respective distributions.  
However, a catalytic residue Asp385 is located in the center in the membrane and not close to the 
internal hydrophobic/hydrophilic border. The PAL motif resides close to this border so its distance to 
Asp385 is larger than in CG simulations. The interesting feature of CE simulations compared to CG Results and Discussion  120
is that secondary structures are not restrained and may unfold and refold. In case of CTF simulation 
in 3.0 nm membrane the helices 7 and 9b were elongated so the catalytic residue Asp385 became a 
part of a helix. However, much longer unconstrained atomistic simulations are required to confirm 
this result
As shown in the molecular dynamics simulations, the structure obtained after simulation in micelles 
is structurally close to that of NMR structure in SDS micelles. However, to get insight into the whole 
structure of γ-secretase complex the additional investigations are required for structure of other parts 
of the complex and also to reveal molecular role of AD mutations and substrate recognition. 
The CTF structures obtained in bilayer simulations (both in coarse-grain (Fig. 8.2) and implicit 
membrane (Fig. 8.3) showed larger difference to that of NMR structure. The angle between helices 7 
and 8 remained relatively stable but dependent on membrane width, whereas that between partial 
helices 9a and 9b were changing. The bilayer environment in the simulations promoted also longer 
membrane helices so additional investigations are needed to validate such effects.Results and Discussion  121
8.1.4 Topology of PS1-CTF
CTF structure revealed by NMR studies has three membrane spanning regions which is in agreement 
with the nine transmembrane domain model of presenilin 1 (Fig.  8.4). However, it has novel 
characteristics   in   order   to   facilitate   intramembrane   catalysis.   It   contains   a   putative 
half-membrane-spanning helix N-terminally harboring the catalytic aspartate, a severely kinked 
helical structure toward the C terminus as well as a soluble helix in the assumed-to-be unstructured 
N-terminal loop.
Fig 8.4 Proposed topologies of CTF. Topologies, as suggested by several groups based on 
biochemical evidence (mutation and immunofluorescence studies) are shown. The first six 
helices belongs to NTF whereas the latter helices belong to CTF. Proposed topology of 
CTF topology based on NMR evidence is bordered in red. Results and Discussion  122
8.1.5 Modeling of Pen-2
Pen-2 is 
• Required for Notch Signalling
• Processing of APP by γ-secretase
• Along with APH-1 it regulates proteolytic 
processing of presenilin
• It stabilizes CTF and NTF of presenilin
• Zebrafish lacking Alzheimer 
presenilin enhancer 2 (Pen-2) 
demonstrate excessive 
p53-dependent apoptosis and neuronal loss
Biochemical cysteine cross-inking experiments have indicated the interactions between PS1 NTF 
and Pen-2. It was proposed that TMD4 of PS1 interacts with TMD1 of Pen-2 [31,56]. GS modulators 
were shown to bind to Pen-2. 
During the simulation in IMM1, if the width of the membrane is increased, the protein tends to form 
longer N terminal helix and and the C-terminal comes out to the ECF as one should expect. 
Otherwise, in few models the C-termini was buried in the membrane. For those models, where 
C-termini was outside the membrane, during both explicit and implicit membrane simulation, they 
form compact structure (often a beta sheet and comes close to the helix). Therefore the conclusion is 
that   most   of   the   models   converge   to   similar   structures   during   MD   simulation  Fig   8.5.
From the  models  of PEN-2,  its  chemical shift  was predicted  using the software SPARTA.  
As found in the size exclusion chromatography, Pen-2 forms monomer of dimer depending upon its
Fig 8.5: Initial (A) and final (B) position of Pen-2 
during   the   simulation   of   DPPC   lipid   bilayer 
formation starting from random orientation of 
Pen-2 and DPPC molecules. Initial(C) and final 
(D) structures of Pen-2 during 20ns simulation in 
IMM1   with   4   nm   hydrophobic   core.   The 
hydrophilic N-terminal loop which is inside the 
membrane in the model, projects outward of the 
bilayer after the simulation.Results and Discussion  123
concentration. Pen-2 could dimerize in plasma membrane. There is only one cysteine at position 15 
at N-terminal helix of Pen-2 which mediating interaction. 
The RMSD change after all atom 80ns simulation in POPC membrane remains close to 3-4 Å for 
backbone atoms. The change in RMSD is mostly in the hydrophilic N-terminal and C-terminal loop 
region of Pen-2 which keeps moving throughout the simulation. Moreover, the loops become more 
compact by the end of the simulation. 
During 20ns simulation in IMM1, the structure of Pen-2 change quite rapidly especially in the loop 
region which become more and more compact in shape and come close to the TM helices. 
Experimental evidence show that the C-terminal loop bind to the Presenilin 1 CTF and is associated 
with the assembly of the γ-secretase complex. In some models where the N-terminal loop is located 
inside the membrane ejects towards the outside during the simulation. This supports the experimental 
results. In addition, formation of Pen-2 embedded in lipid bilyer can be simulated starting from 
random   orientation   of   Pen-2   and   lipid   in   Martini   coarse-grained   forcefield.  During   50   ns 
equilibration in Martini force field, bilayer formation was observed starting from random mixture of 
Pen-2 and DPPC lipids. Further during the simulation of Pen-2 of topology 1, the length of the TM 
helices increase depending on the hydrophobic core thickness used in the simulation and the 
resulting structure becomes close to that of topology 2.
 
Fig  8.6: Starting (A) and final (B) structure for Pen-2 after 20 ns 
Simulation   in   implicit   IMM1   (2.7   nm   hydrophobic   core   thickness   ) 
implemented in CHARMMResults and Discussion  124
In absence of experimental data, the models of Pen-2 can be unreliable since there is no significant 
homology of Pen-2 compared to already solved structures like in GPCRs. So further experimental 
evidence is required in order to verify the models. 
Fig 8.7: Starting (left) and final (right) structure for Pen-2  after 80 ns simulation 
in explicit POPC membrane surrounded by water and ions (not shown).  The 
structure remains almost unchanged except the change in the C-termini which 
becomes more compact and interacts with Presenilin.Results and Discussion  125
8.2 Modeling of PS1 CTF-APP Interface and CTF L383 mutations
By using protein protein docking programs like ClusPro [280], GRAMM [281] and HADDOCK 
[282] which does 6 dimensional conformational search by rotation and translation, models of PS1 
CTF – APP were obtained Fig 8.8. 
After mutating the GLGD motif of CTF to WLWD or WLGD or GLWD etc (big tryptophans should 
cause steric hindrance to decrease the stability  we observe  higher interaction energy (i.e. less 
stability) in mutants. Another interesting fact is that binding site of the APP changes and the new site 
has good interaction energy. Therefore it might be possible that mutating one or two residues leads to 
alteration of binding site of CTF and APP which is away from the catalytic Asp. That's why there is 
sometimes no Aβ production or less production. 
We performed MD in IMM1 with implicit solvent to find out the distance distribution between 
catalytic Asp of CTF and the peptide bond it cleaves for forming Ab40 and Ab42 respectively. So 
MD simulations in IMM1 starting from the docked conformations of the mutants (Fig 8.9 and Fig
8.10). 
It appears that the distances depend on the starting conformation of the CTF-APP interface, it is 
Fig 8.8: Docking of APP (PDB ID:2lp1) C-termini 
(red)   to   PS1   CTF   without   long   N-termini.   The 
catalytic aspartate of CTF and Val of APP which is 
cleaved off during Aβ40 formation has been shown.Results and Discussion  126
changing during MD simulation and one might get more stable distance distribution from prolonged 
MD simulation. However in these short simulations the distance for Ab40 formation decreases a bit 
and that of Ab42 slightly increases which supports the formation of higher Ab42 in these mutants. 
For WLGD (G382W) where is no activity the Ab40 distance slightly increase and Ab42 distance 
decrease a lot. The tryptophan is somehow interfering the catalysis. 
During all atom simulations in POPC membrane, water molecules interacting with catalytic Asp was 
found.  In case of the CTF structure, half of it is in hydrophilic environment. APP is probably in the 
water cavity as found in the cryoEM structure. Another interesting fact he pointed out is that in order 
to cleave the peptide bond in APP, the helix must be unfolded before the cleavage which is typical 
for 
Fig 8.9: In case of L383A mutation, the distance beween catalytic aspartate to the cleavage site for 
Ab42 formation decreases resulting in higher Ab42 production compared to WT. Results and Discussion  127
intermembrane cleaving proteases. Aspartates can't attack the alpha helix directly. There are many 
possibilities of a contact CTF-APP because the APP is probably unfolded in the region of cut. H7 is 
probably unfolded to form a pore but degree of unfolding is not known. Probably D385 is part of a 
helix like in NMR CTF structure. The helix of a substrate is probably also slightly unfolded, 
however,
there is no structure of protease-substrate complex in such reaction step. The APP must be a helix 
before a contact with H7 (probably binding H8 or even APH-1 with the same GxxxG motif). So we 
can trace two structures:  (1) with helical APP not in contact with D385, and (2) with slightly 
unfolded   APP   (possibly   only   one   helix   turn   or   even   a   half)   ready   for   a   cleavage.
We started with a hypothesis that H7 of CTF is longer than that of the reported in NMR structure. It 
would add another GxxxG interactions. However that part of helix unwound more or less in all 
simulations, which supports the most probable hypothesis of water pore. 
It was found in the experiments that the Ab42 production increases maximum in L383W, then L383P, 
L383Y and then L383F. In L383P, there is much more Ab43 produced compared to Ab42 and almost 
Fig 8.10: In case of L383W mutation, the distance for cleavage to produce Ab42 decreases, resulting in 
higher Ab42 levelsResults and Discussion  128
half of Ab40. And in G382W, there is no activity. 
Based on the paper by [35] the substrate binding site of presenilin should lie near the active site. 
During 40 ns simulations in g53a6 ff of CTF (h7 and h8), APP interface in POPC membrane for 
native, L383P and L383W. The Ab40 distance is around 8-10 A and is always less than Ab42 and 
Ab43 distance which is reasonable. But sometimes there is initial velocity effect and the CTF and 
APP tend to move away from each other (It is not reproducible by repeating the simulation). Similar 
things were noticed also in IMM1. From DFT studies [283] found that the cleavage of Val-Ile bond 
(Ab 40) is 9 times more favourable than Ala-Thr (ab40) which is similar to the data we have. 
Mutations probably change the charge distribution or cause steric hindrance among these residues, 
resulting in alteration of cleavage specificity due to different energy barriers for cleavage.  
Therefore  in  the  mutations  L383P, L383W and  G384A:  reduced  activity  and higher  Ab42 
production because of the population of APP conformations close to Asp with Ab42 cleavage site 
increases. G382W: no activity probably due to the presence of Trp close to Asp causing steric 
hindrance and failure of catalysis.
I performed a 20 ns simulation of the native ctf-app complex in Implicit Membrane (2.6  nm 
hyrophobic core and ) in CHARMM. Then I measured the distance between OD1 of Asp and N of Ile 
of APP (the peptide bond it cleaves for Ab40 generation during catalysis in presence of water) over 
the trajectory (as shown in the plot, x axis is represents 20 ns of simulation expressed in 1000 frames 
and y axis represents the distance in Angstrom. The second plot is the histogram of distance 
distribution over the trajectory) It is worth keeping in mind that since there is no friction in implicit 
membrane, the original length of simulation is much higher than 20 ns. Since water is present during 
catalysis, this interaction could further be probed by Molecular Dynamics simulations in explicit 
membrane. 
Due to the topology problem GxxxG motif interactions of APP TMD with the GVKLG motif in PS 
TM7 cannot take place. So the correct situation would be like this:
GVKL   G    LGDFIFYSVLV        G    KASATASG
KKKLMVLTIVIVTAIVVG    G    VML    G    IIA    G    KNSG
Potentially PS TM8 (shown below in the correct orientation relative to substrate) could aid in the 
interaction via helix-helix interaction motifs:
AKKFIALLLLTLCL            G    I   LI    A    VFC    A    I   TTN
KKKLMVLTIVIVTAIVVG    G    VML    G    IIA    G    KNSG
Outlook:
We have made several attempts to help you explain the effects of mutations within GLGD motif in 
PS1 CTF. After thorough review of literature, we have come to a conclusion that we should try 
modeling a situation which is closer to reality. Here is a sequence alignment of gamma-secretase 
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the   substrates   and   strongly   believe   that   we   should   change   our   approach   and   model 
CTF-NTF-substrate complex, where the substrate is a helix heavily tilted so that the cleavage site 
and catalytic center are near. Next, the top three hydrophobic residues would be unwound and the 
basic and polar residues that follow provide the unwinding force by interacting with water pore. 
After the first cleavage, we should model Ab43 being cut to Ab40, but this time charged C-terminal 
carboxyl group would interact with water to play the same role as the basic residues during the first 
cleavage. To do our task the best possible way, we have several questions regarding the complex we 
want to model.
8.2.1 SVM Predictions
Support vector machine (SVM) is a powerful way of machine learning successfully used in various 
fields of Bioinformatics. Here SVM implementation SVMlight was used to train the MOLGEN 
mutation dataset  (http://goo.gl/I7cb7)  of Presenilin 1 mutations which results in alteration of 
Ab40/Ab42 ratio. Increase in the ratio was indicated as positive outcome (+1) and decrease with (-1). 
Fig 8.11: (A) Levels of secreted A38, A40 and A42 species in conditioned media of HEK293/sw cells 
stably expressing H6X-tagged PS1 wt or the indicated PS1 L383 hydrophobic mutants were 
quantified by a highly specific A sandwich immunoassay and plotted as a percentage of the total A 
measured.  Bars represent the mean of three independent experiments ± S.E.  (B, C) Data of (A) 
were plotted such that A42/Atotal ratios (B) and A38/Atotal ratios (C) produced by the PS1 L383 mutants 
were expressed relative to those of PS1 wt that were set 1.00.  (D) Secreted A in conditioned media 
of HEK293/sw cells stably expressing H6X-tagged PS1 wt or the indicated representative PS1 L383 
mutants was immunoprecipitated with antibody 4G8 and subjected to MALDI-TOF MS analysis. 
Note the relative peak changes of individual A species.   Note that the spectrum of L383V is 
representative for the L383G, L383A and L383I mutants, which show a similar profile of Aspecies. 
Source: Prof. Harald SteinerResults and Discussion  130
The amino acids are classified into hydrophobic (1), polar (2) and charged (3) ones, there are 3
2=9 
types of mutation possible. The SVM was trained like increase in Ab40/Ab42: +1 135:12 ,  decrease 
in Ab40/Ab42: -1 25:23 where second column is the residue number and third column is the change 
due to mutation (hydhophobic to polar in first example). Further all the mutations were encoded by 
sparse encoding. 
After filtering when the dataset was used the training set for classification in svmlight [284], it gives 
88% accuracy and with the experimental mutation set of 17 mutations of PS1 L383, it gives 89 % 
accuracy. 
The amino acids are classified into hydrophilic(1), hydropphilic (2)  and polar (3) ones, there are 9 
types of mutation. The machine can be trained like increase in Ab40/Ab42: 
1 135:12 
decrease in Ab40/Ab42 
-1 25:23 
whee second columm is the residue number and third column is the   change due to mutation 
(hydhophilic to polar in first example). So there are 3x3 = 9 possibilities of mutation i.e. 1 ->1 i.e. 11, 
12, 13, 21, 22, 23, 31, 32, 33. But since 22 is double of 11, it can result in false training. So sparse 
encoding   approach   was   used   and   the   following   mutations   are   encoded   like  in   the   figure.
After filtering, there was 57 reliable mutations to train and many of the mutations result in negative 
outcome (-1). When I used the training. Due to lack of structural information of the complex 
modeling did not lead to any convincing results so far. 
Currently the method is being improved by adding information from position specific scoring 
matrices (PSSM) derived from multiple sequence alignments. Further neural network is being used 
to   improve   the   quality   of   the   predictions.
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8.2.2 Modeling APP, PS1 CTF and NTF Interface:
We tried many different arrangements of APP, CTF and NTF fragments including that based on 
recent FlaK protease structure [88]. Inclusion of some restraints will be necessary to keep pieces of 
the active site together because of lack of the rest of the gamma-secretase complex. However we still 
did not obtain a model which can describe properly the experimental findings at least qualitatively. 
We added more cleavage sites (for instance at 49) on the figure to get a more clear picture.  We used 
one predicted helix from NTF that contains the second catalytic aspartate. This  used  a piece 
encompassing aminoacids from 244 to 264 + 3: WTAWLILAVISVYDLVAVL.  2006 SCAM data 
from Iwatsubo and De Strooper it is reasonable to assume a helix, which may be kinked according to 
the Sato data. The helix could also be like this: WTAWLILAVISVYDLVAVL: CP are not in any 
more as shown in most models of PS topology. Fig 8.13 shows  a model of one of arrangements with 
fragment of APP approaching the active site for the first cleavage at L49. APP is in unfolded 
conformation. Other cleavages at 42 and 40 were also shown. 
Modeling based on density functional theory (DFT):
I performed geometry optimizations and transition state search of the APP-PS1 complex with the 
co-ordinated given in that DFT paper usin Gaussian09 [283]. However, the results could not be 
reproduced (i.e. no cleavage of the peptide bond was observed). Further calculations were performed 
Fig 8.13 Proposed interaction sites of APP with PS1 CTF and NTF showing 
catalytic residues D385 and D257 also the first cleavage site L49 and Ab40 
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in PM6-DH2 using Mopac2009 without fruitful results.
9 Modeling of PS1-NTF
Models of NTF were obtained in the similar way to Pen-2 and were scored by a consensus Rosetta, 
ProQ and Prosa2003 scored. Following is the top scoring model of PS1-NTF without the N-terminal 
loop (82 amino acids).
Fig 9.1: Model of PS1 NTF. left: side view showing six transmembrane helices. right: 
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10 Activation mechanism of GPCRs
10.1 Introduction 
GPCRs (also called 7TM receptors) form a large superfamily of membrane proteins, which can be 
activated by small molecules, lipids, hormones,  peptides, light, pain, taste and smell etc. Although 
50% of the drugs in market target GPCRs , only few are targeted therapeutically [285]. Such wide 
range of targets is due to involvement of GPCRs in signaling pathways related to many diseases i.e. 
dementia (like Alzheimer's disease [87]), metabolic (like diabetes [286]) including endocrinological 
disorders  [287], immunological  [288]  including viral infections   [289], cardiovascular  [288], 
inflammatory  [290],  senses disorders  [291], pain  [292]  and cancer  [293].    Upon activation by 
extracellular agonists,  GPCRs  pass the signal to the cell interior. Ligands can bind either to 
extracellular   N-terminus  and   loops   (e.g.  glutamate  receptors)  or  to  the   binding  site   within 
transmembrane helices (Rhodopsin-like family)  (Fig 10.1). They are all activated by agonists 
although a spontaneous auto-activation of an empty receptor can also be observed. 
Biochemical and crystallographic methods together with  MD  simulations, and other theoretical 
techniques provided models of receptor activation based on the action of so-called “molecular 
switches” buried in the receptor structure. They are changed by agonists but also by inverse agonists 
evoking an ensemble of activation states leading toward different activation pathways. Switches 
discovered so far include the ionic lock switch, the 3-7 lock switch, the tyrosine toggle switch linked 
with the nPxxy motif in TM7, and the transmission switch proposed ad hoc based on a flood of 
recent crystal structures (instead of the tryptophan rotamer toggle switch which seems to work in 
another way than it was thought before). The suggested global toggle switch consisting of vertical 
rigid motion of TM6 seems to be implausible based on the recent crystal structures of GPCRs with 
agonists. Because of the intrinsic instability of GPCRs resulting in their multiple functionality, the 
investigations of the action of molecular switches are extremely difficult but may provide highly 
selective drugs acting not even on a single receptor subtype but a single pharmacological subprofile 
[294–296]. The detailed knowledge of the GPCR activation mechanism could be very useful in 
designing specific drugs. We proposed novel activation mechanism of cannabinoid receptors CB1 and 
CB2 [294], and elucidated the role of water in the activation of formyl peptide receptor (FPR1) [296] 
GPCRs interact with very diverse sets of ligands which bind to the transmembrane (TM) segments 
and sometimes also to the receptor extracellular domains. Each receptor subfamily undergoes a series 
of conformational rearrangements leading to the binding of a G protein during the activation process. 
All GPCRs preserved the 7-TM scaffold during evolution but adapted it to different sets of ligands 
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different intramolecular interactions, leading to different  receptor conformations and differential 
effects on downstream signaling proteins. The dynamic character of GPCRs is likely to be essential 
for their physiological functions, and a better understanding of this molecular plasticity could be 
important for drug discovery. 
Experiments suggest that agonist binding and receptor activation occur through a series of 
conformational intermediates. Transition between these intermediate states involves the disruption of 
intramolecular interactions that stabilize the basal state of a receptor. Such profound changes are 
evoked by the action of molecular switches. The switches proposed so far for different GPCRs 
include the “rotamer toggle switch” involving the CWxPxF sequence on TM6, the switch based on 
the NpxxY(x)F sequence linking TM7 and H8, the “3-7 lock” interaction connecting TM3 and TM7 
(involving   Schiff   base-counterion   interaction   in   rhodopsin),   and   the   “ionic   lock”   linking 
transmembrane helices TM3 and TM6 and employing the E/DRY motif on TM3. In the rhodopsin 
structure all these switches are closed (inactive state) [297], however, in the recent crystal structures 
Fig  10.1  Phylogenetic   tree   of   GPCRs   showing   solved   structures  in   cartoon   diagrams.   (Source: 
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of β 1- and β 2-adrenergic receptor complexes with antagonists and inverse agonists the “ionic lock” 
is open while the “rotamer toggle switch” remains closed [298]. 
Highly conserved residues among G-protein-coupled receptors indicate not only molecular switches 
but they are also located at the interior of individual structural segments, suggesting a dual role for 
these segments. Firstly, structural segments stabilize secondary structure elements of the native 
protein, and secondly, they position and hold the highly conserved residues at functionally important 
environments. Two main classes of force curves were observed in SMFS experiments  (Single 
Molecule Force Spectroscopy) in rhodopsin  [299]. One class corresponded to the unfolding of 
rhodopsin with the highly conserved Cys110–Cys187 disulfide bond remaining intact and the other 
class corresponded to the unfolding of the entire rhodopsin polypeptide chain. In the absence of the 
Cys110–Cys187 bond, the nature of certain molecular interactions within folded rhodopsin was 
altered. These changes highlight the structural importance of this disulfide bond and may form the 
basis of dysfunctions associated with its absence.
With the determination of the first structure of the complex between a G-protein coupled receptor 
Fig 10.2 General scheme of topology and location of conserved residues in 
Rhodopsin-like GPCRs. Number of residues and their locations in each TM 
is based on chemokine receptor CXCR4 (H8 is not present in the crystal 
structure so it is shown transparent). Residues in bold are the most 
conserved in each TM. Sequence motifs are shown as gray areas. An 
alternative position of proline residue in TM2 is denoted by (P). Activation mechanism of GPCRs 136
(GPCR) and a G-protein trimer (Gαβγ in 2011 [300,301] a era of GPCR research was opened for 
structural investigations of global switches with more than one protein being investigated. The 
previous breakthroughs involved determination of the crystal structure of the first GPCR, rhodopsin, 
in 2000 [297] and the crystal structure of the first GPCR with a diffusible ligand (β2AR) in 2007 
[266]. How the seven transmembrane helices of a GPCR are arranged into a bundle was suspected 
based on the low-resolution model of frog rhodopsin from cryo-electron microscopy studies of the 
two-dimensional crystals [302]. The crystal structure of rhodopsin, that came up three years later, 
was not a surprise apart from the presence of an additional cytoplasmic helix H8 and a precise 
location of a loop covering retinal binding site. However, it provided a scaffold which was hoped to 
be a universal template for homology modeling and drug design for other GPCRs – a notion that 
proved to be too optimistic [297]. Seven years later, the crystallization of β2-adrenergic receptor 
(β2AR) with a diffusible ligand brought surprising results because it revealed quite a different shape 
of the receptor extracellular side than that of rhodopsin. This area is important because it is 
responsible for the ligand binding and is targeted by many drugs. Moreover, the ligand binding site 
was much more spacious than in the rhodopsin structure and was open to the exterior. In the other 
receptors crystallized shortly afterwards the binding side was even more easily accessible to the 
ligand. New structures complemented with biochemical investigations uncovered mechanisms of 
action of molecular switches which modulate the structure of the receptor leading to activation states 
for agonists or to complete or partial inactivation states for inverse agonists. 
Here I will describe the proposed activation mechanisms together with molecular switches, compare 
them and try to generalize the findings with respect to the other GPCRs not only from family A (the 
most populated Rhodopsin-like family) but also other families of these mysterious receptors. The 
action of molecular switches was most extensively investigated in the case of two types of receptors: 
rhodopsin and the β-adrenergic receptors. The recent reviews on activation and action of molecular 
switches in the Rhodopsin family of GPCRs were published in 2009 by Ahuja and Smith [303], 
Nygaard et al. [304] and also by Hofmann et al. [305]. Some other reviews on activation mechanisms 
were published earlier by Strange [306] and lately by Deupi and Standfuss [307]. The three year 
period since 2009 has been very fruitful for the GPCR research and provided detailed explanations 
on how some of the switches work as well as redefined some hypotheses in this field. In a very 
recent review [308] Unal and Karnik tried to generalize the concept of molecular switches and came 
to the idea of a coordinated domain coupling in GPCRs which could be a consequence of the 
dynamic nature of these receptors. According to this hypothesis when a ligand is bound to a receptor 
extracellular domain a decrease in the intrinsic disorder of this domain cooperatively changes the 
conformation of the neighboring receptor domain. Certainly, some other original concepts will be 
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GPCRs and their complexes. 
10.1.1Superfamily of GPCRs 
The superfamily of G-protein coupled receptors (GPCRs) can be divided into five main families: 
Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2 (consisting of frizzled, smoothened and taste2 
receptors), and Secretin, according to the GRAFS classification system [309] which displaced the 
previous A-F system [310,311]. The GRAFS system was formed using the Hidden Markov Model 
approach to analysis of multiple sequence alignments of all GPCRs from 13 eukaryotic genomes. All 
five families were formed in the early stage of metazoan evolution and the number of GPCRs in each 
family increased during evolution. At present, sequence diversity of GPCRs and their abundance is 
enormous, giving organisms more ways to adapt to various environmental conditions  [312]. 
Additionally, the Rhodopsin family, the largest and the best described of all, is divided into four 
groups: α, β, γ and δ, out of which only the δ group does not have any representative in the PDB 
database. The above internal classification of the Rhodopsin family is still under discussion as other 
methods  such  as  NJ  (Neighbor-joining)  or  UPGMA (Unweighted  Pair  Group Method  with 
Arithmetic mean) provided phylogenetic trees of a different fan-like shape [313,314]. Lately, using 
the multidimensional scaling (MDS), a non-phylogenetic statistical method adapted to evolutionary 
distant sequences, Chabbert and co-workers  [315]  showed that the Rhodopsin family should be 
divided into 4 groups. The central group, G0, is formed by peptide receptors, opsins and melatonin 
receptors. The second group, G1, includes somatostatin and opioid receptors, chemokine and 
purinergic receptors, proteinase activated receptors and acid receptors. The G2 group is formed by 
biogenic amine receptors and adenosine receptors. Finally, the G3 group consists of receptors for 
melanocortin, phospholipids and cannabinoids, glycoprotein hormone receptors and leucine-rich 
repeat   (LRR)   containing   receptors,   prostaglandin   receptors   and   Mas-related   receptors.   This 
classification of Rhodopsin GPCRs emphasized the role of proline residues patterns in TM2 
(transmembrane helix 2) and TM5 (observed in correlated mutations) which was confirmed by the 
recently solved CXCR4 structure [316]. 
Despite the large sequence diversity, all GPCRs most probably share the same fold: seven 
transmembrane helices joined by extracellular and intracellular loops of varied length (see Fig 10.2). 
A 7TM core is well preserved in all known to date protein structures of GPCRs despite the high 
degree of sequence variability within this region. It is worth noticing that the seven helix bundle is 
not a unique feature of G-protein coupled receptors, since there are other proteins in eukaryotic and 
prokaryotic organisms which share this fold. For example in eukaryotes, a 7TM fold appears in 
high-conductance Ca2+-activated potassium channels (BKCa) [34] and in ligand-gated ion channels 
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light-induced structural changes in the 7TM core of bacteriorhodopsin [318,319] or halorhodopsin 
[320]   provoke pumping of protons (hydrogen ions) or halide ions, respectively, through the 
membrane, or induce protein-protein interactions which initiate a signaling cascade associated with 
phototaxis, as in the case of the sensory rhodopsin I-transducer complex [319]. 
While the 7TM core is a typical common feature of GPCRs, the extracellular and intracellular 
regions differ in structure, sequence and length allowing interactions with various signaling 
molecules and ligands: ions, organic odorants, amines, peptides, proteins, lipids, nucleotides and 
photons [309]. Moreover, many GPCRs, so-called orphan receptors, still lack a reliable assignment 
of interacting ligands and some of them may not even need ligands for activation but, most probably, 
are self-activated through heterodimerization [321]. In general, ligands bind to the extracellular loops 
and the N-terminus, while the intercellular part of GPCRs is involved in protein-protein interactions 
with G proteins, arrestin or other subunits. 
Depending on the GPCR family different regions of receptors are involved in the activation process 
(see Table 1). The common role of GPCRs is a signal transmission to the cell interior through 
interactions with molecules, such as the G protein or arrestin, by changing the structure of their 
transmembrane domains and/or extracellular and intracellular parts after the ligand binding. G 
protein-coupled signal transduction involves dissociation of G protein into Gα and Gβγ subunits 
which modulate enzymes or membrane channels leading to a highly amplified signaling cascade. In 
the absence of any ligand a G-protein coupled receptor is believed to be in a dynamical equilibrium 
between the inactive (R) and the less populated active (R*) state. Binding of an agonist molecule 
(full or partial) is thought to increase the probability of the receptor converting to R* [322]. Such a 
scheme is preferred in the case of GPCRs with diffusible ligands, however, in the case of rhodopsin, 
endowed with a very tight ligand binding site, probably the induced fit mechanism is employed 
[323]. It is possible that in most GPCRs both mechanisms are operational but in different 
proportions. These two types of activation paths, the dynamic equilibrium of receptor states and the 
agonist-induced conformational change, will be described in detail later on. Antagonists prevent the 
binding of both agonists and inverse agonists into the orthosteric site (a binding site for endogenous 
agonists) but they can also change the receptor structure (or choose a particular state of the receptor 
according   to   ensemble   of   conformational   receptor   states)   which   can   even   induce   receptor 
internalization in some cases. GPCRs activation and signal transmission can also be influenced by 
allosteric or ago-allosteric modulations induced not only by several ligands known to date [324] but 
also through either negative or positive cooperation between protomers within a dimer. Many 
functional studies proved dimerization of GPCRs [325] although even a monomer is able to activate 
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kinases) [327]. The role of oligomerization in activation and signal transduction by GPCRs is still 
not clear although some experimental and theoretical studies involving not only Rhodopsin but also 
the Glutamate and Secretin families proved its relevance  [328,329]. Moreover, many GPCRs, 
so-called orphan receptors, still lack reliable assignment of interacting ligands and some of them are 
probably self-activated i.a. through heterodimerization [321]. 
GPCRs were traditionally considered to be monomeric and recent studies of GPCRs reconstituted in 
high-density lipoprotein particles have confirmed that these receptors can exist and function as 
monomers  [326,330]. However, as evidenced by biochemical measurements of cooperativity, 
biophysical determinations of fluorescence or by bioluminescence resonance energy transfer between 
protomers, co-immunoprecipitation and other methods GPCRs from various families can assemble as 
dimers or higher-order oligomers [331–333]. Currently, dimerization was proposed to play a role in 
processes ranging from ligand binding to receptor signaling, maturation, trafficking and regulation. 
For the glutamate receptor family of GPCRs activation involves a movement of the N-terminal 
Venus flytrap domain (VFTD) within a dimeric GPCR entity to activate the membranous domains, 
which suggests that dimerization is mandatory for agonist-induced activation [334]. It is likely that 
various allosteric interactions between monomers in an oligomeric complex represent those that 
occur between distinct sites within a given GPCR monomer  [335]. To date, experimental data 
suggest that GPCR dimers and oligomers are functionally asymmetric which was characterized 
especially for GABABR and the mGluR receptors from the glutamate family [336,337]. Because of 
asymmetric functionality the subunits in a GPCR dimer possibly adopt different conformations in a 
particular receptor state (inactive or active). Recent studies on dopamine D2 receptor dimers have 
also demonstrated asymmetric communication between an agonist-bound and an antagonist-bound 
protomers within the D2 dimer [333]. 
Homo- and hetero-dimerization can modulate the signaling properties of receptors and mediate 
cross-talk between GPCR pathways  [338]. Crystal structures can also directly suggest novel 
allosteric sites with specific properties and selectivity. For example, a cholesterol binding site located 
in the interface between protomers consisting of helices TM1 and H8, has been observed in many 
dimeric   β2-adrenergic   receptor   crystal   structures  [339].   Cholesterol   can   modulate   receptor 
thermostability and ligand affinities. However, even for the most studied dimers the identification of 
the functionally relevant interface is still very difficult. This is partly due to the transient mode of the 
interactions and the technical problems of differentiating between specific and nonspecific binding in 
membrane environment [340]. On the other hand, it was observed in crystallization studies that 
nonspecific or partial dimerization of GPCRs can prevent crystal formation because it introduces 
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analyzed so far the receptor molecules have been found in non-functional (antiparallel or tilting) 
orientations. The recent crystal structures of CXCR4 [316] are rather exceptions revealing a parallel 
dimer arrangement involving helices TM5 and TM6. The dimer interface is virtually identical in five 
different crystal packing forms of CXCR4 with both peptide and small-molecule antagonist, which 
can suggest that it is functionally relevant [341]. 
Using a fluorescence resonance energy transfer (FRET) to characterize the oligomerization of β2AR 
Fung et al.  [332]  proposed that β2AR forms predominantly tetramers when reconstituted in 
phospholipid vesicles. Agonists and antagonists had little effect on the relative orientation of 
protomers in the oligomeric complexes so it was suggested that the tetramer structure is loose 
enough to accommodate a large, outward movement of the cytoplasmic part of TM6. In contrast, 
binding of inverse agonists led to a significant increase in FRET efficiencies for most labeled amino 
acid pairs. This could suggest that inverse agonists can induce tighter packing of protomers and/or 
stimulate the formation of larger oligomers (possibly octamers or larger structures) by employing the 
additional   interface   at   the   receptor   surface.   The   results   provide   new   insights   into   β2AR 
oligomerization and reveal a possible mechanism for the functional effects of inverse agonists. The 
interface involving helices TM1 and H8 was proposed for a symmetrical dimer (as it was found in 
the crystal structures of this receptor type) so the tetramer would be a dimer of dimers. Upon binding 
of an inverse agonist the dimers could form a tighter structure and additionally the tetramers could 
stick together to form octamer engaging an interface involving helices TM4 and TM5. In this way a 
larger oligomer can be formed using more tetramers. Similar interfaces were proposed for rhodopsin 
oligomers based on the AFM measurement  [342,343], however in this case the interface in a 
rhodopsin dimer involved helices TM4 and TM5 while contacts between rows of dimers were 
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10.2 Switches in rhodopsin-like receptors 
The activation of GPCRs occurs most probably through series of conformational changes called 
molecular switches. The crystal structures enables the researchers to almost see them in action by 
comparing structures of the same receptors with agonists and antagonists (Fig 10.3). Based on the 
crystal structures we describe those molecular switches that are well characterized and proposed to 
work in most of GPCRs. 
10.2.1The Ionic Lock Switch 
The presence of the first switch, the ionic lock, has been shown in the first GPCR X-ray structure 
obtained by Palczewski et al.  [297]. The inactive state of bovine rhodopsin shows a strong 
intramolecular interaction between residues Glu3.49/Arg3.50 of the conserved (d/e)Ry motif in TM3 
and residues Glu6.30/Thr6.34 in TM6 (Fig 10.3G). The authors of that paper concluded that "it could 
be one of the critical constraints keeping rhodopsin in the inactive occupation", but also noted that 
this region has high crystallographic B-values, meaning that the side chains may assume different 
conformations. Following that work as well as mutagenesis studies, which showed the importance of 
the (d/e)Ry motif [344], the activation mechanism of GPCRs has been described as a cascade of 
altering molecular switches in conserved microdomains [303,345]. In this mechanism, ligand binding 
triggers a series of molecular switches (including the TM3-TM6 ionic lock) to unlock the G 
protein-binding site in the intracellular face of the receptor, leading to G protein activation. 
Apart from inactive rhodopsin there are only few crystal structures in which this particular ionic lock 
is observed. The dopamine D3 receptor [346] and adenosine A2A receptor [347] (but only with 
selected antagonists) are the only other GPCRs that show the Arg3.50-Glu6.30 ionic lock in the 
crystal structure. In addition, the residues Asp3.49 and Arg3.50 are forming hydrogen bonds with 
Tyr3.60 (located in IC2), possibly stabilizing the ionic lock and restraining a helical conformation of 
IC2. The turkey β1-AR structure has the ionic lock open but because of the close proximity of 
helices TM3 and TM6, the different rotamers of these residues would yield the switch closed. The 
AA2R-T4L chimera has a similar structure in this region and the (d/e)Ry motif is forming a 
Asp3.49-Tyr3.60 hydrogen bond which restrains the conformation of intracellular loop 2 (IC2). In 
the human β2AR structure the ionic lock between Arg3.50 and Glu6.30 is absent; instead, a hydrogen 
bond between the highly conserved Tyr3.60 and His6.31 is present. CXCR4 is lacking the Glu6.30 
residue and no ionic lock is present between TM3 and TM6. In the histamine H1 receptor the ionic 
lock is also absent; instead, Arg3.50 adopts a different conformer and forms a hydrogen bond with 
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lock despite the presence of residues capable of forming strong interactions has been intriguing; 
some attribute it to the inclusion of the T4L fusion protein in crystal structures, which may affect the 
interactions in TM6. 
10.2.2The 3-7 Lock Switch 
In rhodopsin the key restrain which is broken first upon retinal isomerization is a salt bridge between 
a protonated Schiff-base of retinal-Lys7.43 and a counterion, Glu3.28 (Fig 10.3J). This switch is 
called the 3-7 lock because a link between TM3 and TM7 is broken during activation. A similar 
mechanism probably exists in other receptors, especially with amine-type ligands (aminergic 
receptors) e.g. histamine H1 [348] or dopamine D3 [346], which were crystallized with antagonists 
bound and also in opioid receptors (OPR) for which an extensive modeling was done [349–351]. In 
these receptors the switch is composed of different residues: Tyr7.43 (which is more conserved than 
lysine present in rhodopsin) and Asp3.32 which substitutes for the rhodopsin’s counterion, Glu3.28. 
Asp3.32 is located on the same face of TM3 and deeper in the receptor interior which compensates 
for a shorter length of its side chain. In β1- and β2-adrenergic receptors there is also a hydrogen 
bond, Asp3.32-Tyr7.43, but additionally, the Asn7.39 residue, positioned one turn of helix away of 
Tyr7.43, is linked to Asp3.32 by a protonated nitrogen atom of aminergic receptor ligands. This is 
why disruption of the Asp3.32-Tyr7.43 hydrogen bond does not break the link between TM3 and 
TM7 so the 3-7 lock switch is not functioning in adrenergic receptors. Opening of the 3-7 lock was 
suggested by Khorana [352] to be the first switch activated in rhodopsin and possibly it is one of the 
first switches that can be activated upon ligand binding in some other GPCRs. In (Fig 10.3) it is 
represented by one panel with rhodopsin structures. 
10.2.3Transmission Switch (Former Trp Rotamer Toggle Switch) 
In all crystal structures with agonists there are movements of TM5 and TM6 but they vary 
considerably. Several similarities can be observed including a relocation of conserved residues 
Trp6.48 and Phe6.44 towards Pro5.50 (Fig 10.3A-C). Such movements were called “a transmission 
switch” by Deupi and Standfuss [307] instead of the previous name “rotamer toggle switch”. This 
novel and larger switch links the agonist binding site with the movement of TM5 and TM6 through 
rearrangement of the TM3-5-6 interface. This is possibly the most common switch among GPCRs. 
After movement of Trp6.48 in rhodopsin the Phe6.44 residue situated one helix turn away toward the 
cytoplasmic side of TM6, is displaced toward Leu5.51 as the whole TM6 is rotating horizontally. In 
β-adrenergic receptors a little contraction of the binding site is observed while in rhodopsin 
isomerization of retinal makes the binding site much larger. The interaction of Ser5.42 and Ser5.46 
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about a 1.4 Å movement of Pro5.50 whereas, unlike in rhodopsin, there is no movement of Trp6.48. 
However, there is a rotation and movement but only of the cytoplasmic part of TM6. This is 
translated to a relocation of Ile3.40 from its position at Pro5.50 and a motion of Phe6.44 due to 
rotation of TM6. Activation of this switch seems to be limited to some classes of GPCRs. Apart from 
these differences the activation mechanism of A2AR is similar to that of rhodopsin because Trp 6.48 
is also moved and TM6 rotated. There are also similar rearrangements in β2AR and rhodopsin in 
TM5 and TM6, by movements of Phe6.44 towards Pro5.50 and Leu5.51 together with the movement 
of Ile3.40 away from Pro5.50 – such translocations are part of the transmission switch. Agonist 
binding in A2AR results in the relocation of Ser7.42 and His7.43 which, together with Thr3.36 in 
TM3, coordinate a part of the agonist. These interactions resemble the 3-7 lock between the 
protonated Schiff base of the retinal-Lys7.43 and Glu3.28, which is critical for rhodopsin activation. 
Although the TM3-agonist-TM7 interactions in the adenosine receptor are formed, rather than 
broken, upon activation, they could fulfill a similar role in arranging TM3 and TM7 in the active and 
inactive conformations [307]. 
The switches together with the hydrogen bond network between conserved residues, motifs and 
structural water molecules constitute an extended interface between different areas in GPCRs which 
facilitate the large movements linking ligand binding to cell signaling. Based on the recent crystal 
structures of inactive and activated, as well as constitutively active rhodopsin, one can elucidate the 
activation scheme of this protein and the role of particular switches as it was done by Standfuss et al. 
[307]. The structure of retinal in all-trans conformation, but unbound from Lys7.43, represents the 
active structure of rhodopsin nearly identical to the Meta-II state. This structure was published nearly 
simultaneously with the Meta-II rhodopsin structure with covalently bound retinal with and without 
GαCT (C-terminus of Gα subunit) [353]. The structures agree with each other in location of the main 
conserved amino acids. A covalently bound all-trans retinal behaves as a full agonist, whereas when 
unbound, it behaves as a partial agonist but maintains the critical interactions between the β-ionone 
ring and helices TM5 and TM6. The structure of a constitutively active mutant Glu3.28Gln [354] 
represents probably a trapped intermediate when retinal is either entering or exiting the binding site. 
The transition from an inactive to active state of GPCR includes large rigid motion of TM6. In the 
case of rhodopsin this is not a vertical hinge movement (named a global toggle switch) but a 
horizontal (in plane of the membrane) rotation of TM6 that leaves the shape of the helix intact. The 
characteristic bend of TM6 is imposed by Pro6.50 which is a part of the CwxP motif. The other 
highly conserved amino acid, Trp6.48, is tightly packed against retinal in the ground state of 
rhodopsin as it has a central role in the transmission switch model (previously called a rotamer toggle 
switch) of activation of these receptor. The structure of the Glu3.28Gln mutant places this residue 3.6 
Å from its ground state position. However, no rotamer change is observed as it was proposed based Activation mechanism of GPCRs 145
on biochemical experiments and also computer simulations. Instead, Trp6.48 follows the retinal (its 
β-ionone ring) maintaining contact with the C18 methyl group. 
10.2.4Tyrosine Toggle Switch (nPxxy Motif) 
A region called the hydrophobic barrier (Fig 10.4A) separates the water mediated hydrogen bond 
network from the (d/e)Ry motif which is critical for G protein activation  (Fig 10.3D-F). In the active 
Glu3.28Gln-GαCT structure, a rotation of TM6 disrupts the water mediated link between Trp6.48 
and Ser7.45 and reorganizes the ground-state hydrogen bond network. The hydrophobic barrier 
opens and Tyr7.53 of the nPxxy motif, together with Tyr5.58, rearrange to fill the hydrophobic gap 
and to extend the hydrogen bond network towards the (d/e)Ry motif and GαCT peptide (Fig 10.4B). 
The role of this barrier in molecular switching was explained by Standfuss et al. [354] based on 
studies involving the crystal structure of rhodopsin with all-trans retinal in the binding site. The 
hydrophobic barrier was described earlier also by Schertler’s group [355] upon crystallization of 
inactive rhodopsin in a trigonal crystal form. A more extended motif nPxxy(x)5,6F was proposed by 
Fritze et al. [356] to explain the presence of the interaction between Tyr7.53 in TM7 and Phe7.60 in 
helix H8 in the inactive structure of rhodopsin (Fig 10.3D). Such an interaction can additionally 
stabilize the inactive state of the receptor. However, in crystal structures of other GPCRs, such as the 
adrenergic and adenosine receptors (Fig 10.3E-F) such interaction is not seen despite the fact that 
Phe7.60 is present. It probably indicates that these receptors could be partially activated. 
The hydrophobic barrier consists of six residues between helices TM2, TM3 and TM6 (Leu2.43, 
Leu2.46, Leu3.43, Leu3.46, Met6.36 and Met6.40) and many of them are conserved in the 
rhodopsin-class of GPCRs. The rearrangement of hydrogen bonds is relatively minor but they 
directly link changes in the CwxP motif in the retinal binding pocket with the most conserved 
residues in TM1 (Asn1.50) and TM2 (Asp2.50) and nPxxy in TM7. On the cytoplasmic side, the 
rotation of TM6 opens the hydrophobic barrier allowing Tyr5.58 and Tyr5.53 to swing into the 
protein interior. They provide additional interactions with water molecules extending the hydrogen 
bond network toward the hydrophobic barrier to the (d/e)Ry motif at the cytoplasmic surface of 
TM3. The ionic lock involving residues in this motif, Glu3.49-Arg3.50 and Glu6.30, is broken and 
allows binding of GαCT peptide in a position that is occupied by TM6 in a ground state. Thus, 
rotation of TM6 and displacement of Trp6.48 results in a hydrogen bond network connecting 
residues from the retinal binding site to those at a cytoplasmic surface critical for activation of G 
protein. 
Also the recently obtained A2AR-T4-lysosyme structure exhibits features of agonist induced 
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Leu5.51, Phe6.44 and Trp6.48) similarly to the active structures of β2AR [301,357] and rhodopsin 
[353,354]). However, although Tyr7.53 from the nPxxy motif is relocated towards the receptor center 
the relocation of TM6 is only 3Å which is much smaller than in active rhodopsin (6 Å), nanobody 
β2AR (8 Å) and in the complex with trimeric G protein (14 Å). These changes may be blocked by 
the presence of the fused lysozyme structure. However, the changes of residues close to the binding 
site suggest that this conformation resembles the Meta-I structure of rhodopsin which does not allow 
binding to G protein. Possibly in some GPCRs the full adaptation to G protein binding may be 
achieved in the presence of a G protein or other interaction partners that stabilize the cytoplasmic 
domain. 
10.2.5The Elusive “Global Toggle Switch” 
The number of conserved motifs found in transmembrane helices of the Rhodopsin family receptors 
is significantly higher than in the other GPCR families (see Table 1 and Fig 10.2) indicating their 
potential role in receptor stabilization and activation. It was proposed that receptors of the Rhodopsin 
family most probably share the common mechanism of activation - the so-called "global toggle 
switch" [358]. According to this model the TM6 helix performs a vertical see-saw move around the 
central Pro6.50 residue during receptor activation induced by binding of an agonist. The upper part 
of TM6 is closing around the ligand, while the lower (near the intracellular surface) is opening to 
prepare for the G-protein binding. It was suggested that during activation by an agonist the 
rearrangement of TM3 and TM5 also takes place, though to a minor extent than in the case of the 
TM6 movement [307]. An accompanying kink in TM7 is induced by changes in the hydrogen-bond 
network between TM7 and TM1, TM2 and TM6  [304]. 
Using the metal ion site engineering techniques and based on the obtained distance constraints for 
β2-adrenergic receptor Elling et al. [359] developed the so-called “global toggle switch” mechanistic 
model. In this model Asp3.32 was an anchoring point for monoamine binding in TM3 helix. The 
authors engineered metal ion sites, which activated the receptor, between the extracellular parts of 
TMs. Copper and zinc ions alone and in complex with aromatic chelators acted as potent agonists in 
sites constructed between position 3.32 (Asp - known to bind ligand directly - or its mutation to His) 
and the Cys or His mutations of specific amino acids at TM6 and TM7 close to the binding site. To 
fulfill the distance constraints the residues involved in the orthosteric ligand binding pocket had to 
move closer to each other during receptor activation. In this model an inward movement of the 
extracellular segments, especially those of TM6 and, to some extent, TM7, was coupled to the 
well-established outward movement of the cytoplasmic segments of these helices. The authors 
suggested that the pivot points for these vertical seesaw movements are the highly conserved proline 
bends of the involved helices. Based on the present crystal structures of β2AR the global toggle 
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detected. In rhodopsin there is even an increase of the retinal binding site and the same is in the case 
of A2AR – the binding site is smaller for antagonists regardless if they are smaller (caffeine) or 
bigger (ZM241385) than the agonist (adenosine). TM3, and not extracellular part of TM6 which is 
not moving, is responsible for this shrinkage of the binding site. There is an unusual bend on TM3 
(close to Val3.32) in receptor structures with bound antagonists. This residue (located in the same 
position as extremely important Asp3.32 in receptors for monoamine ligands) may be now regarded 
as a part of the agonist/antagonist sensor. 
10.2.6Role of Conserved Residues 
Rhodopsin-like GPCRs lack a long N-termini except for PARs (protease-activated receptors which 
do not need agonist-binding to be activated) with an N-terminal thrombin-cleaved part releasing a 
tethered   ligand,   LGRs   (GPCRs   containing   LRRs   –   leucine-rich   repeats)   interacting   with 
glycoproteins and LDLa (a low-density lipoprotein receptor class A). In most Rhodopsin-like GPCRs 
an agonist interacts with extracellular loops and the TM region. Although sequence diversity in the 
TM region is quite high even within the Rhodopsin family the motifs involved in the activation 
mechanism are well conserved, i.e. (d/e)Ry, CwxP and nPxxy. In Table 1 we indicated all conserved 
residues in the Rhodopsin family of receptors and underlined these which are believed to be involved 
in molecular switches. The residues are also visualized on the topological scheme of GPCR (7TM 
receptor) in (Fig 10.2). 
In   TM1   the   most   conserved   residue   is  Asn1.50,   involved   in   a   structural   water-mediated 
hydrogen-bonding network between TM1, TM2 (Asp2.50), TM6 (Trp6.48) and TM7 (Asn7.45, 
Ser7.46, Asn7.49, Tyr7.53). The Asn 1.50 residue is an arguable element of the receptor activation 
process, namely the TM3, TM5 and TM7 movements [304]. The conserved proline residue in TM2 
[314], either in position 2.58 (e.g. in a recently solved CXCR4 structure) or 2.59 (rhodopsin and 
adenosine receptors), which induces a helix kink in the first case or a helix bulge in the latter, is 
crucial for the ligand binding, but does not play a significant role in the receptor activation. As in 
most of GPCRs cysteine residues are highly conserved in the Rhodopsin family and form disulphide 
bridges stabilizing the receptor structure. The most important cysteine pair is Cys3.25 connected with 
Cys in EC2. Glu3.28, which is present only in the Rhodopsin PDB structure, serves as a counterion 
with the protonated Schiff base in 11-cis-retinal and possibly stabilizes an inactive state of opsin 
[360]. Asp3.32 with Trp7.40 and Tyr7.43 (instead of Lys7.43, more frequent in the Rhodopsin family 
– see Table1) are a unique fingerprint only for biogenic and trace amine receptors (a G2 group) not 
shared by any other Rhodopsin-like GPCR. Asp3.32 with Tyr7.43 were proved to form the TM3 – 
TM7 ionic lock stabilizing the unbound, inactive state of the receptor [361]. Asp3.32 is believed to 
serve as a counterion for the amine groups of native ligands [362]. A residue in the 3.36 position is 
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site-directed mutagenesis, that this residue interacts with Trp6.48 and stabilizes the inactive state not 
only in the β2-adrenergic receptor (Val3.36, van der Waals interactions) [266] but also in serotonin 
receptors (Ser/Cys/Thr3.36, hydrogen-bonding)  [361],  the opsin subclass (Gly3.36)  [363]  and 
cannabinoid receptors (Phe3.36 aromatic stacking with Trp6.48 – a rotamer toggle switch) [294,364]. 
Glu/Gln3.37 is a key residue in agonist binding to LH and TSH receptors [365]. A well-conserved 
Leu3.40 residue which is close to Pro5.50 before activation and becomes distant after, plays a key 
role in the TM3 – TM5 movement [307]. 
A well-conserved Trp4.50 is a cholesterol binding-site which is visible in the structure of human 
β2-adrenergic receptor [339]. Phe5.47 stacks against Phe6.52 and possibly interacts with agonists 
[366] but still little is known about its function. Phe6.44 together with Phe6.52, Leu3.40 and Leu5.51 
is   forming   a   hydrophobic   and   aromatic   cluster   around  Trp6.48  involved   in   conformational 
rearrangements of TM5 [307,361]. Pro6.50, like Pro7.50, produces a helix kink around which TM6 
performs movements during activation. Tyr7.53 in the nPxxy motif interacts with Phe7.60 in helix 
H8 and forms a molecular switch between active and inactive conformation. 
10.2.7Role of Extracellular Loops in Ligand Binding and Switching 
The extracellular loops also have an influence, although sometimes transiently, on ligand binding and 
could participate in some types of molecular switches. The recent crystal structures of GPCRs 
revealed that the part of the receptor extending from the orthosteric ligand-binding site in the 
transmembrane domain to the cytoplasmic side is highly structurally conserved. In contrast, the 
extracellular surface of GPCRs is substantially diverse and, therefore, could be a target of highly 
selective drugs. However, still little is known about the coupling of the extracellular surface to the 
ligand-binding   compartment.   Bokoch   et   al.  [367]  used   NMR   spectroscopy   to   investigate 
ligand-specific conformational changes around a salt bridge linking extracellular loops EC2 and EC3 
(Asp192-Lys305) in β2AR. It was demonstrated that small-molecule hydrophilic drugs that bind 
within the transmembrane core and exhibit different efficacies towards G-protein activation (agonist 
– formoterol, neutral antagonist – alprenolol or unliganded receptor, and inverse agonist - carazolol) 
also stabilize distinct conformations of the extracellular surface. Such conformational coupling 
supports the possibility of an efficient allosteric action of specific drugs targeting this diverse surface 
with high subtype selectivity. Although the specific salt bridge used to monitor these conformations 
may not be present in other GPCRs it is likely that ligand-induced changes at the extracellular 
surface are relevant for other family A GPCRs. 
In adrenergic receptors only one residue in the EC2 loop can interact with ligands in the binding site: 
this is Phe201 in β1AR and an equivalent residue, Phe193, in β2AR. A disulphide bridge located two 
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that such interactions with the ligand will be preserved. In the recent crystal structures of these 
receptors with agonists the ligands do not appear to interact with this residue, however, if we 
examine the possible entrance way of the ligand into the receptor binding site we can notice that the 
ligand may interact transiently with Phe193/201. Therefore, it is possible that Phe 193/201, together 
with other residues from the extracellular loops, could participate in the action of molecular switches. 
The binding sites of other receptors with diffusible ligands are more spacious so the binding of a 
ligand is more straightforward and could be done without a transient binding to the EC2 loop. 
However, even in those receptors the ligands can interact with the EC2 loop. An interesting case is a 
recent crystal structure of a chemokine receptor CXCR4 with a peptide ligand CVX15 consisting of 
16 amino acids [316]. Binding of that ligand involves a large number of residues from the EC2 loop 
and also from the N-terminus. However, because of the lack of structures of CXCR4 with agonists, 
there is no direct data on the involvement of extracellular surface residues in molecular switching. 
Even in the case of rhodopsin the EC2 loop, which tightly covers the retinal binding site, is moving 
upon retinal isomerization and this movement, from the retinal-binding site, is coupled to the rotation 
of TM5 and to the inward motion of the TM6-EC3-TM7 segment [368]. 
The hydrophobic ligands, like retinal in the case of rhodopsin, are probably entering the receptor 
binding site directly from the membrane. There are two openings of the retinal-binding site in the 
crystal structure of opsin (ligand-free rhodopsin) [369] one between the extracellular ends of TM5 
and TM6, and another between TM1 and TM7. It was suggested that the opening between TM5 and 
TM6 could be selective for the uptake of 11-cis-retinal. The smaller opening between TM1 and TM7 
could be a site for the release of all-trans-retinal. A putative external binding site for retinal is 
possibly located in the kink region between TM7 and H8 closely to palmitoyl chains [370]. The 
mechanism of retinal movement is potentially significant for vision in the regeneration pathway, the 
disorders of which have been associated with different forms of blindness. In the recent structure of 
CXCR4 there is also a gap between EC ends of helices TM5 and TM6 which is filled up by lipids. 
The hydrophobic ligands of this receptor could potentially enter the receptor binding site through this 
hole. However, the open question remains which residues could be responsible for sensing the ligand 
type and which ones participate in switching mechanisms. 
10.3 Activation Schemes 
The recent period proved to be very fruitful in GPCR research – many new structures were 
crystallized and, what is even more important, first time with agonists (β1- and β2-adrenergic and 
adenosine receptors and recently also rhodopsin with all-trans retinal). This greatly facilitated 
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i.e., the long awaited crystal structure of the complex of GPCR with the whole G protein is available 
and one can expect that similar structures of other GPCRs will be also available. Possibly, a new and 
exciting mystery to be solved is the allosteric influence of dimers on the process of activation. In a 
very interesting review compiled by Deupi and Kobilka about the energy landscapes of GPCR 
activation it is shown how structural changes of GPCRs during their activation can be visualized on 
energy landscapes. Because of high structural similarity of all crystallized GPCRs, the activation 
scheme is probably similar for all GPCRs so it is suggested that the receptors are passing through the 
same stages during the activations process. This similarity is much higher in the cytoplasmic side of 
the transmembrane bundle. This region contains residues involved in receptor activation and binding 
of a G protein. Similar conformational changes underlying activation of GPCRs are also deduced 
from numerous biochemical and biophysical experiments. Probably also a sequence of events is 
nearly identical and involves the following steps: first, small changes in TM5 and TM7, then a large 
change in TM6, and then neutralization of Asp3.49 in the (d/e)Ry motif (Fig 10.4). Two-dimensional 
energy landscapes seem to be more advantageous over one-dimensional energy plots but currently 
too   little   is   known   for   precise   construction   of   such   plots.   Possibly   new   crystal   structures 
supplemented by long molecular dynamics simulations will help in designing so useful but also 
elegant and eye-catching charts. 2D or even 3D energy plots make possible dissection of the reaction 
pathway into discrete non-sequential conformational changes providing alternate routes of activation 
through the energy landscape. In this way some events may be skipped for some ligands and a full or 
partial activation state can still be achieved. 
10.3.1Two Types of Activation Paths 
The substantial amount of data obtained from rhodopsin and also adrenergic receptor activation can 
serve as a framework to reveal activation of other GPCRs. There are some variations, though. It is 
suggested [42] that the β2AR is not trapped in a fully inactive conformation in the absence of agonist 
but its internal flexibility allows the receptor to explore different conformations. This may suggest a 
shallow energy landscape with several conformational states separated by relatively low energy 
barriers. On the contrary, for rhodopsin (and similarly activated GPCRs) it is supposed that binding 
of agonist is invoking an induced fit of the receptor structure. Therefore, agonists have to bind to the 
receptor with high affinity and this high binding energy is used to initiate conformational changes 
(“jump”) over the highest initial barrier of energy. Retinal isomerization in rhodopsin provides such 
high energy. In case of other receptors (although being classified in the Rhodopsin-like family 
because of their sequence) the ligands have relatively low affinity and rapid dissociation rates; these 
features may indicate a conformational selection procedure of activation. After ligand binding the 
sequence of events during receptor activation is regarded as being similar in all these receptors. Any 
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energy minima depths. The well-known example of differences in the activation scheme is the 
existence of an open ionic lock in crystal structures of β1AR and β2AR adrenergic receptors with 
antagonists and inverse agonists bound that may suggest a very low energy barrier for opening of this 
switch. The late stages of β2AR activation, which are supposed to be analogous to achieving the 
Meta-II stage in rhodopsin activation, involve a similar set of conformational changes, i.e. 
rearrangement of TM6 and neutralization of Asp3.49 in the (d/e)Ry motif of TM3. According to the 
above two schemes of activation, the partial agonism can be also explained in two ways. For those 
GPCRs from which partial agonists dissociate faster than full agonists, not all binding events last 
long enough to promote activation of the G protein. Another possibility is that the partial agonists 
stabilize different intermediate conformations that lead to alternate activation pathways and to 
non-optimal G protein activation. Particular steps can be achieved either by induced fit upon binding 
of a ligand or by conformational selection but the achieved equilibrium states would be completely 
indistinguishable. It is suggested that the induced fit mechanism is present in rhodopsin and 
angiotensin AT1 receptor whereas β2AR may function by selecting specific receptor substates by the 
ligand.
10.4 Theoretical Studies on the Action of Molecular Switches
10.4.1Single TM Studies
One of the first computational studies aimed at GPCRs switches was done in 2001 by Ballesteros et 
al. [344] who simulated the disruption of the TM3-TM6 ionic lock. Simulations presented in that 
work concerned only TM6 and short MD runs to simulate the bending of TM6 at the Pro6.50 
position were performed. From those computational studies combined with experimental mutations 
of the Glu6.30 residue it was concluded that a conformational rearrangement of TM6 is highly 
correlated with the extent of constitutive activity of different mutants. A similar approach was used 
later to study the conformational switch in the 5-HT2C  receptor  [371]. Again, a combined 
computational-experimental study showed that a conserved Tyr7.53 residue is interacting with the 
conserved Tyr7.60 (in helix 8) contributing to the switching of the receptor among multiple active 
and inactive conformations. Although the ‘ionic lock’ is still regarded as an important switch it can 
be open in crystal structures of GPCRs even with antagonists and inverse agonists. Currently, only in 
the inactive and partially active rhodopsin structure (batho and lumi intermediates) that switch is 
closed [372]. 
A similar approach was presented in the 2002 paper by Shi et al. [373]. In this work Monte Carlo 
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human β2AR model of TM6. The results show a high correlation between the conformation of side 
chains of these residues and the helix kink at the Pro6.50 position, which was consistent with the 
experimental data for rhodopsin [374]. While it was clear that simulations on isolated helices could 
not predict the global interaction and changes in GPCRs, the results showed the usefulness of 
computational methods for studying ionic locks.
The same ionic lock has been studied in the 5-HT2A system in the 2002 paper by Visiers et al. [345]. 
Here,  I   focus  on   the   electrostatic   properties   of   the   conserved   residues.   By   solving   the 
Poisson-Boltzman equation to obtain electrostatic potentials of the different conformers of important 
residues on the TM3-TM6 model, it was found that Glu3.49 may undergo protonation upon 
activation of the GPCR. The activation of the protein has been also explained as a change in the kink 
at Pro6.50 which allows the ends of TM3 and TM6 to move away from each other. Based on the 
computational   results   it   was   suggested   that   selected,   single-point   mutations   (Glu6.30Asn, 
Glu6.30Gln, Glu6.30Leu) would disrupt the electrostatic interactions of the (d/e)Ry motif with this 
residue. This prediction was confirmed later by the results of site directed mutagenesis, where it was 
shown that a neutral residue at the 6.30 position increases the activity of 5-HT2A in the absence of 
the ligand, similarly to the human β2AR case.
10.4.2Studies on a Complete GPCR Model
Investigations of the Ionic Lock Switch 
The most prominent method to study the dynamics of GPCRs is nowadays Molecular Dynamics 
(MD) of the complete GPCR model. One of the first MD simulations focusing on TM3-TM6 ionic 
locks was performed in 2002 by Greasley et al. [375], who simulated the β1AR model based on the 
rhodopsin structure of Palczewski. The methodology used the united atom model and included a 
large number of short (150 ps) MD runs of the protein only (without environment), using NOE 
constraints to preserve the α-helix structure of TMs. The short time of simulations was due to the 
limited computational resources available at that time. The results showed a very high stability of the 
Arg3.50-Glu6.30 salt bridge. Combined with experimental mutational data (Glu6.30 mutations that 
weakened this ionic lock constitutively activated the receptor) the results showed that the transition 
from the inactive to active state of α1bAR involves a rearrangement of helices TM3 and TM6. The 
structure of α1bAR is still not available but predicted movements were confirmed by crystal 
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In the same year Rohrig  et al.  presented their work in which a full-atom model of the bovine 
rhodopsin has been immersed in a layer of a n-octane mimicking lipid bilayer [376]. The goal of 
these simulations was to show the effect of retinal cis-to-trans isomerization on the dynamics of the 
protein. Indeed, it was found that retinal isomerization serves as a trigger for propagation of the 
signal to the surrounding helices. Despite the limited simulation time authors were able to see some 
rearrangements in TM6 and to a lesser extent also in TM4 and TM5. They have also noticed cleavage 
of selected hydrogen bonds in these helices, however the ionic lock remained stable over the course 
of simulations. In 2003 a team led by Thomas B. Woolf applied MD simulations to the full atom 
bovine rhodopsin model including DOPC lipid membrane and surrounding by water molecules 
[377]. Their 40 ns simulation (a huge amount in those days) became a basis for a number of similar 
MD simulations on GPCRs in the following years. Similarly to the Rohrig studies this work 
concentrated on the rhodopsin vicinity and the changes in residues interacting directly with the 
rhodopsin ligand. The authors noted a strong interaction between residues forming the ionic lock 
(Arg3.50-Glu6.30) throughout the whole simulation time ( Fig 10.3G).
A similar approach as in the Crozier work has been applied to a large number of GPCR MD studies, 
although the advances in computational powers allowed to lengthen the simulation scale to tens and 
hundreds of nanoseconds. One of the interesting works showing the stability of various locks was the 
MD investigation of the opioid receptors models. In the μ-OPR opioid receptor there is no glutamic 
acid residue in the 6.30 position, but the TM3-TM6 lock is still present in the modeling studies due 
to the hydrogen bond between Arg3.50 and Thr6.34 [349,378]. In the most recent simulations this 
lock remains unbroken even in the presence of selected antagonists or agonists [350,351], most 
possibly because of a rather short length of simulations (nanosecond time scale) compared to the 
time needed for activation of the receptor (milliseconds). Binding of antagonists has also no effect on 
the   Trp6.48   rotamer   switch   which   remains   in   the   initial,   rhodopsin-like   vertical   position. 
Interestingly, μ-OPR agonists toggle the Trp6.48 position to a horizontal one which, during 
simulations, forces the change in positions of aromatic residues around the highly conserved Pro6.50. 
It is also worth noticing that the mutation of Leu6.30Glu in the μ-OPR system inactivates this 
receptor [379]. Simple calculations of the electrostatic interactions for two helices (TM3 and TM6) 
have shown that the Leu6.30Glu mutation enhances the hydrogen bond network around the mutated 
residue and stabilizes the inactive state.
Breaking of the 3-7 Lock Switch 
During the MD simulations of μ-OPR it was noticed that another switch, the 3-7 lock, a link between 
TM3 and TM7 (a hydrogen bond Asp3.32-Tyr7.43), remains stable for the apoprotein simulations 
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break [349]. For one of the agonists it was also shown that rotation of Trp6.48 was linked to the 
cleavage of the Asp3.32-Tyr7.43 hydrogen bond and occurred within 1 ns after its breaking. Later, 
MD studies have shown that a similar cascade of events is likely to occur also upon agonist binding 
and activation of δ-OPR and κ-OPR  [350].  Recently, a structurally similar κ-OPR agonist and 
antagonist pair, guanidinonaltrindole (GNTI) compounds, were investigated by molecular dynamics 
simulations [351]. 5′-GNTI is an antagonist while 6′-GNTI is an agonist. Ligands were relaxed in the 
receptor binding site by the simulated annealing routine. During a series of MD simulations of the 
ligand-receptor complexes in DPPC membrane, the 3-7 lock was broken when the agonist was 
bound, but remained unbroken upon binding of the antagonist. The hypothesis of 3-7 lock breaking 
on the agonist binding still awaits confirmation, since no experimental structure of any opioid 
receptor is available at this time.
Beyond Classical MD Techniques 
In 2009 Provasi et al. studied the dynamics of the δ-OPR system using a metadynamics approach 
[380]. This approach allows for an efficient exploration of multidimensional free energy surfaces of 
GPCRs (and other biological systems) by adding a history-dependent bias to the interaction potential 
of the system. The required microsecond-scale well-tempered metadynamics has been achieved 
using the united-atom model for lipids (DPPC and cholesterol molecules) and the full-atom model 
for protein and ligand. It allowed the authors to suggest a preferential entry pathway of the NLX 
antagonist, starting from the δ-OPR surface and ending in the proper binding pocket of the GPCR, 
and to evaluate the bonding constants for the ligand. The observed binding pocket was extremely 
close to the previously predicted one and the starting structure for their system had all the known 
locks including the Arg3.50-Thr6.34 of TM3-TM6 lock (or ‘3-6 lock’ instead of ‘ionic lock’ since no 
salt bridge can be formed in this case) and the Asp3.32-Tyr7.43 of 3-7 lock. 
It is also worth mentioning that other computational techniques have been used to model the 
activation of rhodopsin and they gave similar results. In 2006 Niv et al. used an Elastic Network 
Model to study the inactive form of rhodopsin [381]. In this model, a harmonic potential with a 
single force constant accounts for pairwise interactions between all Cα atoms within a certain cutoff 
distance. The analysis of the structural relation of the inactive normal modes to the transition vectors 
towards the active conformations has been discussed. It has been found that the active form of 
rhodopsin should be characterized by structural changes in TM5-6-7, while helices TM1-2-3-4 were 
shown to be the most stable ones which were confirmed later by crystal structures of Meta-II 
rhodopsin. Niv et al. also predicted the rotamer toggle switching of Trp6.48 and they claimed that it 
was in agreement with the early spectroscopic data [382]. However, this was not confirmed by later 
crystal structures of opsin and also rhodopsin with all-trans-retinal bound [353] and unbound but still Activation mechanism of GPCRs 155
present in the binding site  [354]. The spectroscopic properties of Trp6.48 really change during 
activation of rhodopsin but it is a result of large movement of cytoplasmic part of TM6 and smaller 
movements of adjacent helices so a local environment of Trp6.48 is altered even if a rotamer of 
Trp6.48 itself does not change. 
Much more detailed approach to the study of ionic-lock induced activation of GPCRs has been 
proposed in the work of Balamaran et al. [383]. In this work the all-atom force field has been used to 
evaluate the relative stability of various point-mutations in β1-adrenergic receptor. The results 
showed good correlation with the experimental data for over 90 single and multiple point mutants of 
this protein. It was found that Tyr5.58Ala and Val5.61Ala mutations stabilize the Arg3.50–Glu6.30 
ionic lock, while Phe7.48Met mutation alters the interaction between the conserved NPxxY motif of 
TM7 and TM8. 
Consequences of the Ionic Lock Instability and TM Movements 
The first experimental structure of GPCR, opsin, provided structural data which confirmed the 
importance of molecular switches and ionic locks [369]. While some of the structures of the early 
photoproducts of rhodopsin showed only an increased Arg3.50-Glu6.30 distance [372], in the opsin 
structure these residues are no longer interacting with each other. Arg3.50 is released from the 
Glu6.30 and Glu3.49 interactions and engages with Tyr5.58 on TM5, an interaction that was not 
suggested before. At the same time a new interaction between Lys231 and Glu247 is formed to 
stabilize TM5-TM6 interactions. Also, the Tyr7.53 of the nPxxy motif (TM7) aromatic stacking 
interaction with Phe7.60 (H8) is broken due to a different orientation of the helices. On the other 
hand the Trp6.48 toggle switch is in exactly the same position as in the inactive rhodopsin, even 
though it was indicated by NMR studies that it must change its position and interaction partners 
during activation [384]. 
A very similar structure of the active opsin, albeit with a different Trp6.48 rotamer, has been 
predicted computationally by Bhattachary et al. at the same time [385]. The authors started from the 
inactive (dark) state and have predicted TM conformational changes that are induced by the 
isomerization of 11-cis retinal to all-trans retinal with good accuracy. In another study Hornak et al. 
used nanosecond MD guided by NMR distance restraints to simulate the activation of rhodopsin 
[386]. Results of this work were also in agreement with experimental data and showed the coupling 
of retinal isomerization to the motions of helices and activation of the receptor which proceeds via a 
series of multiple switches.
To solve this inconsistency in behavior of Trp6.48, a MD simulation of β2AR and bovine rhodopsin 
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simulation of inactive rhodopsin with 11-cis-retinal present, showed no change in the Trp6.48 
conformation. The removal of retinal, however, allowed this residue to change its rotameric state. 
After additional 9 ns of simulation Trp6.48 established a moderately strong and not very stable 
interaction with Phe5.47 on TM5. In the β2AR case removal of its ligand (carazolol) did not result in 
large conformational changes of Trp6.48 and no additional interactions have been observed. 
Additional data obtained from metal ion site engineering confirm the close proximity of these two 
residue. Mutational data from ghrelin receptors experiments show, on the other hand, that both of 
these residues are important for constitutive activity and agonist-induced efficacy. Authors suggest 
that the ionic lock may be one of the several molecular switches that form an allosteric interface 
between the TMs performing global toggle switch movements that mediate the intramolecular signal 
which leads to G protein activation. However, since ~30% of GPCRs lack the Trp6.48 residue, it may 
not be a part of the general activation pathways for 7TM receptors.
The problem of the lack of interaction between Arg3.50 and Glu6.30 in the β2AR crystal structure, 
despite their presence in the sequence, has been addressed in a 2009 paper by Dror et al. [388]. For 
this system there was also a variety of biochemical evidence suggesting that an ionic lock between 
those residues is formed in the inactive state [375]. It was suggested that the broken lock may be a 
consequence of the techniques used to stabilize β2AR for crystallization or of the binding of 
carazolol or timolol, which might reflect the ability of some partial agonists to induce signaling 
through disruption of this interaction. An all-atom simulation of β2AR over 10 microseconds showed 
that an ionic lock forms reproducibly both in apo β2AR and in the carazolol-bound system. 
Interestingly, the ionic lock had a tendency to break in simulation every few hundred nanoseconds 
and the conformation with this lock broken remained stable for tens of nanoseconds. In conclusion 
the authors suggested that the inactive β2AR alternates between several major conformations with 
the ionic lock present and a few minor conformations without the ionic lock. Their long, 
microsecond simulation time allowed to describe the inactive state of this GPCR as an ensemble of 
states.
Almost at the same time another MD work on β2AR and β1AR appeared [389]. 500 ns MD runs for 
carazolol-bound β2AR model and cyanopindol-bound β1AR model showed the formation of the ionic 
lock, which remained stable during the stimulation runs, in both systems. In this work no breaking of 
the ionic lock has been observed; however, the timescale of the simulations might have been too 
short for such event to occur. Interestingly, water-mediated interactions Trp6.48-Asp2.50 and 
Asp2.50-Asn7.49-Tyr7.53 have been observed, some of which have been suggested to be important 
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during the simulation runs. The results of this study were different than the earlier theoretical 
investigation of the impact of ligand binding on the conformational state of the protein. Bhattachary 
et al. investigated the perturbations in the helical rotational orientations induced by ligand binding in 
the TM region of the β2-adrenergic receptor [390]. They found that norepinephrine (full agonist) and 
dopamine (a weak partial agonist) break the Arg3.50–Glu6.30 ionic lock and engage the Trp6.48 
rotamer toggle switch, while salbutamol (a partial agonist) only breaks the ionic lock and catechol (a 
very weak agonist) only switches the rotamer toggle. 
A longer, 1.02 microsecond simulation of β2AR presented by Romo et al. allowed the researchers to 
show the interconversion between ionic lock substates [391]. Similarly to previous results authors 
showed that the Arg3.50-Glu6.30 ionic lock is able to break and reform in the wild-type β2AR 
simulations. The lock-breaking event is followed by the reorganization of the cytoplasmic end of 
TM6 through a clockwise rotation of the helix and movement of the end of TM5 away from TM6. 
These events were in agreement with the predicted activation models of this system. In 2011 
Moukhametzianov et al. followed the work of Dror and showed that also β1AR may have at least two 
distinct conformations in the inactive state [392]. Their new X-ray structures of this receptor show 
that TM6 and IC3 loop (connecting TM5 and TM6) may have a bent form, stabilized by previously 
unseen interactions Met281-Leu282 and His286-Gln237. They also noticed that the new TM6 
conformation positions Arg3.50 and Glu6.30 only 3.8 Å apart, which is a distance significantly 
longer than in the rhodopsin case (with the ionic lock), but also much shorter than in the other 
conformation of TM6 (where the distance is 6.2 Å).
Experimental structures of active states of rhodopsin and β2AR have shown that MD predictions of 
the behavior of ionic locks during activation were generally accurate. The constant development of 
computational methods and the more and more powerful computers allow us now to reach 
microsecond simulations [393,394] and obtain information about the general energy landscapes of 
GPCRs. Such theoretical energy landscapes and activation pathways, even though simplified to 
include only one or a few coordinates, give a very good means to look inside the GPCR activation 
mechanisms. The latest experimental results, e.g. highlighting the role of the highly-conserved 
Tyr5.58 in the stabilization of the active state of rhodopsin [395] are perfect examples of data and 
events that may be simulated by computational methods to gain more understanding of their 
mechanism of activation/inactivation and molecular processes involved in them.
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Development of selective drugs for GPCRs is challenging because 
• there is a high degree of homology among many closely related receptor subtypes that can 
regulate diverse physiological functions; 
• a single receptor may couple to more than one G protein or even signal through G protein 
independent pathways; 
• a receptor can be regulated by multiple allosteric ligands (small molecules but also proteins 
including GPCRs – what implicate allosteric influence by dimerization or oligomerization 
either homomers or heteromers; 
• predominant signaling behavior of GPCRs may differ in different cells or organs. 
Despite the progress which led to insights into the three-dimensional structures of GPCRs in both 
active and inactive states, the process of developing a drug for a particular GPCR target has become 
more complex, time-consuming and expensive  [396].  Detailed characterization of agonist and 
antagonist binding behavior provided insight into the allosteric effect of G proteins on receptor 
structure and agonist binding affinity. The efficacy of ligands for activating the arrestin pathways can 
differ from those that activate G proteins. Some ligands possess a complex pharmacological behavior 
acting as agonists and simultaneously antagonists or inverse agonists depending on the pathways 
they activate and inactivate. Carvedilol is an inverse agonist for β2AR activation of Gs but a partial 
agonist for β2AR activation of arrestin [397]. The complexity of GPCR signaling pathways and 
ligand efficacy profiles complicate the process of drug discovery. Moreover, specific receptors might 
exhibit cell type-specific signaling as a consequence of the cell-specific complement of different 
proteins: signaling, regulatory and scaffolding. 
As can be seen from crystal structures the structural diversity of GPCRs is much greater for amino 
acids lining the pathway into the ligand binding pocket. Although these amino acids do not make 
direct contact with a bound ligand the size of carazolol, they could contribute to initial transient 
interactions between the ligand and receptor that affect the ligand association rate. These residues 
might also play a role in binding larger ligands that extend into the vestibule of the binding pocket, 
such as the long-acting β2AR agonist, salmeterol, that is used in the treatment of asthma [396]. The 
recent crystal structure of the chemokine CXCR4 receptor with an antagonist in the form of a peptide 
ligand, which extends from the receptor binding side toward the extracellular surface, show such 
kind of binding for the first time for GPCRs (PDB id 3OE0) [316]. Although many aspects of GPCR 
function can be explained by a simple two-state model, evidence from biophysical and functional 
studies support a multistate model in which ligands stabilize a specific conformational state or set of 
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10.6 Conclusions 
Investigations of molecular switches in the superfamily of GPCRs is extremely challenging but may 
be truly rewarding because the detailed mechanism (or mechanisms) of activation of these receptors 
could help to design highly selective drugs acting not even on a single receptor subtype but on a 
single pharmacological receptor subprofile. Because of the intrinsic instability of GPCRs resulting in 
their multiple functionality, the investigations must proceed via elucidation of multiple structures 
with inverse agonists, antagonists and agonists, possibly also with trimeric G proteins and arrestins. 
Dimerization is a separate large issue currently unresolved but possibly the allosteric action of 
GPCRs via dimerization is the most common mechanism influencing receptor functioning. GPCRs 
are the biggest and one of the most mysterious single group of molecular targets for drugs, therefore, 
one can be sure that studies on their structures and mechanisms will be continued with an increasing 
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Fig 10.3 The action of molecular switches in GPCRs. Four switches are shown: transmission switch, 
tyrosine toggle switch, ionic lock, and 3-7 lock. They are shown based on the crystal structures of 
rhodopsin, β2AR and A2AR with agonists and antagonists/inverse agonists. Their id numbers from 
Protein Data Bank are provided – first number for inactive and second for active receptor. 
Additionally, the structural formulas of agonists from the crystal structures of active receptors are 
shown. The general scheme of GPCR structure is shown based on the crystal structure of chemokine 
receptor CXCR4 with a small ligand. Blue arrows in circular panels indicate motions of receptor 
structure during action of particular switch. Inactive receptor structure is shown in gray while active 
one in color. The residues are numbered according to the Ballesteros-Weinstein numbering scheme 
[265]Activation mechanism of GPCRs 161
Fig  10.4  Rearrangement of hydrogen bond network in rhodopsin during its activation. A. The 
crystal structure of inactive rhodopsin (Protein Data Bank id 1GZM). B. The crystal structure of 
constitutively active Glu3.28Gln mutant of rhodopsin with all-trans retinal unbound from Lys7.43 
but still present in the binding site (Protein Data Bank id 2X72). Both structures include water 
molecules (shown as red spheres) which participate in hydrogen bond network. In the inactive 
rhodopsin there is a hydrophobic area consisted of five residues located in helices TM2, TM3 and 
TM6 (in yellow) which form a hydrophobic barrier (area in green) separating residues in CwxP 
(cyan) and nPxxy (blue) motifs from those of (d/e)Ry motif (orange). In the activated rhodopsin a 
rotation of TM6 disrupts the water mediated link between TM6 and TM7 and reorganizes the 
hydrogen bond network. Two tyrosine residues Tyr5.58 and Tyr7.53 reposition and fill the 
uncovered gap between TM3 and TM6 to extend hydrogen bond network toward (d/e)Ry motif and a 
fragment of G protein GαCT (pink). Figure is based on  [354]. The residues are numbered 
according to the Ballesteros-Weinstein numbering scheme [265].Activation mechanism of GPCRs 162
10.7 Modeling of ligand binding to G protein coupled receptors: cannabinoid 
CB1, CB2 and adrenergic β2AR 
Cannabinoid and adrenergic receptors belong to the class A (similar to rhodopsin) GPCRs. Docking 
of agonists and antagonists to CB1 and CB2 cannabinoid receptors revealed the importance of a 
centrally located rotamer toggle switch, and its possible role in the mechanism of agonist/antagonist 
recognition. The switch is composed of two residues, F3.36 and W6.48, located on opposite 
transmembrane helices TM3 and TM6 in the central part of the membranous domain of cannabinoid 
receptors. The CB1 and CB2 receptor models were constructed based on the adenosine A2A receptor 
template. The two best scored conformations of each receptor were used for the docking procedure. 
In all poses (ligand-receptor conformations) characterized by the lowest ligand-receptor 
intermolecular energy and free energy of binding the ligand type matched the state of the rotamer 
toggle switch: antagonists maintained an inactive state of the switch, whereas agonists changed it. In 
case of agonists of β2AR, the (R,R) and (S,S) stereoisomers of fenoterol, the molecular dynamics 
simulations provided evidence of different binding modes while preserving the same average 
position of ligands in the binding site. The (S,S) isomer was much more labile in the binding site and 
only one stable hydrogen bond was created. Such dynamical binding modes may also be valid for 
ligands of cannabinoid receptors because of the hydrophobic nature of their ligand-receptor 
interactions. However, only very long molecular dynamics simulations could verify the validity of 
such binding modes and how they affect the process of activation [294]. 
Fig 10.5  The rotamer toggle switch in cannabinoid receptors is comprised of two residues, F3.36 
and W6.48, which are located on transmembrane helices TM3 and TM6. Docking of agonists and 
antagonists to CB1  and CB2  cannabinoid receptors revealed the importance of this centrally 
located switch and its possible participation in the mechanism of agonist/antagonist sensing. The 
best scored poses (ligand-receptor conformations) were obtained for the ligands matching the 
switch state: antagonists maintained the state of the rotamer toggle switch, whereas agonists 
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10.7.1Introduction
The recent crystal structures of class A (similar to rhodopsin) G protein coupled receptors (GPCRs), 
namely β1- and β2-adrenergic receptors (β1AR [298] and β2AR [266,399,400]) and adenosine receptor 
(A2AR [401] ) showed nearly identical structures of transmembrane domain but also differences in 
states of molecular switches as compared to rhodopsin [297] which was the first crystallized GPCR. 
Based on experimental data it was proposed that agonist binding and the receptor activation occur 
through a series of conformational intermediates. Transition between these intermediate states 
involves the disruption, creation or reorganization of intramolecular interactions that stabilize the 
basal states of a receptor. Such changes are made by the action of molecular switches (also called 
microswitches). The major switches proposed so far for different GPCRs, reflecting shared activation 
mechanisms, include the “rotamer toggle switch” involving the CWxPx(F/H) sequence on TM6 
[373], the switch based on the NPxxY(x)(5,6)F sequence linking TM7 and H8 [356], and the “ionic 
lock” linking transmembrane helices TM3 and TM6 and employing the (E/D)RY motif on TM3. 
There are also switches not connected to any particular sequence motifs like the “3-7 lock” involving 
the interaction connecting TM3 and TM7 and present only in selected receptor types: this switch 
involves Schiff base-counterion interaction in rhodopsin [71,402] and it was proposed to operate in 
opioid receptors [349–351]. 
In the rhodopsin structure which is completely inactive in the basal state i.e. when retinal is in 11-cis 
conformation, all switches are assumed to be in their off positions. However, recent crystal structures 
of GPCRs, assumed to be in inactive state because they were complexes with antagonists and inverse 
agonists, showed remarkable similarities of states of switches that are different from those of inactive 
rhodopsin: ionic lock is in open state (broken connection between helices TM3 and TM6), and a 
connection between TM7 and H8 is broken because of change of rotamer of Y7.53 (part of NPxxY 
motif on TM7). On the other side, the “rotamer toggle switch” involving W6.48 residue remains in 
its off state (identical as in inactive rhodopsin structure) in all receptor crystal structures even in 
Meta-II rhodopsin structure assumed to be in activated form [369,403]. Therefore, based on existing 
crystal structures, different states of switches may not describe on and off positions but different 
states adopted during activation processes because these receptors may be partially activated in their 
basal state. In our earlier papers we investigated early activation steps occurring simultaneously to 
ligand binding for opioid receptors MOR (mu), DOR (delta) and KOR (kappa). The first switch that 
was   broken   by   agonist   binding   was   “3-7   lock”,   a   hydrogen   bond  D3.32-Y7.43  linking 
transmembrane helices TM3 and TM7. It was the first activation event observed. We also detected 
action of the second switch: rotamer toggle switch involving simultaneous change of side chain 
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of opioid receptors the other residue in this extended switch was H6.52. This residue also 
participated in agonist-antagonist sensor based on propensity for creating a hydrogen bond with 
Y3.33 for antagonists and H6.52 for agonists. All studied ligands, being analogs of morphine – with 
common tyramine structural scaffold, created a salt bridge with D3.32 with their protonated nitrogen 
atom of tyramine group. This sensor was studied for MOR [349] and later for DOR  and KOR [350]. 
The proposed mechanism of its action was later confirmed via molecular dynamics simulations of 
tightly related agonist-antagonist pair of KOR ligands: 5’- and 6’-GNTI [351].  
Ligands of opioid receptor are similar to ligands of β1- and β2-adrenergic receptors because they 
interact in the binding site of the receptor in protonated form. This is not the case for ligands of 
cannabinoid receptors because of their hydrophobic properties. Following our earlier research on 
opioid receptors where we proposed agonist-antagonist sensor we investigated early activation states 
in CB1 and CB2 receptors focusing on the centrally located rotamer toggle switch involving residues 
W6.48 and F3.36 located on two different helices. Here we show our latest results on cannabinoid 
receptors CB1 and CB2 regarding binding of ligands and possible activation steps simultaneous to 
ligand binding. Ligands of cannabinoid receptors are mostly hydrophobic what reflects the presence 
of large number of hydrophobic residues in the binding sites of their receptors. Therefore, the 
microswitches may be modified but they are still operational according to the structural mimicry 
rules. A mechanism for differentiation between agonists and antagonists is not clear for ligands of 
cannabinoid   receptors   because   their   structures   are   mostly   highly   flexible   so   finding   the 
agonist-antagonist sensor is more difficult using simulation techniques, therefore we decided to start 
with simple docking method including flexible amino acid residues. This method was used to check 
the possibility whether a W6.48/F3.36 rotamer toggle switch may participate in mechanism of 
agonist/antagonist sensor.  
We also show our results regarding interactions between β2-adrenergic receptor (β2AR) model and 
two   enantiomers   of   fenoterol:   (R,R)-fenoterol   and   (S,S)-fenoterol   investigated   by   molecular 
dynamics (MD) simulations. Fenoterol is a selective β2AR agonist and exists in four stereoisomers 
which significantly differ in β2AR efficacies and selectivities. Racemic mixture of (R,R)- and (S,S)- 
isomers, rac-fenoterol is clinically used for the treatment of asthma. Radioligand binding studies 
evidence that fenoterol stereochemistry greatly influences the binding affinity to the  β2AR  with 
relative order (R,R)>(R,S)>(S,R)>(S,S) and a similar trend was found in functional assays [404]. 
Moreover,  fenoterol stereochemistry also affects the mode of coupling of activated β2AR to G 
proteins studied in experiments with addition of pertussis toxin, a selective blocker of Gi mediated 
signaling. In this experiments the toxin has no effect on the activity of (R,R)-fenoterol what indicates 
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When other stereoisomers of fenoterol were tested in such experiments, the addition of pertussis 
toxin significantly reduced a functional effect what implies that binding of non (R,R)- stereoisomers 
activates β2AR to the form which couple both Gi and Gs protein [405].
10.7.2Results
To investigate influence of ligand binding on amino acid residues in the binding site of CB1 and CB2 
receptors to see a potential action of the rotamer toggle switch we used two best scored by Modeller 
conformations of cannabinoid receptors. These two conformations of the same receptor were similar 
to each other in transmembrane domain but quite different in extracellular loops area especially for 
CB2  receptor   (Fig.  10.7).   Calculated   root   mean   square   distance   (RMSD)  between   the   two 
conformations of CB1 model was 0.258 nm and of CB2 0.265 nm (counting all heavy atoms in the 
receptor structure excluding N- and C-termini). The residues forming the rotamer toggle switch were 
located in the same positions whereas most of other residues from the binding site took different 
conformations.   For   each   pose   of   ligand-receptor   pair   the   free   energy   of   binding   and   the 
ligand-receptor intermolecular energy were calculated. Intermolecular energy (Eint) is defined as a 
sum of four components: energies of van der Waals interactions, electrostatic interactions, hydrogen 
bonds and desolvation of a ligand. An error of Eint estimation is about 2.5 kcal/mol.  ∆G is defined as 
a sum of Eint and the entropy term which is a change of entropy of a ligand and of a set of flexible 
amino acid side chains of a protein. The results obtained for two different conformations of each 
receptor are presented in Table 1. Usually  ∆G and Eint had similar values with the exception of 
anandamide, which flexibility increased  ∆G values. Nevertheless, the highly negative value of Eint in 
case of AEA compared to other ligands preserved a negative value of  ∆G. Such exceptionally low 
value of intermolecular energy of anandamide inside a binding pocket of cannabinoid receptors is 
also associated with its flexibility leading to the highest match with the amino acid from the binding 
site, especially hydrophobic ones. Regardless of which conformation of the receptor was used the 
poses with lowest Eint  and   ∆G were obtained for the ligands matching rotamer switch state 
(involving residues W6.48 and F3.36): antagonists maintained state of the rotamer toggle switch, 
whereas agonists changed it (values of Eint and  ∆G in bold in Table 1). They were selected as having 
the lowest energy from two receptor conformations and from two states of the switch. The deviations 
from the pure gauche+ and trans rotamers of W6.48 and F3.36 for chi1 angle were high, usually 
about ±30º and sometimes even higher up to ±60º which is half the way between pure gauche+ and 
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Fig 10.6 Agonists (a) anandamide (AEA) and (-)-Δ
9-THC) (both unselective for 
CB1 and CB2), and antagonists (b) AM630 (CB1 selective) and NESS-0327 (CB2 
selective) used in the study. (c) (R,R)- and (S,S)-fenoterol - agonists of β2AR. 
For the best pose (characterized with the lowest energies Eint and ΔG) of the selective antagonist 
NESS-0327 in complex with CB1 receptor (Fig.10.6a) we observed the π-π aromatic interactions of 
the ligand with F268 residue. The piperidine ring of the ligand was located close to helices TM2 and 
TM7 while other rings in the area among helices TMs:3-4-5-6. For the selective antagonist of CB2, 
AM-630, we analyzed both the protonated and unprotonated form and got similar results of docking 
but slightly different energies of binding (Table  ). The protonated form tended to bind to 
conformation one of CB2, while the unprotonated form to conformation two (although the energies 
for both conformations were very similar). Interestingly, the charged ligand was classified with 
higher energies than the ligand in unprotonated form for both receptor conformations. The ligand 
was bound to the receptor with the morpholine ring located close to the rotamer toggle switch area 
(Fig. 10.6b). The cation-π interaction was possible after a slight rotation of the phenyl ring (change 
of the χ2 angle by 25º with no change of the χ1 angle). An oxygen atom from the morpholine ring Activation mechanism of GPCRs 167
formed a hydrogen bond with S5.42(193), rather than S4.53(161) and S4.57(165) residues which are 
more distant to the ligand and covered partly by helix TM3. These serine residues in TM4 were 
important for binding of antagonist SR-144528 but not CP-55940 or WIN-55212-2 as pointed out by 
mutagenesis studies described in  [406]. WIN-55212-2 contains a morpholine ring similarly to 
AM-630 and is also CB2 selective. Interestingly, the serine residues, S4.53 and S4.57, are present 
only in CB2  receptor so the other residue should be responsible for selectivity. According to 
mutagenesis studies done in Reggio group [407] such a residue is F5.46(197) and in fact in our model 
this residue is close to morpholine ring of AM-630. The anisole ring was located close to helices 
TM6 and TM7, while the iodobenzene ring close to helices TM3, TM4 and TM5. Among many 
analyzed poses of the antagonist AM-630 at the binding site of the CB2 receptor one conformation 
appeared noteworthy due to a salt bridge formed by a protonated nitrogen atom of the morpholine 
ring of the ligand and the carboxylic group of E5.37 (not shown). Nevertheless, that pose was 
energetically less favorable (as scored by docking procedure). It means that appropriate hydrophobic 
interactions were a predominant feature of the best poses of this antagonist. Activation mechanism of GPCRs 168
Fig 10.7 Two views of the binding site, parallel to the membrane and from the extracellular side, of 
CB1  (a)  and   CB2  (b)  receptors   of   two   the   best   scored   conformations   for   each   receptor 
superimposed. All presented models are based on the A2AR template. Residues forming the rotamer 
toggle switch and some characteristic residues of the binding site are shown.
Binding of nonselective agonists (-)-Δ9-THC and anandamide (AEA) changed the rotamers of the 
W6.48 and F3.36 residues in the rotamer toggle switch in both receptors (Fig.10.9). In the CB1 
receptor an alkyl tail of AEA interacted with F268 (EC2 loop) through σ-π interactions. The polar 
part of AEA was located between helices TMs:3-4-5, near the residues T3.33 and E5.37. The same 
location of the polar part of AEA was observed at the binding site of the CB2 receptor, although the 
polar head of AEA was translated more toward TM4, possibly because TM4 in CB2 contains more 
polar residues (two serine residues S5.53 and S5.57 instead of alanine residues in CB1). Additionally, 
a nitrogen atom in the polar head of AEA formed a hydrogen bond with S5.42. The alkyl tail of the 
ligand was elongated and its end was located in the hydrophobic pocket of CB2 between TM2 and Activation mechanism of GPCRs 169
TM3 so it could interact with phenylalanine residues F2.61, F2.64, F3.25 and the hydrophobic part of 
K3.28 (charged part of this lysine residue projected outward of the receptor). The middle part of the 
tail of AEA interacted with F183 from the EC2 loop, similarly as in the AEA-CB1 complex. Such 
interactions between phenylalanine in EC2 and CB1  agonists was confirmed by mutagenesis in 
[259]. As regarding the other agonist, (-)-∆9-THC, its hydroxyl group formed a hydrogen bond with 
E5.37 in the THC-CB1 complex, while its alkyl tail was located in the hydrophobic area between 
helices TMs:3-6-7 close to the rotamer toggle switch. In the THC-CB2 complex the similar hydrogen 
bond was created between the hydroxyl group of a ligand and the carboxylic group of E5.37. The 
alkyl part of THC was located between helices TMs:3-5-6 of the receptor and also close to the 
switch, while the opposite part of the ligand interacted with F2.64 (σ-π interactions). 
Fig  10.8  Selective antagonists NESS-0327 and AM630 bound to the CB1  (a)  and CB2  (b) 
respectively, in complexes characterized by the lowest energies. Interactions involving   orbitals are   
shown as orange solid lines and hydrogen bonds as green dashed lines. Residues important for the 
binding of the ligand are labeled.
For analyzed β2AR complexes with fenoterol the molecular dynamics simulations revealed different 
binding modes for (RR)- and (SS)-fenoterol isomers. The starting positions of two ligands were very Activation mechanism of GPCRs 170
similar. Two hydroxyl groups of ligand’s 1,3-benzenediol moiety were located in the vicinity of 
S5.42 and S5.46 residues from TM5, whereas ligand’s protonated nitrogen atom was at close 
distance   to   residues   D3.32   from   TM3   and   N7.39   from   TM7.   During   MD   simulation   of 
(R,R)-fenoterol the ligand’s hydroxyl group located at first stereogenic center formed hydrogen 
bonds with side chains of D3.32 and N7.39 residues. The position of D3.32 side chain was also 
stabilized by interaction with Y7.43 residue from TM7 helix. The hydrogen bond between hydroxyl 
group of ligand’s phenolic moiety and D192 residue located in EC2 loop was also well preserved 
during MD simulation. The two hydroxyl groups of ligand’s 1,3-benzenediol moiety were oriented 
toward S5.42 and S5.46 residues from TM5, but the distance was to large to form a direct hydrogen 
bonds. In addition, the N6.55 residue, which is believed to play a crucial role in agonist binding and 
receptor activation [250], did not form any stable interaction with ligand during MD simulation. In 
contrast to (R,R) enantiomer, the (S,S)-fenoterol isomer did not maintained a stable position in the 
receptor binding cavity. Only one well preserved contact during each of 11 MD simulations was 
formed between protonated nitrogen atom of (S,S)-fenoterol and a carboxyl group of D3.32 residue. 
Interaction between N7.39 residue and the ligand was temporarily formed but frequently broken. The 
average distance between the hydroxyl group of the ligand phenolic moiety and the carboxyl group 
of D192 (EC2 loop) residue was too large (> 0.45 nm) to establish a stable hydrogen bond. The 
movement of the ligand in the binding cavity allowed two hydroxyl groups of the molecule 
1,3-benzenediol moiety to move closer toward S5.42 and S5.46 residues from TM5, but no stable 
connections were made. Representative conformations of both (R,R)- and (S,S)-fenoterol isomers 
were extracted from 22 MD simulations based on the lowest RMSD values when compared to 
average position of the ligand observed during 5 ns MD trajectory. Superimposition of all extracted 
structures for each complex is shown in Fig 10.10.Activation mechanism of GPCRs 171
Fig 10.9  Nonselective agonists (-)-Δ
9-THC and AEA bound to the CB1 (a) and CB2 (b) in 
complexes characterized by the lowest energies. Interactions involving π orbitals are shown 
as orange solid lines and hydrogen bonds as green dashed lines. Residues important for the 
binding of the ligand are labeled.
10.7.3Discussion
Docking of agonists and antagonists to cannabinoid receptors revealed that centrally located rotamer 
toggle switch can take part in mechanism of agonist/antagonist differentiation and be the first switch Activation mechanism of GPCRs 172
changing its state simultaneously to the ligand binding. The state of the switch was able to change, 
even without a change of the backbone of the receptor, indicating ability to change in early activation 
stages of the receptor. Following the structural mimicry principle in class A of GPCRs one can 
identify this switch as a pair of residues W6.48/F3.36 in cannabinoid receptors CB1 and CB2. These 
two residues being in contact with each other are located on two opposite helices TM6 and TM3. 
McAllister et al. [364] based on biochemical experiments highlighted the importance of this switch 
as a constraint for the CB1-inactive state that may need to break during activation. Their modeling 
studies using inactive and fully activated CB1 receptor models indicated that the W6.48/F3.36 contact 
can exist in the inactive state of CB1 and be broken in the activated state via a 1 rotamer switch: 
W6.48(gauche+trans) and F3.36(transgauche+). So it may represent a "toggle switch" for 
activation of CB1. Our docking studies confirm their findings, however, because our modeling did 
not include movement of backbone of helices one can regard such state as early activation state of 
the receptor. In such a state there is still a partial interaction between W6.48 and F3.36 residues (Fig 
10.11) although they are located in new places ready to start rearrangement of adjacent residues 
through modification of the hydrogen bond network and imposing forces on adjacent helices for their 
later displacement. 
Fig 10.10 Superimposition of representative ligand conformations extracted from 22 molecular 
dynamics simulations of fenoterol-β2AR complex; 11 conformations per each isomer of fenoterol: 
(R,R)fenoterol (a), and (S,S)-fenoterol (b). Green dashed lines indicate hydrogen bonds. 
The presence of pure χ1 gauche+and χ1 trans rotamers of W6.48 and F3.36 was rare in the obtained 
poses especially for agonists of cannabinoid receptors: frequently the χ1 angle deviated by about 
±30º and sometimes (for the lowest energy pose of AEA-CB1 complex) even by ±60º which is in 
between gauche+and trans states. This is possibly because of crowding in the binding site and the 
mismatch (which is a driving force for receptor activation) between the inactive structure of the Activation mechanism of GPCRs 173
receptor and docked agonists, as we analyzed the initial stages of activation by binding of all ligands 
to the receptor in the inactive state. Because of such discrepancies in the χ1 angle of W6.48 and 
F3.36 residues, we decided to introduce another notation of the state of the switch indicating the 
mutual positions of the two residues in relation to each other. In this way the so called inactive state 
(present in the template and maintained by antagonists) is right-right (R-R), whereas the state 
preferred by agonists is left-left (L-L). The definition is based on the position taken by these two 
residues with regard to the line connecting their Cβ carbon atoms viewed from the extracellular side 
(it is further explained and visualized in Fig.10.11). The χ2 angle of W6.48 and F3.36 residues was 
also able to change and helped to define the state of the switch: if a change of the χ1 angle was not 
big enough to differentiate between gauche+and trans rotamers, then the location of the ring (via χ2 
angle - especially for W6.48) indicated the specific R-R or L-L state. Therefore, by incorporating the 
χ1 and χ2 angles, the proposed naming rule properly differentiated inactive and activated states of the 
rotamer toggle switch in the early stages of receptor activation. The conformations of the receptor for 
the best scored poses of the ligand-receptor complex were different but the switch was always in the 
L-L state for agonists while it was in the R-R state in the case of antagonists (the values in bold in 
Table 1). The poses with an opposite state of the switch (also obtained during docking procedure) 
were always classified with higher free energies and intermolecular energies. The docking procedure 
also provided right-left (R-L) and left-right (L-R) states of the switch among the docking results but 
all of them were of higher energy and are not shown.Activation mechanism of GPCRs 174
Fig  10.11  The location of W6.48 and F3.36 residues (forming the rotamer toggle switch) in 
molecular models of CB1 (a) and CB2 (b) receptors viewing from the membrane (left panels) and 
from extracellular side (right panels). Residues in grey indicate so called  inactive  state (from 
complexes with antagonists), residues in green indicate activated state (from the complexes with 
agonists). Red arrows show the change of positions of W6.48 and F3.36 residues during the 
activation process. Based on location of these two residues to the line connecting their Cβ carbon 
atoms, viewing from extracellular side, one can identify the states of the switch as right-right (R-R) 
state (both side chains on their right positions) or left-left (L-L) state (both side chains on their left 
positions).
The observations of the possible ligand poses in the cavity of cannabinoid receptors led us to the 
conclusion, that the most important for the ligand binding are the van der Waals interactions while 
hydrogen bonds and even ionic interactions are less important. The highly scored poses (i.e. with the 
lowest energies) were often lacking strong hydrogen bonds (defined as donor-acceptor distance less 
than 0.25 nm), although some weak (donor-acceptor distance less than 0.45 nm [408]) could still be 
formed. The common interactions between the ligands and cannabinoid receptors involved   orbitals   
in phenyl rings, which are present in large amounts in the CB1 and CB2 receptors’ binding sites, 
especially in the cavity between helices TM2, TM7 and EC2 loop (Fig. 3 and Fig. 4). For the most 
flexible ligand, AEA, about 5*10
6 poses generated for each ligand for each receptor conformation by 
docking procedure (2.5*10
5 energy evaluations * 20 runs) was still too small number to properly 
sample conformational space of AEA even in confined space of the receptor binding site. However, 
obtaining the activated state of the switch for the lowest energy poses of this agonist indicates that Activation mechanism of GPCRs 175
such poses are not rare and maybe they are dominant even for inactive receptor structure that was 
used for docking. 
In the computational studies Gonzalez et al. [409] preformed docking on homology modeled  CB1 
receptor.  They  docked  WIN55,212-2 (agonist),  SR-141716a  (inverse  agonist)  and  CP-55940 
(non-classical agonist) ligands to the conformation of CB1 in basal state and to the model of activated 
receptor obtained by translation and rotation of TM6. Docking results were similar to obtained earlier 
by McAllister  et al.  [410]  and confirmed preferential binding of ligands using two aromatic 
microdomains of CB1 confined by helices TMs:3-5-6-7 and helices TMs:1-2-3-7. Docking revealed 
that all three ligands preferred the same binding site (TMs: 3-5-6-7), and only in the model of 
activated receptor (R*), one ligand, the non-classical agonist CP-55940, was docked to the second 
binding site. Another computational study on CB1  and CB2  receptors modeled on β2AR and 
rhodopsin templates [411]  revealed binding modes of AMG3 ligand. Both templates proved to be 
useful and provided similar docking results. Aromatic residues were also an important part of the 
binding site. Shim et al. [412] conducted 105 ns molecular-dynamics simulations of empty CB1 
receptor embedded in POPC bilayer for obtaining the structural and functional features of CB1 over 
time. The helical bundle maintained a structure very similar to the x-ray structures of GPCRs. It was 
also revealed that the CB1  receptor is stabilized by the formation of extensive, water-mediated 
hydrogen bond networks and aromatic stacking interactions within the helical core region. It is likely 
that these interactions, involving specific functional motifs, are the molecular constraints imposed on 
the inactive state of the CB1  receptor. It was also suggested that disruption of these specific 
interactions is necessary to release the molecular constraints to achieve a conformational change of 
the receptor suitable for G-protein activation. 
Based on accumulated biophysical and biochemical knowledge in the recent review of Shim [412] 
the initial stages of CB1 receptor activation as well as a usefulness of functional residues of CB1 
receptor for drug discovery are discussed. The role of loops between transmembrane helices in ligand 
binding and differentiation for CB1  was tested by Ahn  et al.   [259]  based on alanine scanning 
mutagenesis of CB1 EC2 loop. Their findings are consistent with a dual role for EC2 in stabilizing 
receptor assembly and in ligand binding. Selectivity issues i.e. how to develop compounds with high 
affinity for the CB2  receptor and little affinity for the CB1  receptor, are discussed in  [413]  for 
classical cannabinoids and cannabimimetic indoles. Interestingly, two opposite approaches, receptor 
mutations and molecular modeling, have been employed to obtain binding data. The selectivity of 
cannabinoid receptors was also investigated using molecular modeling and automated docking 
procedures [414]. An analysis of the interaction of WIN55212-2 with both receptors showed that 
CB2/CB1 selectivity is mainly determined by the interaction with the nonconserved residues S3.31 Activation mechanism of GPCRs 176
and F5.46 in CB2 receptor. Importance of these residues was suggested by site-directed mutagenesis 
experiments.
Another type of selectivity involving coupling of β2AR to Gs and Gi proteins was recently reported 
for fenoterol stereoisomers [405]. Based on conducted MD simulations of β2AR-fenoterol complexes 
we observed different binding modes for (R,R)- and (S,S)-fenoterol isomers which are in agreement 
with recent results from docking experiments [414]. (R,R)-fenoterol adopted stable conformation 
inside the binding cavity and created a network of hydrogen bonds involving D3.32 and N7.39 
residues, which was well preserved during simulation. In contrast, (S,S)-isomer showed much higher 
conformational flexibility. Interaction between ligand’s protonated amine group and D3.32 residue 
was the only one well preserved during MD simulation. This findings can be important in explaining 
the differences of the β2AR active states leading to Gs or Gs/ Gi selective coupling. W6.48 did not 
change its state during any of the 5 ns simulations possibly because of short length of them. 
However, such length was enough to show critical differences in ligand binding modes of tightly 
related compounds. 
A number of conformational switches in β2AR has been reported so far. Two the best characterized 
are the R3.50-E6.30 ionic lock and W6.48 rotamer toggle switch. It was demonstrated that 
norepinephrine and dopamine break the ionic lock and engage the rotamer toggle switch whereas 
salbutamol, a noncatechol partial agonist, only breaks the ionic lock while the weak agonist catechol 
only engages the rotamer toggle switch [391,415,416]. The activation mechanism is linked to the 
disruption of the network of interactions in the ionic lock. According to Romo et al. [391] the ionic 
lock can exist in three states: closed (or locked), semi-open with a bridging water molecule, and 
open. Recently Bokoch at al. [367] suggested that the extracellular domains of β2AR also take part in 
the activation process. NMR spectroscopy and X-ray studies showed the functional role of the 
extracellular surface in ligand-specific conformational changes around a salt bridge linking D192 
(EC2 loop) and K7.32 of β2AR. This connection is formed in the unliganded β2AR as well as in the 
complex with an inverse agonist – carazolol [298,339] but certain agonists (including formoterol, a 
molecule structurally related to fenoterol) were reported to induce its breaking. Our results show that 
(RR)-fenoterol isomer forms well preserved interaction between the hydroxyl group of the ligand’s 
phenolic moiety and the carboxyl group of D192 (EC2 loop) residue during  MD simulations in a 
similar manner as suggested by Bokoch et al. [367]. Such interaction is not observed in simulations 
on β2AR - (S,S)-fenoterol complex.
Presence of the ionic lock switch is not questionable in nearly all GPCRs, however its influence for 
basal receptor activity is not obvious. Using D6.30N mutant of CB1 and CB2 receptors Nebane et al. Activation mechanism of GPCRs 177
[417] found that D6.30 is essential for full activation of both cannabinoid receptors. Both CB1 and 
CB2 D6.30N mutants demonstrated a level of constitutive activity not greater than that of their wild 
type counterparts, indicating that either D6.30 does not participate in a salt bridge with R3.50 (DRY 
motif), or the  salt bridge is  not critical for keeping cannabinoid  receptors  in  the inactive 
conformation. The same conclusion was drawn from 2  s simulations of empty β  2AR conducted to 
resolve the question about the open ionic lock in the crystal structure of this receptor with inverse 
agonist bound [388]. It turned out that ionic lock in empty receptor may be open or not indicating 
two distinct inactive conformations of β2AR in the basal state. 
10.7.4Conclusions
The flexible docking procedure for cannabinoid receptor CB1 and CB2 and molecular dynamics 
simulations for β2-adrenergic receptor revealed important differences in binding modes and provided 
additional insights into the activation processes of GPCRs. New structures of these receptors awaited 
due to progress in stabilization, overexpression and crystallization techniques may help explain to 
what extent the structural mimicry is applied to GPCRs during activation processes. The longer 
molecular dynamics simulations even beyond the microsecond and reaching millisecond timescale 
will provide additional information about dynamics of ligand-receptor complexes and possibly also 
the course of the action of particular micro-switches. Taken into account the hypothesis of an 
ensemble of receptor conformations in the basal state one can also consider an ensemble of possible 
conformations of flexible ligands inside the binding site of the receptor, like anandamide in 
cannabinoid receptors and (S,S)-fenoterol in β2AR, leading to dynamical binding modes in case of 
some ligand-receptor pairs that also could be investigated using simulations techniques.Activation mechanism of GPCRs 178
10.8 Water mediated activation mechanism of Formyl peptide receptor 1 (FPR1)
10.8.1Introduction
Human N-formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) involved in 
many physiological processes, including host defense against bacterial infection and resolving 
inflammation [418–424]. The three human FPRs (FPR1, FPR2 and FPR3) share significant sequence 
homology and perform their action via coupling to Gi protein. Activation of FPRs induces a variety 
of responses, which are dependent on the agonist, cell type, receptor subtype, and also species 
involved. FPRs are expressed mainly by phagocytic leukocytes. Together, these receptors bind a 
large number of structurally diverse groups of agonistic ligands, including N-formyl and nonformyl 
peptides   of   different   composition,   that   chemoattract   and   activate   phagocytes.   For   example, 
N-formyl-Met-Leu-Phe   (fMLF),   an   FPR1   agonist,   activates   human   phagocyte   inflammatory 
responses, such as intracellular calcium mobilization, production of cytokines, generation of reactive 
oxygen species, and chemotaxis [425]. This ligand can efficiently activate the major bactericidal 
neutrophil functions and it was one of the first characterized bacterial chemotactic peptides [426]. 
Whereas fMLF is by far the most frequently used chemotactic peptide in studies of neutrophil 
functions, atomistic descriptions for fMLF-FPR1 binding mode are still scarce mainly because of the 
absence of a crystal structure of this receptor. Elucidating the binding modes may contribute to 
designing novel and more efficient non-peptide FPR1 drug candidates. Molecular modeling of FPR1, 
on the other hand, can provide an efficient way to reveal details of ligand binding and activation of 
the receptor. However, recent modelings of FPRs were confined only to bovine rhodopsin [297,427] 
as a template. 
Recently, Fujita  et al.  [428]  investigated binding of calpain inhibitors as well as short peptides 
including fMLF to FPR1 and FPR2 receptors. Their findings suggest that potent calpain inhibitors 
could stimulate phagocyte functions via activation of FPR1, FPR2 and/or other G-protein coupled 
receptors depending on the inhibitors used. Using molecular docking they obtained different binding 
modes of fMLF in the above receptors and compared qualitatively the estimated energies of ligand 
binding to experimental data. They also provided a list of residues in a vicinity of a ligand but they 
did not show ligand-receptor interactions in the binding site. In another paper, Khlebnikov et al.
[429] investigated binding of a set of benzimidazole derivatives as well as other agonists of FPR1 
including fMLF. After the docking the 2 ns molecular dynamics (MD) simulations confined to the 
binding site were conducted. The rest of the FPR1 structure was kept rigid. In the best scored pose of 
fMLF-FPR1 the C-terminus of the ligand interacted with R205
5.42 while the formylated N-terminus 
interacted with main chains of residues L198
5.35-V200
5.37 which could suggest that this part of the 
helix was unfolded. In another report Movitz et al. [430] identified the shortest sequence of the FPR1 Activation mechanism of GPCRs 179
ligand annexin A1 [431] which was still able to activate FPR1 and they also investigated the binding 
modes of this tetrapeptide. The Gln
9-Phe
12  (Ac-QAWF) peptide was the shortest peptide of 
annexin A1 possessing the capacity both to trigger a neutrophil NADPH oxidase response and to 
inhibit the activity induced by other FPR agonists. Two alternative binding modes of Ac-QAWF were 
found having the same position of N-terminus of this peptide close to residues D106
3.33, R201
5.38 and 
R205
5.42. However, in both configurations there was no interaction with R86
2.65 predicted to be a part 
of the binding site for fMLF by the mutagenesis experiments [432]. In all the above studies the 
rhodopsin structure was taken as a template and no molecular dynamics simulations of the receptor 
in the membrane were performed to investigate an influence of the ligand on the receptor structure. 
To locate specific ligand-receptor interactions based on a more appropriate template than rhodopsin 
we generated the homology models of FPR1 using the crystal structure of the chemokine receptor 
CXCR4 [316], which shares over 30% sequence identity with FPR1 and is located in the same γ 
branch of phylogenetic tree of GPCRs (rhodopsin is located in α branch). Docking and model 
refinement procedures were pursued afterward. Finally, 40 ns full-atom MD simulations were 
conducted for the Apo form as well as for complexes of fMLF (agonist) and tBocMLF (antagonist) 
with FPR1 in the membrane. Based on locations of the N- and C-termini of the ligand the FPR1 
extracellular pocket can be divided into two zones, namely, the anchor and activation regions. The 
formylated M1 residue of fMLF bound to the activation region led to a series of conformational 
changes of conserved residues. Internal water molecules participating in extended hydrogen bond 
networks were found to play a crucial role in transmitting the agonist-receptor interactions. A 
mechanism of initial steps of the activation concurrent with ligand binding is proposed. 
10.8.2Results
FPR1 structure and the binding pocket
Currently, in the γ branch of the most populated family A of GPCRs there are five receptors whose 
structure has been determined, the chemokine receptor CXCR4 [316] and opioid receptors: µOR 
[433], δOR [434], κOR [435] and the nociceptin FQ receptor [436]. For the homology modeling of 
FPR1 we used the one most similar in sequence and the closest in the phylogenetic tree, the 
chemokine receptor. The model obtained for the FPR1 structure consists of a seven transmembrane 
(TM) helix bundle (TM1 to TM7), a cytosol helix H8 and a β-hairpin loop between TM4 and TM5 
(Fig 10.12A). Although the structure of CXCR4 does not contain helix H8 it exists in all crystal 
structures of opioid receptors which suggests that H8 is unfolded in the crystal of CXCR4 because of 
crystal packing. The model of FPR1 was relaxed in a POPE membrane using detailed relaxation 
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FPR1 is quasi symmetrical (Figure 10.12C). At both ends of the binding site there are positively 
charged residues: R84
2.63 and K85
2.64 located in TM2 as well as R201
5.38 and R205
5.42 on helix TM5. 
They are complemented by negatively charged residues: D284
7.38 in TM7 interacting with K85
2.64 
and, at the other end, D106
3.33 in TM3 interacting with R201
5.38. However, D106
3.33 is located much 
deeper in the receptor structure than D284
7.38 and is tightly interacting with R201
5.38. Between both 
areas there are hydrophobic residues separating these charged areas and also interacting with the 
ligand. They can also be divided into two zones: residues F81
2.60, V101
3.28 and F102
3.29 on helices 
TM2 and TM3 are located on one side of the ligand whereas Y257
6.51 and F291
7.43 on helices TM6 
and TM7 on the other side. All abovementioned residues are located in the vicinity of 4 Å from the 
ligand. Because of such distribution of residues the entrance to the binding site is nearly uniformly 
positively charged so that the negatively charged ligands will be selectively attracted and in case of 
both agonist fMLF and antagonist tBocMLF (Fig 10.13) they would enter the binding site most 
preferably with the negatively charged C-terminus. The residue D106
3.33 is buried under R201
5.42 and 
is not visible in the figure. The red spot of negative potential in the center of the receptor comes from 
residue N108
3.35. To facilitate comparison of our structure to other GPCRs the Ballesteros-Weinstein 
numbering scheme [265] was used (numbers in superscript) apart from the sequence numbers of 
FPR1 residues.
Fig 10.12 The structure of homology model of FPR1 and its binding pocket. (A) overall view of 
FPR1 model; (B) alternative view of FPR1 model from extracellular side; (C) important residues in 
binding site of FPR1. The whole pocket was visually divided into two zones: the anchor region (on left 
- in blue) and the activation region (on right – in green).Activation mechanism of GPCRs 181
Interactions of ligands with binding site of FPR1
The three best scored binding configurations of the 2000 conformations for agonist and antagonist, 
respectively, were characterized by the C-terminus of both ligands bound to the charged area at TM2 
(the anchor region) whereas the N-terminus of the peptide was bound to the second charged area at 
TM5 (the activation region). Employing docking and the Glide docking score we found that the 
agonist fMLF was bound more strongly to the binding site of FPR1 (-7.8 kcal/mol) than the 
antagonist tBocMLF (-7.2 kcal/mol). The same hydrophobic residues of both ligands can suggest 
similar preferential binding modes. Next we conducted equilibration calculations of both complexes 
in a model of POPE membrane. After equilibration the C-terminal residue F3 of the agonist was 
engaged in a stable hydrogen bond network (Fig 10.14A) formed by the side chains of R84
2.63, 
K85
2.64 and D284
7.38 while a water molecule mediated the hydrogen bonds between fMLF carbonyl 
group and D284
7.38. The hydrophobic side chain of residue F3 was surrounded by four hydrophobic 
residues, namely F81
2.60, V101
3.28, F102
3.29 and F291
7.43. Similarly to the agonist in the C-terminal 
region, the antagonist tBocMLF also formed the hydrogen bonds directly with R84
2.63 and K85
2.64 
(Figure 5A), while the hydrophobic side chain of F3 was also stabilized by residues F81
2.60, V101
3.28, 
F102
3.29 and F291
7.43. Differently from the agonist a hydrogen bond of tBocMLF with D284
7.38 was 
not created or even bridged by a water molecule but instead by a NH group of the peptide bond in 
residue F3 which formed a hydrogen bond with D284
7.38 directly.
At the other end of the two ligands the N-terminal formyl group of the agonist (Figure 10.14B) was 
involved in a complex water-mediated hydrogen bond network including residues R205
5.42 and 
D106
3.33 while the carbonyl group of the peptide bond in residue M1 formed a hydrogen bond with 
Y257
6.51. Similarly to the agonist no direct interactions with charged residues of the receptor were 
found in the N-terminus of tBocMLF and only a water mediated hydrogen bond network was located 
between the carbonyl group of tBoc and both arginine residues R201
5.38 and R205
5.42. Moreover, there 
was also a direct hydrogen bond between Y257
6.51 and the main chain of the antagonist.
Fig 10.13 The chemical formulas of fMLF (agonist) and tBocMLF (antagonist). 
Both ligands share most of the structure so only differences in N-termini are shown 
in detail and colored in blue.
To investigate the changes in FPR1 structure that can be induced concurrently with agonist binding Activation mechanism of GPCRs 182
we performed 40 ns MD simulations starting from systems equilibrated in a model membrane. The 
simulations were conducted for FPR1 in its Apo form, as well as for complexes with agonist and 
antagonist. The root mean squares deviation (RMSD) plots of protein backbone show small 
rearrangements (0.7 Å) compared to the starting structures so the investigated structures were stable 
as early as at 5 ns of MD simulation indicating that equilibration procedure was sufficient to stabilize 
the receptor. The binding pocket remained similar to the starting conformations in all conducted 
simulations suggesting that only local rearrangements took place at least at this time-scale. 
During the simulations both agonist and antagonist changed their positions, however, the agonist 
stayed bound to the anchor region for the whole simulation while the antagonist unbound and finally 
its charged C-terminus interacted directly with K170 from a long EC2 loop (between TM4 and 
TM5). Additionally the benzene ring of F3 of antagonist formed π-π stacked interactions with W91 
of the EC1 loop. In case of the agonist the side chain of F3 was stably located between F81
2.60, 
W91
EC1 and F102
3.29 (Fig 10.14A). At the N-terminus of the antagonist there was a large movement of 
residue M1 from an interior position toward EC2 and especially residue F178. The tBoc group did 
not change much its position but a hydrogen bond to Y257
6.51 was lost (Fig 10.14B). In case of the 
agonist there was also a change of the M1 side chain but here towards the interior of FPR1 close to 
position previously occupied by formyl group of this ligand i.e. close to residues R205
5.42, Y257
6.51 
and W254
6.48. M1 also displaced one water molecule and stayed close also to F291
7.43. The formyl 
group interacted with S287
7.39 and indirectly with Y257
6.51. The electrostatic interactions between 
D106
3.33 and both arginine residues, R201
3.38 and R205
5.42, were stable in the Apo form of FPR1. 
However, for antagonist and agonist the interaction D106
3.33-R201
3.38 was broken and restored many 
times. For both ligands the residue R205
5.42 moved away from D106
3.33 but in case of agonist it was 
separated by one water molecule only. 
Similarly to other structures of GPCRs in partly activated state a hydrogen bond network has been 
found throughout the whole transmembrane region of FPR1 (Fig 10.15). This network started from 
W254
6.48 and consisted of residues N108
3.35 (the residue also present in CXCR4 and opioid receptors 
but not in muscarinic receptors), D71
2.50 (the most conserved residue in TM2), N297
7.49 and Y301
7.53 
(from the NPxxY motif). The above residues were connected directly by hydrogen bonds. Y301
7.53 
formed π-π stacking interaction with Y64
2.43 but also participated in water-mediated hydrogen bond 
networks involving also residues at the cytoplasmic part of the receptor: Y64
2.43, D122
3.49  and 
R123
3.50 (from the DRC motif – corresponding to DRY in other GPCRs) and also R137
4.37 interacting 
directly with D122
3.49 (Fig 10.15B). During MD simulation of the fMLF-FPR1 complex a water 
molecule initially located between R205
5.42 and W254
6.48 diffused toward the center of FPR1 and 
transiently (4-18 ns in MD simulation) bridged the hydrogen bond between W254
6.48 and N108
3.35. A 
similar scenario was observed at the other side of FPR1 when water molecule from the cytoplasmic Activation mechanism of GPCRs 183
side diffused into the receptor and bridged a hydrogen bond between N298
7.49 and Y301
7.53 in NPxxY 
motif. This bridging was stable till the end of simulation. The network of interactions between 
residues of the agonist-receptor complex as well as a movement of bridging water molecules is 
depicted schematically in Fig 10.16.
Fig 10.14 The ligand-receptor interactions after 40 ns MD simulation. View from extracellular 
side. (A) The agonist fMLF (in orange). (B) The antagonist tBocMLF (in cyan). The M1 residue 
of agonist went down toward W254
6.48 while that of antagonist went up toward EC2 loop.
Models of FPR2 and FPR3 receptors
To obtain models of the related receptors FPR2 and FPR3 we performed homology modeling based 
on the equilibrated structure of FPR1. The FPR2, which shares 69% sequence identity with FPR1, is 
a low affinity receptor for fMLF with a Kd of 430 nM [437–439]. The obtained model of FPR2 
showed many differences compared to FPR1 including residues in the binding site: (FPR1 to FPR2) 
F81L
2.60, R84S
2.63, K85M
2.64, F102H
3.29, Y257F
6.51 and D284N
7.38 (Figure 10.16A). Since K85
2.64 and 
R84
2.63 has been experimentally proven to be crucial for fMLF binding [432], the mutations at these 
two positions in FPR2 might be responsible for the low binding affinity of fMLF. We also performed 
docking of this agonist and the obtained scores had indicated that fMLF binding in FPR1 is more 
favorable than in FPR2 with scores 7.8 kcal/mol and -6.1 kcal/mol, respectively. The FPR3, which 
shares 56% sequence identity with FPR1, binds the agonist fMLF with undetectable affinity [432]. 
The obtained homology model of FPR3 also exhibited many differences including residues in the 
binding site: (FPR1 to FPR3) F81R
2.60, R84S
2.63, K85V
2.64, F102H
3.29 and D284N
7.38 (Fig 10.17B). The 
loss of fMLF binding affinity can be attributed to the mutations K85V
2.64 and R84S
2.63 both of which 
had been shown to be important for binding. Moreover, F81R
2.60 could also contribute to the lack of 
fMLF binding since hydrophobic properties were lost at the position where the F3 residue of the 
ligand is located. Furthermore, residues in the activation zone at positions 201 and 205, namely 
R205H
5.42 and R201F
5.38, were also found to have properties different from FPR1 indicating that the 
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10.8.3 Discussion
The choice of CXCR4 as template structure
Our study is the first attempt, to our knowledge, to show changes in the molecular structure of FPR1 
that occur upon agonist binding. The structure was constructed based on a novel template, the 
chemokine receptor CXCR4, belonging to the same γ branch of the phylogenetic tree of GPCRs as 
the formyl receptors. Molecular dynamics simulations were conducted including an all-atom model 
of the membrane. Because there are two structures of CXCR4 complexed with different antagonists 
we chose the one in which helices are not distorted by the presence of detergent used for 
crystallization. The structure with small agonist (PDB id 3ODU) contains two detergent molecules 
between helices TM5 and TM6. They do not affect the binding of antagonist IT1t of CXCR4 which 
is bound mainly to helices TM2, TM3 and TM7. In case of FPR1 the experimental evidence is that 
TM5 participates extensively in binding of agonists and antagonists. Therefore, we decided to use the 
structure of CXCR4 complexed with cyclic peptide CVX15 being also an antagonist of this receptor 
(PDB id 3OE0) in spite of its lower resolution 3.2 Å compared to 2.5 Å of the structure with IT1t. 
Comparison of structures based on rhodopsin and CXCR4 templates 
Earlier modeling attempts of FPR1 [428–430] were all based on the rhodopsin template. There are 
several important differences between the rhodopsin and CXCR4 structures which can affect 
homology modeling and binding of ligands. First, the EC2 loop is outside the binding site of CXCR4 
so there is much more space for binding of ligand, and second, there is a bulge at extracellular part of 
TM2 of rhodopsin (located at positions S76
2.55 and T77
2.56 of FPR1) which is not present in the 
CXCR4 structure. Using the CXCR4 template this part of TM2 is rotated about 100° compared to the 
rhodopsin template so another part of TM2 is facing the binding site (Fig 10.17). Especially residue 
R84
2.63 which was predicted, based on rhodopsin structure, to be outside the binding site can now 
interact with ligand jointly with K85
2.64. Interestingly, these both residues were predicted by Mills et 
al. [432] to strongly interact with ligands of FPR1. Additional confirmation of the obtained structure 
is a presence on a salt bridge between K85
2.64 and D284
7.38 which was proposed by Mills based on 
site-specific fluorescent photoaffinity labeling and mass spectrometry [432]. The mutual location of 
helices other than TM2 is also different in both templates so the binding site is dissimilar enough to 
prefer other ligand binding modes. The presence of the bulge in TM2 in rhodopsin could severely 
influence the structure and interactions in the binding site of homology models and it was one of 
major reasons for very poor docking results during modeling of complex of CXCR4 structure during 
GPCR Dock 2010 assessment [440]. 
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be visually divided into two zones: the activation zone where the modified N-terminus of fMLF and 
tBocMLF is bound, and the binding zone where the C-terminus of ligand is bound. The nearly 
symmetrical binding site of FPR1 enables reversed binding configurations of agonist and antagonist 
and one cannot exclude that initially the ligands can bind in both ways with N-terminus docked 
either to TM5 or to TM2. However, only one way can be appropriate for activation of the receptor. 
The receptor binding site is more spacious close to TM5 because this helix is located farther from the 
EC2 loop and this could be the reason for preferential docking of tBoc moiety to this area as well as 
further unbinding of the C-terminus of the antagonist from TM2 during MD simulation. fMLF was 
stably bound to TM2 during the entire MD simulation. Such findings are also supported by 
experimental data because fMLF shows higher binding affinity than tBocMLF in the case of native 
FPR1.
Binding of tripeptide and tetrapeptide ligands
Movitz et al. [430] identified a tetrapeptide of the ligand annexin A1, Gln
9–Phe
12 (Ac-QAWF), as the 
shortest sequence of annexin A1 which is still able to activate FPR1. Although the modeling that was 
also performed in this paper was based on the rhodopsin template the authors proposed a possible 
binding mode of this peptide. It directly binds to both TM2 and TM5 and spans across the entire 
binding site. Tripeptides like fMLF are shorter than the Ac-QAWF so the binding mode must be 
different. We found that the water molecules can bridge interactions between N-terminus of agonist 
and charged residues D106
3.33, R201
5.38  and R205
5.42  and therefore they can participate in the 
activation process. Based on experimental results   [441–444], four hydrophobic residues, namely 
F81
2.60, V101
3.28, F102
3.29 and F291
7.43, had been shown to be important for fMLF binding. Moreover, 
the residues Y257
6.51, K85
2.64 and R84
2.63 [432,444] were also identified by mutagenesis to have a 
significant effect on FPR1 binding affinity, while D106
3.33 [432,443], R201
5.38 and R205
5.42 [444] were 
confirmed to be crucial for FPR1 activation. All these residues were found in close vicinity of the 
docked, optimized and simulated agonist fMLF. 
During MD simulation the side chain of the M1 residue of the agonist went down toward the center 
of the receptor close to residues regarded to be crucial for activation of most of GPCRs including 
W254
6.48 from CWxP motif in helix TM6. This residue participates in the so called transmission 
switch, the action of which leads to rearrangements of residues in the central part of GPCRs and is a 
prerequisite for outward movement of cytoplasmic part of helix TM6 (a recent review on the action 
of molecular switches in GPCRs can be found in [295]). Contrary to the agonist the side chain of 
residue M1 in tBocMLF was displaced toward the EC2 loop. There is a similarity of the location of 
the side chain of the first amino acid of fMLF and of the tetrapeptide Ac-QAWF. In both cases this 
side chain is located in close vicinity of W254
6.48. The tetrapeptide was manually docked in [430] to 
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simulation the formyl part of the M1 residue was initially bound to TM5 via bridging water 
molecules while the side chain of M1 was outside of this region (Figure 4B and 7A) but after MD 
simulation the side chain of M1 was localized much deeper than the formyl group (Figure 6 and 8) 
similarly to the binding mode of Ac-QAWF proposed by Movitz et al. [430]. 
Role of water molecules in ligand binding
Water molecules were found important also in a recent paper of Vanni et. al. [445] in 800 ns MD 
simulation of β2-adrenergic receptor. They bridged interactions between agonists and serines located 
in TM5 while the ligands were closely bound to D113
3.32 in TM3 with their protonated amine group. 
Displacement of these water molecules may be a step toward an activation of the receptor because it 
was found that the binding site of β2-AR is shrinking during activation [367]. Two water molecules 
were also found to bridge interaction between phenolic hydroxyl groups of antagonists and the side 
chain of H(6.52) in three crystal structures of opioid receptors  µOR,  δOR and κOR. Identical 
arrangements of these water molecules in three different receptors suggest that their presence is 
crucial to stabilize the antagonist and possibly they participate in receptor activation when an agonist 
is bound. In our earlier papers on activation of opioid receptors [349–351] we postulated, based on 
MD simulations, that antagonists can bind to residues in TM3, namely D(3.32) and Y(3.33), but 
agonists can swap from Y(3.33) to H(6.52) in helix TM6 and such change of location is probably one 
of the first activation steps. Since no structures of opioid receptors with agonists are available, this 
hypothesis still needs to be validated. Possibly, during the activation these water molecules are 
displaced and the agonist can bind directly to H(6.52). This can shrink the binding site and facilitate 
rearrangement of residues of the central part of the receptor being a part of the transmission switch. 
This switch was previously called the rotamer toggle switch and was linked only to residue W(6.48), 
however, the suggested action of this switch was not confirmed by later crystal structures of GPCRs 
with agonists.
During MD simulation of fMLF-FPR1 we observed a movement of water molecules toward the 
receptor center from the extracellular as well as from the cytoplasmic side (Fig 10.15). Because of 
the small simulation time one cannot postulate these movements as being part of activation process 
but rather as thermal movements of water tending to populate the receptor interior because the initial 
structure of the receptor was free of individual water molecules separated from bulk water. In a 
recent structure of the muscarinic receptor M2 [446] there is an aqueous channel extending from the 
extracellular surface into the transmembrane core with well-ordered water molecules. This channel is 
interrupted by a layer of hydrophobic residues located in helices TM2, TM3 and TM6 close to 
residue Y(7.53) in NPxxY motif. Although the Tyr toggle switch is in an active state (i.e. the side 
chain of Y(7.53) is directed toward the receptor center contrary to that residue in the rhodopsin 
structure which is directed toward a cytoplasmic helix H8)  [295]  there is no a hydrogen bond Activation mechanism of GPCRs 187
network linking Y(7.53) with N(7.49). Possibly, after the action of the transmission switch in the 
muscarinic M2 receptor the channel will be rearranged and an extended hydrogen bond network will 
connect both sides of the receptor to enable final stages of receptor activation. Such an extended 
network of hydrogen bonds involving water molecules crossing the hydrophobic barrier was found 
recently in the structure of constitutively active rhodopsin [354]. In the model of FPR1 we also found 
an extended network of hydrogen bonds (Fig 10.15). Such network was broken at residue Y301
7.53 
since it created a π-π stack interaction with Y64
2.43. However, because the switch involving Y301
7.53 
is already in its active state and Y301
7.53 forms a hydrogen bond with N297
7.49 (from the same NPxxY 
motif) the water molecules can easily pass the hydrophobic barrier even in a relatively short 40 ns 
MD simulation.  
To resolve unanswered questions of activation details and ligand docking as well as ligand selectivity 
the MD simulations in a microsecond time scale have to be conducted, preferably based on the 
solved crystal structures of FPRs. Knowledge of these structures and the activation processes 
initiated by binding of the diverse ligands will lead to better understanding of mechanisms of action 
of these highly elusive receptors and also to a design of safer and more efficient drugs. 
Fig 10.15 A hydrogen bond network in the structure of the agonist-FPR1 complex. A side view of 
initial equilibrated structure. (A) The binding site showing the hydrogen bond network involving 
water molecules. (B) A continuation of the hydrogen bond network of the same complex at 
intracellular side. Activation mechanism of GPCRs 188
Fig 10.16 A scheme of interactions in the final 
structure of the agonist-FPR1 complex after 
MD  simulation.  A movement  of two water 
molecules   during   MD   simulation   is   shown. 
These molecules can bridge the hydrogen bonds 
between   some   residues.   A   water   molecule 
transiently bridge a hydrogen bond between 
W254
6.48  and   N108
3.35  while   another   water 
molecule   from   cytoplasmic   side   enters   the 
receptor cavity and can bridge the hydrogen 
bond between residues N297
7.49  and Y301
7.53 
from NPxxY motif.
Fig 10.17 Comparison of FPR1 models constructed on different templates. A 
model based on rhodopsin is colored in cyan while that based on CXCR4 in 
green. Some residues in TM2 are shown in red dashed ellipses to exemplify 
differences between both models. A change of a template from rhodopsin to 
CXCR4 leads to the rotation about 100° of extracellular part of TM2 starting 
from S76
2.55 and removal of a bulge at T77
2.56.Activation mechanism of GPCRs 189
10.9 GPCRDock 2010 Results
Results from the competition are given in the following table and figure showing the RMSD 
differences of the models and crystal structures. 
Fig 10.18: Performance of modeling groups in GPCR Dock 2010
Fig 10.19: Superimposition of D3 and CXCR4 models with the crystal structureReferences 190
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12 Appendix
List of crystallization  screens  used  in  the CrystalMation  automated  robotic  parameter 
screening of CF expressed Pen-2 
• The CubicPhase I Suite (Qiagen GmbH ,Germany), 22 °C 
• The CubicPhase II Suite (Qiagen GmbH ,Germany), 22 °C 
• The MbClass Suite (Qiagen GmbH ,Germany), 4 °C 
• The MbClass II Suite (Qiagen GmbH ,Germany), 4 °C 
• MemGoldTM (Molecular Dimensions Ltd., UK), 4 and 18 °C 
• MemStart and MemPlusTM (Molecular Dimensions Ltd., UK), 4 and 18 °C 
• MemSysTM and Sigma Membrane Kit (Molecular Dimensions Ltd., UK and Sigma-Aldrich 
• Chemie GmbH, Germany), 4 and 18 °C 
• PGA ScreenTM (Molecular Dimensions Ltd., UK), 4 °C 
• JBScreen Pentaerythritol HTS (Jena Bioscience GmbH, Germany), 4 °C 
Sequencing primers for pET-Vectors 
pET - T7-promoter: 5’ TAA TAC GAC TCA CTA TAG GG 3’ 
pET - T7-terminator: 5’ CTA GTT ATT GCT CAG CGG T 3’ Appendix 208
Fig  12.1  Calibration curves of the size exclution chromatography 
columns (linear relationship between logMW of the protein and 
elution volume)Acknowledgements 209
13 Acknowledgements
First of all I would like to convey my sincere regards to Prof. Dr. Volker Dötsch, Prof. Dr. Slawomir 
Filipek and Dr. Frank Bernhard for giving me the opportunity for PhD studies and continuous 
supervision, support and encouragement throughout the project.
In course of the PhD studies, I have received numerous support from many scientists, coworkers and 
friends. Especially I would like to thank Prof. Harald Steiner for continuous guidance on gamma 
secretase and performing activity assay of the complex, Dr. Jan Hoffmann for mass spectrometry, Dr. 
Thomas C. Marlovits for electron microscopy, Dr. Frank Löhr for NMR spectroscopy, Dr. Dorota 
Latek, Krzysztof Mlynarczyk, Dr. Bartosz Trzaskowski, Wojciech Pulawski for help with modeling, 
molecular dynamcis simulations and constructive discussions. 
Also I would like to take the opportunity to say sincere thanks to Yi Ma, Christian Roos, Lei Kai for 
help with cell-free expression, Dr. Sebastian Richers, Dr. Ratnesh Kumar Srivastav, Dr. P. Shaik 
Syed Ali, Susanne Stefer, Alexis Rozenknop, Stefan Haberstock, Vladimir Rogov, Birgit Schäfer for 
fruitful discussions. And Shuguang Yuan, Szymon Niewieczerzal, Rongliang Wu, Michal Kolinski 
for discussions on modeling and simulations, Paweł Pasznik and Manfred Strupf for IT consultations. 
Many thanks to Dr. David Popp, Dr. Akihiro Narita and Dr. Robert C. Robinson for initial training, 
continuous   support   and   collaboration.   I   would   not   forget   the   contribution   of   Sigrid 
Oğuzer-Fachinger,   Magdalena   Powierża,   Monica   Nowicza,   Beata  Thakz   for   taking   care   of 
administrative issues. I would like to apologize to those whose names were omitted due to space 
constraints. Special thanks to Ivan Corbeski for help with the German translation.
I have no words to thank my parents and brother for supporting me since childhood. Also I am 
indebted to all my teachers. Finally I would like to say 'thank you all' to my family, friends and 
patrons.
Funding:  The   research   leading   to   these   results   has   received   funding   from   the   European 
Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 211800. 
I am also thankful to FEBS (Federation of European Biochemical Societies) for 3 months Short Term 
Fellowship. 
Hardware:  I would like to acknowledge CSC-FUCHS at Goethe University, Frankfurt and the 
supercomputer at Technical University Darmstadt, Darmstadt for providing simulation time. Acknowledgements 210
Eidesstattliche Versicherung 
Ich erkläre hiermit an Eides Statt, dass ich die vorgelegte Dissertation über “Cell-free expression and 
molecular modeling of the γ-secretase complex and G-protein-coupled receptors” selbständig 
angefertigt und mich anderer Hilfsmittel als der in ihr angegebenen nicht bedient habe, insbesondere, 
dass alle Entlehnungen aus anderen Schriften mit Angabe der betreffenden Schrift gekennzeichnet 
sind. 
Ich versichere, nicht die Hilfe einer kommerziellen Promotionsvermittlung in Anspruch genommen 
zu haben. 
Frankfurt am Main, den  Umesh GHOSHDASTIDERCurriculum Vitae of Mr. Umesh GHOSHDASTIDER
PERSONAL DATA
Born: 15th Sep, 1985 at Kolkata, India Citizenship: Indian Marital Status: Single
Address: Max-von-Laue Str. 9, Biocenter N230/1OG, Frankfurt 60438, Germany
Mobile: +49 15734 919755 Email: ugd1985@gmail.com
DEGREES
2008 Jul: 2nd best in college in 2-year M.Sc. in Human Physiology, University of
Calcutta (ranked 3rd in India by India Today)
2008 Jan: 1-year of M.Sc in Computer Application, Indira Gandhi National Open
University, New Delhi
2006 May: 3-year B.Sc. in Physiology (Honours) with Physics and Chemistry, University of Calcutta
2003 Apr: 2nd best in school in ﬁnal Matura Exam, West Bengal Council of Higher Secondary Education
2001 Mar: 2nd best in school in ﬁnal Secondary Exam, West Bengal Board of Secondary Education
RESEARCH EXPERIENCE
2009 Aug - 2012 Nov: PhD Studies
Prof. Volker Dötsch and Dr. Frank Bernhard, Institute of Biophysical Chemistry, Centre for Biomolecular
Magnetic Resonance, Goethe University, Frankfurt am Main, Germany
Cell-free expression and structural studies of γ-Secretase complex involved in Alzheimer’s disease.
Prof. Slawomir Filipek, Laboratory of Biomodeling, International Institute of Molecular and Cell Biology,
Warsaw, Poland and Faculty of Chemistry, University of Warsaw, Poland
Molecular modeling of the components of γ-Secretase complex and the rhodopsin, cannabinoid, opioid, formyl
peptide GPCRs
2008 Nov - 2009 Apr: Postgraduate Research Fellow
Dr. David Popp, RIKEN Harima Institute at SPring-8, Hyogo, Japan and Dr. Akihiro Narita, Nagoya
University Graduate School of Biological Sciences, Nagoya, Japan
Structural biology of the bacterial cytoskeleton and DNA segregation proteins AlfA, SopA, ParM, MreB etc.
2008 Sep - 2008 Oct: Research Assistant
Dr. Annalisa Perna, Dept. of Biostatistics and Dr. Marina Noris, Dept. of Molecular Medicine, Mario Negri
Institute for Pharmacological Research, Bergamo, Italy
Analysis of Genetic Linkage of Type-2 Diabetes and Clinical Trials Data
2006 Aug - 2007 Dec: Research Internship
Dr. Banani Saha, Dept. of Computer Science and Engineering and Dr. Subhashis Mukherjee, Dept. of
Biophysics, Molecular Biology and Genetics, University of Calcutta
DNA and Protein Sequence Analysis Algorithms and Protein Structure Prediction
EXPERIMENTAL SKILLS
PCR, Protein Expression (cell-free and in vivo) and Puriﬁcation, SDS-PAGE, Western Blotting, Size-exclusion
Chromatography, NMR, X-ray Crystallography, Electron Microscopy, Polymerization and Enzyme Kinetics, Basic
Biochemistry and Physiology techniques.
COMPUTATIONAL SKILLS
Computational Chemistry: protein modeling (Modeller, Rosetta, HHPred, Yasara, ProQ), visualization (Py-
Mol, VMD, UCSF Chimera, JMol), molecular dynamics (Gromacs 4.5.5, CHARMM, NAMD, Desmond), Ligand
docking (AutoDock, DOCK, Ligplot), Schrödinger Suite 2012
Bioinformatics: ClustalW, Blast, JalView etc
Programming: Bash Shell Scripting, C, Python (Numpy, Scipy, Matplotlib, Flask (web), Biopython, Statistics:
Pandas, Mlpy, RPy, scikits etc), R (Basic), L ATEX
GRANTS
2012 Sep: FEBS (Federation of European Biochemical Societies) Short Term Fellowship (3 months)
2009 Aug: Fellowship from Marie Curie Initial Training Network (MC-ITN) of EU’s 7th Framework Programme
(FP7) (3 years)
2008 Nov: Research Stipend, Japanese Science and Technology Agency (JST) (6 months)
Language Proﬁciency: English (Excellent), German (Beginner), Bengali (Native Speaker), Hindi (Very Good),
Sanskrit (Basic)
Hobbies: Yoga, Reading, Listening to Music, Poetry, Playing Chess, Traveling etc.
Professional Memberships: Marie Curie Fellows Association (MCFA), Polish Biochemical Society, Biophysical
SocietyRESEARCH ACHIEVEMENTS
• Cell-free expression, puriﬁcation, structural and functional characterization of the γ-Secretase operon and
its subunits Pen-2, Presenilin 1 and Aph-1 involved in Alzheimer’s disease
• Molecular model of γ-Secretase component interactions with substrate amyloid precursor protein
• Molecular model of GPCR (cannabinoid and formyl peptide receptors) activation mechanisms
• Molecular model of binding between the let-7g microRNA precursor and the human Lin28B protein involved
in cell diﬀerentiation and cancer
• Deﬁned polymeric structures of bacterial homologs of actin and tubulin like ParM, MreB, AlfA, Alp12 etc.
required for cell division, DNA and plasmid segregation using electron and light microscopy, light scattering
and by modeling of polymerization kinetics
CONFERENCE AND WORKSHOP POSTERS AND TALKS
1. “2nd Annual Meeting of Structural Biology of Membrane Proteins (SBMPs) Marie Curie Initial Training
Network”, June 8-11, 2010, Biozentrum, University of Basel, Basel, Switzerland (Talk and Poster)
2. (Invited) EMBO Practical Course “Computational aspects of protein structure determination and analy-
sis: from data to structure to function”, Sep 6-10, 2010, European Bioinformatics Institute (EMBL-EBI),
Hinxton, Cambridge, UK (Poster, Full expenses grant)
3. (Invited) Marie Curie TranSys ITN International conference “Membrane protein structure, biogenesis and
bioinformatics”, Oct 25-29, 2010, Maratea, Italy (Poster, Full expenses grant)
4. “3rd Annual Meeting of SBMPs”, May 23-25, 2011, Utrecht, Netherlands (Talk and Poster)
5. “The Relationship of Numerical Simulations and Experimental Methods”, May 26-28, 2011, Warsaw, Poland
(Poster)
6. (Invited) “Expression, Puriﬁcation, Crystallization and Structure of Membrane Proteins”, Bilbao Advanced
Courses on Biophysics, Sep 12-18, 2011, Bilbao, Spain (Poster, Full expenses grant)
7. (Invited) “Bacterial Cytoskeleton to γ-Secretase”, Dec 20, 2011, Rammohan College, Kolkata, India (Talk)
8. “Final Annual Meeting of Structural Biology of Membrane Proteins (SBMPs) Marie Curie Initial Training
Network”, May 30-June 2, 2012, Maratea, Italy (Poster)
PEER-REVIEWED PUBLICATIONS (h-index = 6, citations>110)
1. Roos C, Kai L, Haberstock S, Proverbio D, Ghoshdastider U, Ma Y, Filipek S, Wang X, Dötsch V, Bernhard
F. High Level Cell-Free Production of Membrane Proteins into Nanodiscs. Methods Mol Biol In Press
2. Yuan S, Ghoshdastider U, Trzaskowski B, Latek D, Debinski A, Pulawski W, Wu R, Gerke V, Filipek S. The
role of water in activation mechanism of human N-formyl Peptide Receptor 1(FPR1) based on molecular
dynamics simulations. Plos One In Press IF 4.537
3. Shaik Shaik Ali P, Ghoshdastider U, Hoﬀmann J, Brutschy B, Filipek S (2012) Recognition of the human
Lin28B by let-7g microRNA precursor. FEBS Lett 586(22):3986-90 IF 3.33 #cit 0
4. Ma Y§, Ghoshdastider U§, Wang J, Ye W, Dötsch V, Filipek S, Bernhard F, Wang X (2012) Cell-free
expression of human Glucosamine 6-phosphate N-acetyltransferase(HsGNA1) for inhibitor screening. Pro-
tein Expres Purif 86(2):120-126 IF 1.654 #cit 0 § Co-ﬁrst Author
5. Roos C, Kai L, Proverbio D, Ghoshdastider U, Filipek S, Dötsch V, Bernhard F (2012) Co-translational
association of cell-free expressed membrane proteins with supplied lipid bilayers. Mol Membr Biol Jun
20 (Epub ahead of print) #cit 1
6. Popp D, Narita A, Lee LJ, Ghoshdastider U, Xue B, Srinivasan R, Balasubramanian M, Tanaka T, Robin-
son RC (2012) A novel actin-like ﬁlament structure from Clostridium tetani. J Biol Chem 287(25):21121-
29 IF 5.117, #cit 0
7. Pulawski W, Ghoshdastider U, Andrisano V, Filipek S (2012) Ubiquitous Amyloids. J Appl Biochem
Biotech 166(7):1626-43 IF 1.998, #cit 0
8. Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, Filipek S (2012) Action of molecular
switches in GPCRs - theoretical and experimental studies. Curr Med Chem 19(8):1090-109 IF 4.961,
#cit 1
9. Ma Y, Muench D, Schneider T, Sahl HG, Bouhss A, Ghoshdastider U, Wang J, Dötsch V, Wang X,
Bernhard F (2011) Preparative scale cell-free production and quality optimization of MraY homologues in
diﬀerent expression modes. J Biol Chem 286(45):38844-53 IF 5.117, #cit 6
10. Latek D, Kolinski M, Ghoshdastider U, Debinski A, Bombolewski R, Plazinska A, Jozwiak K, Filipek S
(2011) Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic
beta-2 AR. J Mol Model 17(9):2353-66 IF 2.242, #cit 3
11. Kufareva I, Rueda M, Katritch V, participants of GPCR Dock 2010 (including Ghoshdastider U), Stevens
RC, Abagyan R (2011) Status of GPCR modeling and docking as reﬂected by community-wide GPCR Dock
2010 assessment. Structure 19(8):1108-26 IF 5.931, #cit 4212. *Sobhanifar S, Schneider B, Löhr F, Gottstein D, Ikeya T, Mlynarczyk K, Pulawski W, Ghoshdastider U,
Kolinski M, Filipek S, Güntert P, Bernhard F, Dötsch V (2010) Structural investigation of the C-terminal
catalytic fragment of presenilin 1. Proc. Natl. Acad. Sci. USA 107(21):9644-9 IF 10.472, #cit 22
13. Popp D, Narita A, Maeda K, Fujisawa T, Ghoshdastider U, Iwasa M, Maéda Y, Robinson RC (2010)
Filament structure, organization, and dynamics in MreB sheets. J Biol Chem 285(21):15858-65 IF 5.117,
#cit 17
14. Popp D, Narita A, Ghoshdastider U, Maeda K, Maéda Y, Oda T, Fujisawa T, Onishi H, Ito K, Robinson RC
(2010) Polymeric structures and dynamic properties of the bacterial actin AlfA. J Mol Biol 397(4):1031-41
IF 3.981, #cit 8
15. *Popp D, Xu W, Narita A, Brzoska AJ, Skurray RA, Firth N, Ghoshdastider U, Maéda Y, Robinson RC,
Schumacher MA (2010) Structure and ﬁlament dynamics of the pSK41 actin-like ParM protein: implications
for plasmid DNA segregation. J Biol Chem 285(13):10130-40 IF 5.117, #cit 11
*Recommended by Faculty of 1000, IF = Journal Citation Reports 5-year Impact Factor
CONFERENCE PROCEEDINGS
1. Ghoshdastider U, Mlynarczyk K, Pulawski W, Kolinski M, Filipek S (2010) Molecular Dynamics Simu-
lations of NMR structure of C-Terminal Fragment of Presenilin 1. Front Neurosci Conference Abstract:
Neuroinformatics 2010 doi: 10.3389/conf.fnins.2010.13.00124
2. Ghoshdastider U, Saha B (2007) GenomeCompress-A novel algorithm for DNA compression. Proceedings
of International Conference on Information Technology, Haldia, WB, India (ISSN 0973-6824) #cit 1
SUBMITTED MANUSCRIPTS
1. Ghoshdastider U, Xu R, Trzaskowski B, Mlynarczyk K, Miszta P, Viswanathan S, Renugopalakrishnan V,
Filipek S (2012) Modeling of encapsulation of glucose oxidase with graphene ﬂakes.
DRAFT MANUSCRIPTS
1. Ghoshdastider U, Latek D, Dötsch V, Bernhard F, Filipek S (2012) Cell-free Expression, NMR and com-
putational modeling and validation of Pen-2
2. Ghoshdastider U, Dötsch V, Steiner H, Bernhard F, Elofsson A, Filipek S (2012) Prediction of the eﬀects
of presenilin mutations in Alzheimer’s disease by machine learning
3. Ghoshdastider U, Dötsch V, Steiner H, Bernhard F, Filipek S (2012) Cell-free synthesis of the γ-secretase
operon